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Abstract 
The use of stem cells for cartilage repair and treatment of osteoarthritis has been a 
subject of much debate. To date, there is no consensus on the appropriate cell source that has 
chondrogenic potential for cartilage repair. The present study examined whether differentiation of 
stem cells derived from human amniotic fluid (AFSCs) are proliferative and increase gene 
expression and protein production of extracellular matrix (ECM) components in agarose culture 
after treatment with growth factors (TGFb1 and TGFb3) and/or agents which promote natriuretic 
peptide signalling (CNP, Dex). Following short (up to 7 days) and long-term culture (28 days) of 
AFSC/agarose constructs, markers for ECM synthesis (GAG, collagen, DNA) were quantified by 
biochemical assay. Proteoglycan and collagen distribution profiles of AFSC/agarose constructs 
were examined with Alcian blue staining of histological specimens and by second harmonic 
generation (SHG) confocal imaging. The gene expression of SOX-9, aggrecan and Type II 
collagen was examined by RT-qPCR.  
In addition, the development of sophisticated scaffold materials which release biologically 
active agents to incorporated cells is an increasing area of scientific research for tissue 
engineering applications. In separate experiments, I investigated whether the application of CNP 
containing microcapsules to bovine chondrocyte/agarose constructs over a 48-hour time period 
constituted any effect to the GAG synthesis of encapsulated cells compared to exogenous 
application of CNP. CNP microcapsule structures were characterised via SEM and confocal 
microscopy and markers for ECM synthesis (GAG, DNA) were quantified by biochemical assay.  
GAG synthesis was not stimulated in TGFb treated AFSCs embedded within alginate 
bead structures. Alginate beads also suffered from significant structural weakness after prolonged 
culture periods suggesting they were unsuitable for the chondrogenic differentiation of AFSCs. 
Co-treatment of AFSC/agarose constructs with either CNP + TGFb1, CNP + TGFb3 or Dex + 
TGFb1 enhanced GAG synthesis (p<0.01) but not collagen synthesis compared to growth factor 
only conditions after 28 days (p>0.05). Weak positive homogenous histological staining was 
detected in co-treated samples at both core and edge sections of constructs while SHG imaging 
confirmed some collagen deposition in co-treated samples at the core of constructs investigated. 
SOX-9, aggrecan and type II collagen gene expression were unaffected by all treatments 
investigated after 28 days relative to day 0 (all p>0.05). Treatment of bovine chondrocyte/agarose 
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constructs with CNP microcapsules enhanced GAG synthesis relative to exogenous application 
after 48 hours (p<0.01). 
In summary, I demonstrate significant upregulation of GAG synthesis but not collagen in 
AFSC/agarose constructs stimulated with TGFb1/3 and Dex or CNP for 28 days but not 7 days. In 
addition, I also show that localised release of CNP is conducive to enhanced GAG synthesis in 
bovine chondrocyte/agarose constructs after 48 hours relative to exogenous application. The lack 
of a substantial increases in GAG synthesis upon chondrogenic growth factor treatment in 
conjunction with CNP or dexamethasone suggest that AFSCs may not be suitable for a cartilage 
tissue engineering in comparison to other stem cells types. This would therefore have an obvious 
impact on the use of AFSCs for cartilage engineering field but may have ramifications for their 
use in other tissue engineering fields. Future investigations should focus build upon the 
investigations carried out here with a focus on the effect of CNP on hypertrophic/osteogenic gene 
expression in AFSCs and the effect of CNP microcapsules on the process of AFSC chondrogenic 
differentiation. 
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Chapter 1: Cartilage structure, pathology and 
tissue repair 
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1.1 Anatomical features and functions of healthy articular cartilage 
Hyaline articular cartilage is a specialised connective tissue that covers the opposing 
osseous ends of bones in the synovial joint (Fox et al., 2009, Mow et al., 1992). The main functions 
of cartilage are to distribute loads, minimise the peak stresses in the subchondral bone, and 
provide a load-bearing surface with minimal friction and wear (Guilak, 2005, Mow et al., 1992, 
Mow and Guo, 2002). Cartilage is not innervated and is avascular which, combined with a low 
chondrocyte cell density, explains why the tissue exhibits limited repair capacity when damaged 
after injury or affected by inflammatory disease (Hunter, 1743). The location of articular cartilage 
in the synovial joint is illustrated in Figure 1.1. 
 
 
 
 
 
 
 
 
 
 
 
 
The most distinguishing features of healthy cartilage are that the tissue appears to be 
relatively smooth and thin, between 2.2 to 2.5 mm thick, and is primarily white turning marginally 
yellow with age (Frisbie et al., 2006). Cartilage has unique viscoelastic and compressive 
properties provided by the extracellular matrix (ECM) and complex interplay of chondrocytes. The 
presence of nutrients in the synovial fluid and biological factors are transferred to the cells by 
diffusion from the synovial fluid.  
 
 
Fibula 
Femur 
Collaterale tibiale 
lig. 
Epicondylus medialis 
Meniscus medialis 
Tibia 
Patella 
A B 
Figure 1.1: Healthy articular cartilage allows smooth articulation. Anatomical schematic of knee 
articular joint as a side view of the femoral condyle (A) and a frontal view of a healthy human joint (B). 
Figure adapted from (Tillmann, 2005, Peters et al., 2018). 
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1.2 Structure and composition of articular cartilage 
The extracellular matrix has a unique constitution dictated by environmental conditions, 
cellular components and genetic disposition. The ECM is mainly composed of water (60 - 80%), 
type II collagen (10 - 20%), proteoglycans (4 - 7%) and glycoproteins (< 5%) (Fox et al., 2009, 
Ratcliffe and Mow, 1996, Mow et al., 1992). In contrast, chondrocytes contribute to only 1 - 10% 
of the total tissue volume and are responsible for the synthesis and maintenance of the matrix 
components (Kim et al., 2008, Muir, 1995, Ratcliffe and Mow, 1996). The composition of the ECM 
and its complex interactions with chondrocytes give the tissue its load-bearing capacity and in the 
presence of the synovial fluid, its lubrication and frictionless properties (Mov, Ratcliffe, Poole, 
1992). Chondrocytes exist in a unique physiological and mechanical environment in the ECM and 
exhibit different sizes, shapes, and metabolic activity in the various zones of cartilage. In fact the 
surrounding ECM limits the number of possible cell-to-cell contacts and also means the cells rely 
on diffusion from the synovial space for their nutritional supply (Cavanaugh, 2007). The cell/ECM 
network is therefore able to help regulate important biological processes such as cell proliferation, 
metabolism, mechanotransduction, ECM synthesis and tissue remodelling mechanisms in an 
effort to maintain tissue homeostasis (Loeser, 2014, Gelse, 2003).  
1.2.1 Collagens 
Collagens are a family of extracellular structural proteins with at least 26 genetically 
distinct chains and are the most abundant fibrous protein within the ECM, accounting for up to 
two thirds of articular cartilage dry mass (Frantz et al., 2010, Luo et al., 2017, Eyre, 2004). Type 
II collagen represents 80 - 95% of collagen subtypes with the remaining subtypes identified as I, 
V, VI, IX, XI. Type II collagen consists of three identical α1 (II) polypeptide chains wound together 
into a left handed helical pattern and then further wound around each other into right handed 
helices to produce chains of approximately 300 nm length, 1.5 nm diameter and 1000 amino acids 
(Figure 1.2) (Gelse, 2003, Wu et al., 1987).  The collagen network contributes to the tensile 
strength and torsional stability of the ECM but also help to regulate cell adhesion and support 
tissue development. This is achieved by interaction between collagens and specific receptors 
such as glycoprotein VI and integrins.  
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In the initial stages of collagen synthesis, since most genes that encode collagen follow 
a complex exon-intron pattern, several messenger ribonucleic acid (mRNA) species can be 
identified, transcribed at different initiation sites and alternatively spliced; a feature first described 
in type II collagen (Ryan MC, 1990). The events of collagen synthesis within the cell are 
summarised in Figure 1.3. Firstly, the pre-mRNA is capped at its 5’ end with polyadenylation 
occurring at the 3’ end whereby it is termed ‘mature mRNA’. This mature mRNA is then delivered 
to the cytoplasm by ribosome binding for translation within the rough endoplasmic reticulum 
(RER). Once the signal peptide is removed from the N terminus via single peptidase, the 
procollagen molecules are modified post translationally; for example hydroxyprolation of lysine 
and proline residues. This post translation modification is essential for the collagen fibrils ability 
to form stable intramolecular hydrogen bonds which can help crosslinking of other collagen 
molecules and the attachment of carbohydrate chains.  C-propeptide allows the assembly of the 
3 α chains together, allowing the C terminals of the chains to align and initiate the triple helix 
formation up to the N terminus. Heat hock proteins such as HSP47 are essential to ensure correct 
folding of the procollagen chains (Clarke et al., 1991) whilst inter/intra disulphide bonds between 
the molecules are regulated by protein disulphide isomerase (Lang et al., 1987). Once the 
Collagen 
molecule 
Collagen 
microfibrils 
Collagen 
fibrils 
300 nm 
1.5 nm 
crosslinks 
Multiple microns 
80-100 nm 
67 nm 
α2 helix 
α1 helix 
Figure 1.2: Collagen fibril construction. Each individual collagen helix is arranged in a staggered array 
with 40 nm gaps between N and C termini of other linear helices to form collagen fibrils. Adapted from 
(Schwarcz et al., 2017). 
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procollagen structure has been assembled, the structure is transferred to the Golgi apparatus 
where it can be transported to the extracellular space via secretory vesicles (Figure 1.3). Here, 
C and N terminal propeptides are cleaved via N proteinase and C proteinase. Once complete, the 
collagen fibrils then self-assemble based on hydrophobic and electrostatic interactions of the 
collagen monomers which are stabilised by further covalent crosslinks. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2.2 Proteoglycans 
Proteoglycans consist of glycosaminoglycan (GAG) side chains covalently bound around a 
protein core. In cartilage, proteoglycans can be broadly divided into three families based on their 
core proteins, composition and localisation. These families are: 
• Small leucine rich proteoglycans (SLRPs) such as decorin + biglycan (class 1), lumican 
+ fibromodulin (class 2) and epiphycan (class 3). 
• Lecticans such as aggrecan, versican and perlecan. 
• Cell surface proteins such as betaglycan, glypican and syndecan 4. 
Figure 1.3: Collagen synthesis inside the cell. Collagen gene expression triggers the transcription 
of messenger RNA and release from the nucleus. Subsequently, it is modified within the rough 
endoplasmic reticulum (RER) before packaging within the Golgi apparatus into secretion vacuoles 
which are released into the pericellular matrix where they can be further modified and reside or diffuse 
to other regions of the tissue. Figure from (Gelse, 2003). 
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Importantly, proteoglycans possess covalently attached highly anionic GAG (Yanagishita M., 
1993). The sulfate and carboxyl groups on the GAG chains can become ionised due to the 
distance between the charged groups; approximately 1 - 1.5 nm. A strong opposite charge 
repulsion is produced which attracts water molecules into the tissue and causes the cartilage 
tissue to swell. This effect contributes to the compressive stiffness of cartilage up to as much as 
50%. 
Aggrecan is the predominant proteoglycan found within hyaline cartilage consisting of 
covalently attached chondroitin sulfate and keratin sulfate surrounding a core protein structure in 
a bottle brush configuration (Figure 1.4). However, they do not exist on their own but rather form 
aggregates based around a central filament of hyaluronan (HA) via non-covalent attachments 
stabilised by link protein. HA is synthesised within the cytosol of the cell aided by hyaluronan 
synthase at the plasma membrane where it is released from the cell directly to the pericellular 
environment of the chondrocyte (Hubbard et al., 2012, Knudson et al., 2000, Knudson and 
Knudson, 2001). Once bound by link protein, this unique connection between aggrecan and 
hyaluronan is non-dissociating and non-displaceable under physiological conditions and as a 
result represents the principal load bearing proteoglycan of cartilage (Wight et al., 2010). The 
aggrecan gene is made up of 19 exons, with different exons encoding different regions of the 
aggrecan structure (G1: exons 3 - 6, G2: 8 - 10 and G3: 13 - 19) (Roughley and Mort, 2014). The 
core protein of aggrecan is made up of 3 globular regions that are responsible for different 
interactions. The G1 region is responsible for the interaction between HA and link protein whilst 
the G3 region plays more of a trafficking function. Between the G2 and G3 domains, 
glycosaminoglycans are able to bind depending on the domains exposed (Zheng et al., 1998). 
For example, immediately after the G2 domain is a proline-serine sequence which can attach O-
linked oligosaccharides such as those of the linkage region on the GAG keratin sulfate. Following 
this region is the chondroitin sulfate domain where up to 100 chondroitin sulfate chains can bind. 
Importantly for cartilage disease, aggrecan possesses domains that are sensitive to protease 
cleavage (between G1 and G2). Once cleaved, these fragments contain neo-epitopes such as a 
distinegrin and metalloproteinase with thrombospondin motifs-1 (ADAMTS-1), matrix 
metalloproteinase-8 (MMP-8) and ADAMTS-4 which have been implicated in osteoarthritis (OA) 
pathogenesis (Knudson and Knudson, 2001).  
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1.3  Zonal arrangement of cartilage 
The composition of cartilage varies with depth and can be categorised into four zones 
called the superficial, transitional, deep and calcified layer (Figure 1.5) (Hardin et al., 2015, Fox 
et al., 2009, Mow et al., 1992). The superficial zone has an outer layer called the lamina splendens 
and consists of densely packed collagen fibres within a gel like ECM with fibres orientated parallel 
to the articulating surface (Rexwinkle et al., 2017). The superficial zone protects the tissue from 
shear stress, aided by type II and type IX collagen that align parallel to the articular surface in a 
tangential network arrangement. The chondrocytes within this layer have an ellipsoidal 
morphology with low proteoglycan levels (Wong et al., 1996). 
In the middle layer or transitional zone, the collagen fibrils are thicker and the water 
content within the layer is lower when compared to the superficial layer. The chondrocytes have 
a rounded morphology with low cell density and a high proteoglycan content. The collagen fibres 
are aligned obliquely to the surface in an intersecting transitional network which contributes to the 
resistance to compressive and shear forces. Below the transitional layer lies the deep zone which 
gives the tissue its greatest resistance to compressive force primarily due to the perpendicular 
alignment of collagen fibres and columnar orientation of the chondrocytes to the articular surface. 
Here the collagen fibres have the largest diameter with an average of 108 nm compared to 55.8 
nm and 87.5 nm in the superficial and transitional zones respectively, the greatest level of 
proteoglycan components and the lowest volume of water (Changoor et al., 2011, Schenk et al., 
1986). Beneath this layer is what is known as the deep calcified zone which represents a transition 
Figure 1.4: Aggrecan monomer structure aids 
the formation of large aggregates. Aggrecan 
globular regions (G1, G2 and G3) are bound around 
a core protein. Link protein (LP) binds the G1 domain 
to hyaluronan (HA) and stabilises the structure. 
Different glycosaminoglycans can bind between G2 
and G3 domains creating an overall mass of 1 - 4 x 
106 Da. Adapted from (Roughley and Mort, 2014). 
GAGs 
Core 
protein 
Aggrecan 
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between the deformable cartilage and the hard bone below, represented by an undulating 
tidemark (Mow et al., 1999, Pearle et al., 2005). The calcified zone offers a much denser 
mineralised region than that of the subchondral bone beneath it in order to uniquely transfer and 
distribute the mechanical forces experienced during physiological loading which is attenuated by 
the overlying cartilage (Goldring and Goldring, 2016). 
 
 
 
 
 
 
 
 
 
 
There are also regional divisions based on the proximity to the chondrocyte that are 
responsible for signal transduction in the pericellular matrix and mechanical stress protection in 
the territorial matrix and the inter-territorial zone (Figure 1.6). The pericellular matrix consists of 
type VI collagen and high concentrations of proteoglycans which are tightly woven around the 
chondrocyte to form the basic metabolic unit of hyaline cartilage; the chondron (Poole, 1997, 
Wang et al., 2008). The territorial matrix consists of thicker collagen fibres in an effort to protect 
the cells from loading whilst the inter-territorial zone contains the thickest collagen fibres 
responsible for the visual differences observed between collagen fibre alignments when looking 
at histological sections. Chondron shape, size and orientation are dependent on the zone where 
they are observed with chondrons located within the superficial layers taking on a much more 
discoidal shape compared to those within the deep zone where they are perpendicular to the 
articular surface and much more rounded (Thompson, 2013). The chondrocyte is able to interact 
with the pericellular matrix via cell surface integrins (Poole, 1997). However, the pericellular matrix 
Hyaluronic acid Aggrecan 
monomer 
Link protein 
Superficial zone 
Middle zone 
Deep zone 
Tide mark 
Calcified cartilage 
Subchondral bone 
Elastin fibre 
Collagen fibre 
Chondrocyte 
Figure 1.5: Zonal and regional constitution of articular cartilage. H&E (A) and Safranin O (B) staining 
demonstrate how proteoglycan content and cell distribution change with cartilage depth. D) Collagen and 
elastin fibre arrangement change with tissue depth (dashed lines). Figure from (Bo et al., 2014). 
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itself is important to prevent resting chondrocytes from interacting abnormally with components 
present in the inter-territorial and territorial zones. In doing so, the cells are maintained in their 
differentiated, low turnover state vital for cartilage homeostasis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6: Schematic showing the interactions of the pericellular matrix with ECM proteins and 
chondrocytes. Pericellular matrix shields the chondrocyte from overstimulation in response to growth 
factor stimulation, integrin stimulation and ionic channels. In this way, the pericellular matrix is integral 
for maintaining cartilage homeostasis and ECM tissue remodelling. Figure from (Guilak et al., 2018). 
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1.4  Chondrogenic differentiation in development 
The process of chondrogenesis is a multistep complex pathway with the molecular events 
largely contradictory and unclear. Mouse embryonic stem cells are commonly used to study the 
differentiation processes because the in vitro differentiation process closely recapitulates what 
occurs during early human embryonic development. In broad strokes, lateral plate mesoderm 
segments into structures called somites whereby the mesenchymal stem cells (MSCs) commit to 
the chondrogenic lineage within the vertebral skeleton in a process referred to as endochondral 
bone formation (Figure 1.7). During this phase, the mesenchymal condensates formed from MSC 
aggregation begin to express a range of ECM and cell adhesion molecules including collagen 
type IIa, N-cadherin, N-cam, tenascin C and most importantly the transcription factor known as 
SOX-9. This gives rise to what is known as the cartilage primordia, with the cells taking on a round 
phenotype; indicative of immature chondrocytes.  
Within the central region of the cartilage primordia the cells undergo further maturation 
and withdraw from the cell cycle becoming enlarged and begin to mineralise; indicating a 
hypertrophic post mitotic progression. On either side to this area, chondrocytes start to proliferate 
in a unidirectional manner along the longitudinal axis of the long bone. As the cartilage grows 
longitudinally, hypertrophic chondrocytes are gradually deposited. These hypertrophic 
chondrocytes then differentiate further to contribute to the primary ossification centre whereby 
vascular invasion can occur and bone eventually forms. Mature chondrocytes are then restricted 
to the bone surface (epiphysis) to become what is known as the growth plate. At puberty, an 
increase in the number of apoptotic events within the growth plate gradually causes lengthening 
of the long bone to decrease as the growth plate is slowly replaced with bone until only a surface 
layer of cartilage lining the bone is left. 
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It is in these different regions of the developing bone where the distinct differences in 
chondrocyte maturation become evident as a result of complex interactions between hormones, 
growth factors and other signals. This is most notably seen in regard to the changes in gene 
expression that occur (Figure 1.8). Immature chondrocytes express key transcription factors 
SOX-5, SOX-6, SOX-9, COL2a1 and aggrecan. Mature chondrocytes then begin to also express 
an alternate splice form of type 2 collagen known as COL2b1 as well as fibroblast growth factor 
receptor 3 (FGFR3) at low levels. Pre-hypertrophic chondrocytes begin to express markers and 
peptides such as parathyroid hormone related peptide 1 (Pth1r), alkaline phosphatase (ALP), 
Indian hedgehog (Ihh), Runx2 and Osterix further aiding differentiation and future mineralisation 
which controls bone growth (Hegert et al., 2002). Early hypertrophic chondrocytes express 
COL10a1 with a loss of the transcription factors associated with immature chondrocytes. Late 
stage hypertrophic chondrocytes then lose expression of COL10a1 and begin to express vascular 
endothelial growth factor-A (VEGF-A) and matrix metalloproteinase 13 (MMP-13) which indicate 
Figure 1.7: Endochondral bone formation. A: Mesenchymal stem cells proliferate and form 
condensates which differentiate into chondrocytes and an early analgen to the eventual bone structure. 
B: Within the centre of the structure some chondrocytes undergo further maturation which sees an 
increased proliferation occur before the cell’s withdrawal from the cell cycle, indicating hypertrophy. 
Vascular invasion forms a marrow cavity. Cartilage resorbtion and osteoid deposition begins. C: 
Columns of chondrocytes in the growth plate begin to proliferate outwards, become hypertrophic and 
eventually mineralise their ECM which gradually extends the bone structure. The mineralised ECM is 
then replaced with new bone over time until the growth plate fuses. Figure from (Teixeira et al., 2008). 
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their transference into an osteoblast precursor which work together with osteoclasts to help 
remodel bone and enhance vascularisation. Terminally differentiated hypertrophic chondrocytes 
also express MMP-13 to control degradation of the cartilage matrix required for creation of the 
bone marrow space. Despite the broad knowledge already achieved in this area, the control 
mechanisms which govern these gene expression changes are still not completely understood. 
Investigations into events where this process goes wrong enable us to further understand and 
decipher the complex events that are occurring. One important factor which has gained 
considerable attention regarding its role as an important regulator of endochondral ossification 
and abnormal development is C-natriuretic peptide (CNP). The significance of CNP in 
endochondral bone formation and in cartilage tissue homeostasis is described in further detail in 
Chapter 1.9. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8: Changes in gene expression with chondrocyte maturation. Chondrocytes undergo 
extensive genetic changes as they develop to fulfil specific roles within the developing bone. 
Chondrocytes maintain SOX-9 gene expression for ECM production. However, SOX-9 expression 
is lost by hypertrophic chondrocytes and osteogenic cells. Figure from (Zuscik et al., 2008). 
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1.5 Osteoarthritis 
Osteoarthritis is a progressive degenerative joint disease characterised by the breakdown 
of articular cartilage. This is a different disease to that of rheumatoid arthritis (RA) which is defined 
as an autoimmune condition characterised by chronic inflammation of multiple synovial joints. The 
risk of developing OA increases with age with over half of people over the age of 75 seeking 
treatment for OA in the UK (Arthritis Research UK, 2013). Geriatric individuals or those who live 
sedentary lifestyles due to obesity, joint abnormalities, occupation or disability are primarily 
affected by this disease. Overweight (with an average BMI of 28.8) and obese (with an average 
BMI of 31.0) people are 2.5 and 4.6 times more likely respectively to develop OA relative to those 
of a normal body weight (Huaqing and Changhong, 2015, Kearns et al., 2014, National Joint 
Registry, 2017). 4.11 million (18.2%) adults who are aged over 45 in England have OA affecting 
the knee, with an estimated 8.75 million (33% of the UK population) seeking treatment for OA 
(Arthritis Research UK, 2018). Treating the most common forms of OA along with rheumatoid 
arthritis (RA) costs the UK’s national health service £10.2 billion in direct costs (healthcare 
prescriptions and home care), whilst over the next decade the total cost of healthcare for this 
disease is estimated to reach £118.6 billion (York Health Economics, 2017). In terms of the UK 
economy, the cost attributed to the number of working days lost to OA is estimated at £2.58 billion 
in 2017, with that number increasing to £3.43 billion by 2030 (York Health Economics, 2017). A 
sex difference is also present (Figure 1.9), with women accounting for 60% of knee replacements 
in the UK, of which 90% were due to OA (National Joint Registry, 2017).  
 
 
 
 
 
 
 Figure 1.9: Effect of age on osteoarthritis incidence in the UK. Each figure represents 1 million people 
with orange indicating OA sufferers. Figure from (Arthritis Research UK, 2013). 
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1.5.1 Mechanisms/pathophysiology 
Joint tissue integrity can be affected either through an acute injury or progressively over 
time via cell/matrix derived factors that result in an alteration of composition, structure and 
material properties of the tissue. Whilst individual issues can be selectively affected, due to the 
intimate functional association between tissues within the articular joint, OA is commonly 
accepted as a disease that affects all joint structures (Loeser et al., 2012).  As no single cause of 
the disease has been identified to date, studies in animals and analysis of specimens from 
patients suffering from OA have enabled scientists to establish a general sequence of pathological 
progression (Figure 1.10 and 1.11).  
 
 
 
 
 
 
 
 
Initially, changes to the water content of articular cartilage are observed due to a loss of 
proteoglycans within the tissue resulting in a swelling of the ECM (Figure 1.11). This loss of 
proteoglycans is mediated by aggrecanses of the ADAMTS family which are responsible for the 
cleavage of the aggrecan core protein. This results in a disruption of interactions between 
aggrecan and surrounding collagen networks making them more susceptible to degradation by 
MMPs or by physical forces. Fibrillations within the superficial layer start to form which progress 
to deep fissures as cartilage fragments exfoliate, delaminate and ultimately result in the exposure 
of the calcified cartilage and subchondral bone layers. Duplication of the tidemark, which 
separates calcified cartilage from underlying articular chondrocytes, occurs with the zone of 
Osteoarthritis 
Articular  
Healthy 
Articular 
cartilage 
Tidemark 
duplication 
Subchondral 
cortical bone 
Vascular 
invasion 
Surface 
fibrillation 
fissuring 
Chondrocyte 
proliferation 
Chondrocyte 
hypertrophy 
Tidemark 
cartilage 
Figure 1.10: Characteristics of damage to cartilage during osteoarthritis.  Osteoarthritic cartilage 
contains lesional areas in which the tissue has been degraded. The tissue is also much more yellow in 
appearance than younger cartilage although this is commonly observed as cartilage increases with 
age. The loss of cartilage in load bearing areas of the tissue causes significant discomfort for the patient 
when performing basic movements. Figure from (Goldring et al., 2016). 
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calcified cartilage gradually expanding and replacing the overlying articular cartilage. Microcracks 
that form at the osteochondral junctional are penetrated by vascular elements, sympathetic and 
sensory nerves. Bone then forms around these channels resulting in a resurgence of the 
endochondral ossification process.   
Chondrocytes themselves undergo dramatic phenotypic changes throughout the 
progression of OA attributed to abnormal mechanical loading which both directly damages the 
cells themselves but also alters chondrocyte function through interaction with their cell surface 
mechanoreceptors (Goldring and Goldring, 2016). Chondrocytes initially increase their ECM 
synthesis activity in an attempt to repair the developing damage as shown by an increase in 
proteoglycan staining around cells during early stage OA (Lorenzo et al., 2004). However, the 
disruption of the chondrocyte pericellular matrix deregulates chondrocyte function via surface 
receptors integrins and discoidin domain receptors (DDR2) interaction with surrounding ECM. As 
the ECM becomes more depleted, chondrocytes appear in clonal clusters suggesting that a shift 
in the chondrocyte low turnover rate has occurred resulting in proliferation. However, at late 
stages of OA chondrocyte density decreases, likely a result of apoptotic events indicated by the 
presence of cell membrane ‘ghosts’ and fragmented chondrocyte nuclei. Of the chondrocytes that 
remain, an increased number demonstrate features of a senescent associated secretory 
phenotype. This is characterised by the production of MMPs, reactive oxygen species (ROS), 
angiogenic factors and pro-inflammatory cytokines which aid in the endochondral ossification 
process. To redress this imbalance, an increase in ‘tissue inhibitor of MMPs’ (TIMPs) is observed 
but they are insufficient to match the catabolic processes resulting in the typical cracking and 
fissuring of the cartilage associated with the disease.  
The breakdown of the ECM, as a result of the degradative enzyme release from 
chondrocytes, also results in the production of cartilage matrix breakdown products such as 
damage associated molecular patterns (DAMPS) and alarmins. These products can directly affect 
chondrocyte function thorough their surface receptors but are also capable of inducing 
inflammation within nearby synovial tissue. Synovitis induction results in hyperplasia and 
perivascular infiltration of T and B lymphocytes which themselves produce pro-inflammatory 
products (Goldring, 2010, Man and Mologhianu, 2014). The release of such pro-inflammatory 
products can then feedback to the remaining chondrocytes and enhance their catabolic state; 
essentially forming a positive feedback loop. In terms of subchondral bone changes, cortical plate 
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thickness and volume increases are observed whilst subchondral trabecular bone demonstrates 
marked architectural changes. Bone turnover is directly affected, resulting in changes to the 
mineralisation of the bone and its ability to deform under load. Osteophyte and bone cyst 
formation within the tissue eventually leads to flattening and deformation of the subchondral 
articular contour resulting in bone attrition (Figure 1.11). In areas of denuded cartilage, bone 
marrow lesions are common since the protection offered by the overlying cartilage to distribute 
mechanical forces is lost leading to excessive loading of the subchondral bone (Madry et al., 
2010).  
Whilst OA is often regarded as a non-inflammatory disease, there remains a large number 
of animal and human studies which indicate that treatments targeting pro-inflammatory cytokines 
and inflammation in joints have positive effects. IL-1β and TNFα are considered the main pro-
inflammatory cytokines involved in OA by driving cartilage destruction and inflammatory cascades 
respectively. Sources for these cytokines are abundant as they are produced by chondrocytes, 
osteoblasts, synovial tissues and mononuclear cells. Detectable increases in IL-1β and TNFα 
have been shown in the synovial fluids, subchondral bone and cartilage of human joints (Saha et 
al., 1999). TNFα also can induce osteoclastic bone resorption in vitro, which may be responsible 
for subchondral bone remodelling (Bertolini et al., 1986) 
17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C F 
G 
H E 
D 
A B 
Figure 1.11: The sequential changes 
associated with the evolution of 
knee OA. 
A: Schematic demonstrating the layers 
of cartilage  
B: Healthy articular cartilage  
C: Tissue water content increased 
leading to enhanced chondrocyte 
metabolic activity.  
D: Surface fibrillations and microscopic 
cracks develop within the superficial 
zone. Subchondral bone remodelling 
also occurs increasing tissue porosity.  
E: Loss of proteoglycans and collagen 
from the ECM results in deep fissure 
formation into the deep zone  
F: Delamination of superficial cartilage 
progressing towards exposure of 
calcified cartilage and subchondral 
bone.  
G+H: Hyaline cartilage eroded. 
Osteophyte and cyst formation within 
the subchondral bone results in bone 
attrition process. Microfracture repair 
attempted by fibrocartilage deposition 
within surface gaps. Contour of 
articular surface completely altered. 
Chondrocyte apoptosis evident with 
surviving cells adopting a hypertrophic 
phenotype. Safranin O stain used, 
images taken at x5 magnification. 
Images derived from (Pritzker et al., 
2006). 
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1.6  Treatment strategies 
As diseases of the joints are painful and affect a growing proportion of the population due 
to increases in life expectancy, interventions for pain relief and disease-modifying therapy for OA 
are imperative. However, without a clear understanding of how diseases such as OA are caused, 
attempts to prevent the disease progression are limited. To this end, the majority of current drug 
treatments are aimed at delivering pharmacological agents to treat pain and maintain function of 
the joint. Unfortunately, due to the avascular nature and density of the tissue, the delivery of 
therapeutic agents to provide pain relief or disease treatment are extremely difficult. Also, 
evaluation of non-surgical interventions often suffer from poor methodology and small sample 
sizes (Lue et al., 2017). Despite this, there is increasing success in using agents to modify the 
disease, enhance the native cells resistance to disease progression or the generation of healthy 
tissue within the laboratory. 
1.6.1 Cytokine and receptor antagonists 
The presence of TNFa has also been associated with an inhibition of proteoglycan, link 
protein and type II collagen synthesis (Saklatvala, 1986, Seguin and Bernier, 2003). Indeed, an 
overproduction of TNFa also results in upregulation of MMP expression (Dayer et al., 1985). 
TNFa has been utilised successfully as a key target for the treatment of rheumatoid arthritis (RA) 
due to its high level of expression in RA affected joints (Rau, 2002). Further to this, levels of TNFa 
have also been shown to be elevated in the synovial fluid and serum of OA affected joints 
compared to healthy individuals (Hulejova et al., 2007, Smith et al., 1997). However, despite the 
successful use of anti TNFa therapeutics for RA such as adalimumab, the effect on OA affected 
joints have provided generally disappointing results. Further to this, the outcomes of the studies 
have generally focused on pain relief rather than identifying the effect of the drug on disease 
progression. For example, an open label Phase I/II trial of adalimumab published in 2012 by 
Maksymowych et al, showed significant improvements in joint pain through Western Ontario and 
McMaster Universities Osteoarthritis index (WOMAC) assessment, yet assessments such as joint 
space narrowing (JSN) to determine whether the treatment actually affects disease progression 
were not performed (Maksymowych et al., 2012). Therefore, further larger studies with JSN 
incorporated into the study assessments and a homogenous OA patient cohort would be desirable 
to further investigate the use of adalimumab and other anti TNFa treatments for OA. 
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Elevated levels of IL-1b are often observed in the synovial fluid of humans and animal 
models of OA. Since IL-1b stimulates the production of matrix breakdown agents such as MMPs 
whilst also causing a reduction in proteoglycan synthesis, it is likely that targeting IL-1b production 
should improve OA symptoms and reduce progression. However, whilst IL-1 receptor antagonists 
(IL-1Ra) have shown improvements in animal models of OA in terms of cartilage preservation, 
these effects in humans trials have been difficult to replicate or sustain (Chevalier et al., 2009, 
Cohen et al., 2011). One of the successful human clinical trials targeting IL-1b was the 
Canakinumab Anti Inflammatory Thrombosis Outcomes Study (CANTOS) published in 2017. Post 
hoc analysis of the results from this clinical study showed that incidence rates of total knee 
replacements, total hip replacements and OA symptoms were reduced upon treatment with 
different doses of the human antibody canakinumab which targets the IL-1b pathway compared 
to placebo (Ridker et al., 2017). Further responder analysis of this data is ongoing. One 
explanation as to why many human trials have difficulty demonstrating an effect of a particular 
treatment like IL-1b targeting is due to the method of assessing pain in OA patients. Since pain is 
a subjective method of assessment that differs between individuals, determining whether the 
effect of a treatment is having a significant effect is extremely difficult and may contribute to the 
lack of statistical differences observed in many of these studies. Clinical safety of these drugs 
also needs to be carefully controlled since one fully human monoclonal antibody investigated as 
an antagonist of IL-1 receptor type I was also associated with a decrease in neutrophil count 
which could have significant clinical implications for patients if not localised to the articular joint 
(Hernandez et al., 2015). IL-1 Ra therefore are likely most useful for patients with severe OA, 
whereby the pain relief and structural benefits offered by the treatments are most desirable. 
Nerve growth factor (NGF) is a key player in modulating the expression of pain related 
substances released peripherally and centrally within the nervous system whilst also sensitising 
nociceptors adjacent to areas of inflammation (Shang et al., 2017). Inflammatory markers such 
as IL-1b and mechanical overloading are known to increase the levels of NGF whilst increased 
levels of NGF are also detected within the synovial fluid of diseased OA joints compared to non-
diseased joints. Together this evidence serves to suggest NGF as a potential target for disease 
treatment (Aloe et al., 1992). Selective antibodies against NGF such as tanezumab have 
demonstrated significant effects at reducing OA associated knee pain, physical function and 
stiffness in 450 patient study compared to placebo (Lane et al., 2010). However, it has also been 
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associated with significant safety issues including osteonecrosis, rapidly progressive and 
destructive OA and subchondral bone fractures (Food and Administration 2015). The exact cause 
of these effects is not known currently. However, it has been associated with several different 
explanations including the pharmacological profile of the drug, unknown effects of inhibiting of the 
NGF pathway or the fact that the pain relief offered allowed the patients to utilise their joints more 
intensively than before which results in greater wear and tear of the already damaged cartilage 
present. Its efficacy and ability to improve pain and function of OA patients means that tanezumab 
must be studied more intensively. 
With the identification of key pathways such as TGF and Wnt/b-catenin signalling 
pathways in OA, efforts to develop a disease modifying osteoarthritis drug have been approached 
in earnest. In mouse models, inhibitors of MMP13 and ADAMTS-5 effectively demonstrate a 
reduction in cartilage destruction progression, ECM production enhancement and a reduction in 
chondrocyte apoptosis (Wang et al., 2013, Chen et al., 2014). Whilst these findings show extreme 
promise, the inability to reproduce these effects in humans is troubling. MMP inhibition in 
particular has been linked with musculoskeletal toxicity in humans, restricting its use for clinical 
application (Krzeski et al., 2007). Since direct inhibition of these targets might cause unintended 
events, it might be advantageous to try and target upstream effectors or administer directly into 
the articular joint. For example, syndecan 4 is a regulator of ADAMTS-5 and therefore has 
potential to prevent its activation and consequently disease progression. 
1.6.2 Surgical interventions 
There are significant limitations and prolonged clinical trials required to fully evaluate the 
efficacy of pharmacological interventions. Because of this, other established methods must be 
utilised.  Autologous cell implantation repairs small articular cartilage defects by using enzymes 
to isolate chondrocytes from biopsy samples of healthy articular cartilage, expanded and then 
reinjected under an autologous periosteal flap on the defect (Brittberg et al., 1994, Cancedda et 
al., 2003). The effectiveness of this treatment is disputed and also dependent on sacrificing 
normal cartilage tissue for harvest which, by the nature of cartilage, will be slow to heal. This also 
restricts the application of this technique to small OA lesional repair since larger areas of healthy 
tissue would need to be harvested for larger defects. Surgical procedures such as bone marrow 
stimulation technique involve breaking subchondral bone to form microfractures which facilitate 
stem cell infiltration and cartilage deposition for cartilage repair. Yet these defects are typically 
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repaired with fibrocartilage (collagen type I) which do not possess the same mechanical properties 
as type II collagen leading to a focal weakness in the tissue. When mechanical forces are 
reapplied to the joint, these areas are the first to undergo further degeneration. Mosaicplasty 
involves the harvesting and implantation of cylindrical ‘plugs’ of bone and cartilage from donor 
sites which are less weight bearing. In effect, the hyaline cartilage implanted provides a more 
durable surface than the fibrocartilage often formed by implanted cells that subsequently 
differentiate or de-differentiate to a fibrocartilage phenotype. However, complications of excessive 
postoperative bleeding and thromboembolic developments can occur. 
The last resort in terms of surgical options is that of total knee replacement surgery (TKR). 
Over 700,000 TKR are performed every year in the US (Kurtz et al., 2007). However, even with 
the best man-made bearing surface such as Teflon, the coefficient of friction is much greater than 
in the normal articular joints (μ0.04 compared to μ0.01) and does not handle load very well 
resulting in a low wear product but with higher friction bearings. Over time, the body can react to 
the foreign materials present in the joint and try to break it down, as seen in circumstances where 
polyethylene wear and metallic debris accumulation is observed. If the reaction by the body is 
significant enough, granulomatous tissue masses can form which mimic those of a sarcoma 
(Mavrogenis et al., 2009). The joint would therefore need replacing and tissue masses removed 
altogether requiring the patient to undergo another intense significant surgery with the associated 
months of physiotherapy following. 
Figure 1.12: Double tricompartmental knee arthroplasty. A: The ends of the femur and tibia are removed 
and replaced with metal components with a plastic spacer between to create a smooth gliding surface. B: 
Postoperative radiographs of the right knee. Figure from(Mavrogenis et al., 2009). 
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1.6.3 Cell therapy, gene therapy and tissue engineering technology 
In order to work around the pharmacokinetic barriers of drug delivery to the articular joint, 
the use of gene therapeutics have been investigated and recently approved (Evans et al., 2018). 
cDNA delivery to cells within the articular joint encode therapeutic products (such as IL-1Ra) 
which can allow endogenous cells to synthesise therapeutic gene products on a local level. Since 
turnover of chondrocytes is low, genetic manipulation has the potential to produce long term gene 
expression compared with those which have a high turnover. One main area of concern regarding 
gene therapy is possible insertional mutagenesis and tumorigenesis especially in regard to a non-
life-threatening disease such as OA. However, recently advances have been made to use 
allogenic cells that have been irradiated to prevent cell division whilst maintaining growth factor 
synthesis. The types of viruses used are also a consideration since some viruses are too large to 
penetrate the ECM in situ. However, adeno-associated viruses (AAV) are a popular candidate as 
they demonstrate low immunogenicity, effectiveness and good safety. However, whilst the 
advances are promising, there remains a need to monitor and evaluate the results of clinical trials 
before it can be widely accepted. Only 2 gene therapies have been approved for non-lethal 
disease treatment in the world as of 2018 (Evans et al., 2018). Genetically engineered 
chondrocytes transduced to express TGFβ1 completed phase II trials within the last 3 years 
whereby the results showed significant improvements to international knee documentation 
committee score (IKDC), visual analogue scale score (VAS) and pain severity (Cherian et al., 
2015). sc-rAAV2.5IL-1Ra is awaiting Phase 1 trial following safety assessment in a mono-
iodoacetate-induced OA rat model (Wang et al., 2016). Whilst this technology would be beneficial 
to those in early stages of cartilage disease whereby lesional areas are small, larger defects or 
late stage progression OA, it will still require extensive cell culture to provide sufficient cells to 
implant. 
Although surgical interventions such as total knee replacements are commonplace now, 
the risk of surgical complications cannot be completely eradicated. Cartilage repair using cell-
based therapies offers a long-term strategy for the repair and regeneration of cartilage destruction 
caused by OA, stopping or reversing the progression of the disease as a result. Until now, 
autologous chondrocyte transplantation is the only approved cellular based therapy that can be 
used for cartilage restoration (Brittberg et al., 2003, Brittberg et al., 1994). However, the limitations 
in expanding chondrocytes ex vivo and the damage to the donor site required for this technique 
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limits its utility as a treatment for OA patients. Several seed options are available for use including 
chondrocytes (Liu et al., 2002), fibroblasts (Zhao et al., 2009), mesenchymal stem cells (MSCs) 
and induced pluripotent stem cells (iPSCs) (Lietman, 2016). Still, no consensus exists regarding 
the optimal cell source for orthopaedic tissue engineering application. 
Stem cell therapy has become an increasingly popular area of investigation for several 
reasons. Stem cells are able to differentiate into cartilage tissue, proliferate extensively in vitro, 
require no biopsy of cartilage tissue and demonstrate paracrine release of growth factors and 
cytokines beneficial to immunoregulation and reduction in inflammatory processes that play an 
important role in disease progression. Whilst the desired mechanism of action for this treatment 
is stem cell engraftment into damaged articular cartilage and direct differentiation, the mechanism 
of action has actually been poorly defined. Despite this, the field is advancing rapidly as several 
case series and clinically controlled trials have indicated positive result especially in regards to 
sustained pain relief (Davatchi et al., 2016, Orozco et al., 2013). However, MSC usage specifically 
has some notable issues. Firstly, the yield of non-committed MSCs from source tissues like bone 
marrow are quite low. This then requires the significant proliferation and differentiation procedure 
which is time consuming. MSCs extracted from donor sites can also possess different sub 
populations. Ultimately MSCs are also capable of differentiating into other lineages in an 
uncontrolled manner when exposed to inflammatory mediators (Lohan et al., 2014). 
An alternative to this is the use of adipose tissue derived MSCs due to their ubiquity and 
abundance within a mammalian organism. Since these cells can be harvested from the 
infrapatellar fat pad, they also avoid the implications posed by BM-MSC procurement. One 
reported example using adipose tissue derived MSCs for OA treatment was performed by Koh et 
al on a group of 25 patients whereby a significant improvement in WOMAC scores after 2 years 
when applied with platelet rich plasma was observed (Koh et al., 2013). However, the involvement 
of the stem cells themselves has been disputed since the group who performed this study also 
noted that the placebo (in this case platelet rich plasma only) produced the same effect (Koh and 
Choi, 2012). The main issue currently with assessing cell implantation as a therapy is the small 
number of case series available. Without larger studies involving prolonged follow up, this 
technique cannot be effectively applied to more patients than it currently is (Pas et al., 2017). 
Variation in evidence level of primary studies, inherent bias due to inadequate blinding, high risk 
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selection bias also does not offer the confidence required to the claims being made by some 
groups. 
Tissue engineering offers an alternative strategy through the seeding of chondrogenic 
cells within biodegradable scaffolds to produce tissue matching that of native cartilage for defect 
repair (Langer and Vacanti, 1993). In doing so a tissue engineered product theoretically has the 
potential to provide consistent clinical results in filling defects and repairing hyaline tissue. In order 
to be suitable for orthopaedic application, the engineered cartilage must be able to integrate with 
the healthy cartilage surrounding the defect and the underlying subchondral bone. Mechanical 
properties that match that of healthy tissue in terms of stable load distribution and 
mechanotransduction is also an essential requirement to ensure the tissue can survive the 
biomechanical forces that exists within the joint environment and to avoid strain disparity. 
Recreation of the complex zonal arrangement of cartilage is also essential to achieve this. Due 
to these lofty aspirations, no research to date has entirely mimicked these essential properties 
and structure. In particular, the sheer number of options in terms of cell types, scaffold materials 
and bioreactor setups has resulted in a lack of consensus regarding the critical components for 
successful cartilage tissue engineering. This unfortunately has resulted in an inability to move 
technologies into the clinic, although has not restricted this completely.  
Autologous mesenchymal stem cells and chondrocytes to engineer tissues with 
absorbable biodegradable materials have been described, albeit with varying success 
(Jungebluth et al., 2012, Behrend et al., 2002). In terms of tissue engineered products, there have 
been several different materials used and investigated clinically in humans including Biocart™II, 
Bioseed® C, Cartipatch, MACI, Neocart and NOVOCART. Huang et al. published a 
comprehensive review of the literature regarding the different materials summarised in Table 1.1 
(Huang et al., 2016). Each scaffold material used is fairly unique, for example a synthetic matrix 
of polyglactin 910/poly-p-dioxanone fleece is used in the case of Bioseed® C and non-synthetic 
agarose-alginate hydrogels for Cartipatch. Autologous chondrocytes are used for all of these 
products, which requires an initial surgery to take place to remove tissue for cell isolation and 
subsequent in vitro expansion before seeding within their respective scaffold materials. Variations 
in cell density requirements are also observed dependent on the size of the defects they are being 
used to treat as well as the construct preparation time as seen in the cases of Bioseed® C and 
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NOVOCART which require only 3 weeks to prepare a construct for implantation whilst Neocart 
requires 67 days for completion.  
Commonalities in surgical procedure are observed as all methods require initial 
debridement, alteration of the construct material to fit the shape, and attachment in the form of 
gluing using fibrin gel or suture. Rehabilitation times and methods are also shared, typically 
beginning with continuous passive motion physiotherapy building up to free walking exercise at 
the 3-month post op stage. Measurement of clinical benefit outcomes differs between each trial 
with the different methods of assessment including: WOMAC, International knee documentation 
committee (IKDC), magnetic resonance observation of cartilage repair tissue (MOCART), knee 
injury and osteoarthritis outcome score (KOOS), international cartilage repair society (ICRS), 
IKDC, Lysholm and Noyes, SF36, Tegner, Gillquist, VAS, Cincinnati assessment. Because of 
this, comparison of the effectiveness of particular products are difficult to make since there is no 
consensus on the method of assessment. Most importantly these products have primarily been 
investigated for their use in treating focal defects and osteochondritis dissecans. From these 
cartilage implant type technologies, there still remains an inability to show significant clinical 
benefit in comparison to older methodologies such as microfracture and mosaicplasty (Table 1.1).  
These technologies still cannot treat large defects associated with advanced disease like 
OA and have limited potential for reconstruction of entire structural units. The complications, 
safety issues and cost effectiveness of this technology require further development before they 
can provide distinct clinical gains. More recent research has started looking at the possibility of 
percutaneous injection. Self-setting cellulose-based hydrogels have previously been investigated 
in regard to repairing articular cartilage using chondrocytes and MSCs in animal models of OA 
defects (Vinatier et al., 2009). However, no clinical trials have been performed of this technology 
at the time of writing. 
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Table 1.1: Examples of the tissue engineering technologies previously used for clinical OA 
treatment. Product 
(patent) Scaffold 
Cell 
number Key findings Reference 
Biocart™II 
(08618258) 
Fibrinogen/ 
HA 
500,000/cm2 
Phase I trial (N = 8): For defects up to 8 cm2 in size 
with a maximum depth of 5 mm. IKDC score 
demonstrated improvement at 12-month follow up 
compared to baseline.  
 
Phase I trial (N = 31): For an average defect size of 
3.3 cm2 demonstrated increased IKDC and 
MOCART scores at 12-month follow up compared 
to baseline. 
 
Phase II: Unavailable currently. 
(Nehrer et al., 
2008) 
 
(Eshed et al., 
2012) 
Neocart 
Type I bovine 
collagen 
scaffold 
5 - 10 × 106 
cells/ml 
Phase I trial (N = 8): 2 year follow up showed 
significantly improved pain scores + range of motion 
compared to baseline. 66% good fill of defects. 
Phase II (N = 21): 2 year follow up significantly 
improved KOOS, IKDC, VAS scores compared to 
microfracture in 9/21 patients.  
Phase III (N = 245): compared to microfracture 
ongoing (measurements to be performed KOOS, 
IKDC and MRI). 
(Crawford et 
al., 2009) 
(Crawford et 
al., 2012) 
(Medicine, 
2015c) 
Cartipatch 
Agarose-
alginate 
hydrogel 
10 x 107 
cells/ml 
Phase II trial (N = 17): Multi-center study showed 
positives results with Cartipatch
® 
treatment. At 2 
years follow up, IKDC scores significantly improved 
compared to baseline. Arthroscope investigation 
showed normal and nearly normal tissue in 85% of 
patients but hyaline cartilage detected in only 62% 
of patients. 
Phase III (N = 58): Mosaicplasty v Cartipatch 
showed superior repair quality in mosaicplasty 
patients at 2 year follow up.  
Phase III trial comparing Cartipatch to microfracture 
discontinued. 
(Selmi et al., 
2008) 
(Medicine, 
2015a) 
(Medicine, 
2015b) 
Novocart 
Biphasic type I 
collagen 
scaffold 
1.45 x 106 
cells/cm2 
Used in over 6000 European patients. 
 
Phase I trial (N = 23): 2 year follow up showed 
NOVOCART increased IKDC, Tegner Noyes and 
MOCART compared to baseline. Complete or 
slightly incomplete filling of defect. 
 
Phase I trial (N = 41): 6.14 cm2 average defect size. 
Coupled with cancellous bone autograft showed 
improved Lysholm, Cincinnati and MOCART scores 
at 2 and 5 year follow up but graft hypertrophy 
evident in 20 - 27% of patients. 
 
3 Phase III trials ongoing. 
(Zak et al., 
2014) 
 
(Niethammer 
et al., 2014, 
Pietschmann 
et al., 2012, 
Zak et al., 
2014) 
MACI 
Decellularized 
porcine 
peritoneal 
tissue 
0.5 - 1 x 106 
cells/cm2 
Phase III trial (N = 144): for lesions of >3 cm2. KOOS 
scores higher in MACI group than microfracture at 2 
year follow up with no failures registered in MACI 
treated group. 
 
Phase III trial (N = 60): Lysholm, Tegner and ICRS 
scores improved compared to microfracture at 2 
year follow up. 
 
Phase III trial (N = 91): MACI compared to ACI with 
collagen sponge showed no differences after 1 year 
but fibrocartilage development in MACI biopsies 
(36%). 
 
Phase III trial (N = 21): 91% of patients had 
improved clinical scores but 9% failed. 76% 
possessed normal defect filling.  
(Saris et al., 
2014);  
 
(Basad et al., 
2010);  
 
(Bartlett et al., 
2005); 
 
 (Ebert et al., 
2011). 
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1.7 Challenges associated with producing tissue engineered cartilage 
One of the main issues with any attempt to engineer cartilage is the inability to produce 
tissue that has exactly the same structural and mechanical properties to that of naturally occurring 
articular cartilage. Whilst differentiated tissues in the lab are classed as cartilage since they 
express the essential biomolecules such as collagen type II and proteoglycans, the proportions 
of these constituents are usually incorrect, with collagen content frequently less than that found 
in natural cartilage resulting in weak structural tissue (Kafienah et al., 2002, Kafienah et al., 2007, 
Marijnissen et al., 2002). This has connotations for the loadbearing and tensile abilities of the 
tissue itself. If implanted within a joint and subjected to physiological forces, these implanted areas 
become focal points of wear and tear. Similarly, whilst numerous displays of successful 
chondrogenic differentiation has been demonstrated, a recapitulation of the complex zonal 
structure of cartilage has been notably absent. From a cellular standpoint, chondrocytes also 
provide unique challenges in terms of tissue engineering. At maturation, the capacity for 
chondrocytes to proliferate becomes markedly reduced and whilst chondrocytes explants can be 
harvested from tissues with relative ease in adults, the number obtained is usually not high 
enough for the generation of a complete tissue. Chondrocytes are also destined for several fates; 
progressing from immature cells, mature chondrocytes, hypertrophic cells or trans-differentiation 
into an osteoblast precursor (Figure 1.12). Maintaining the cells at the mature stage in 
development is therefore an important concern in order to maximise the production of ECM.  
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Figure 1.13: The evolution of a chondrocyte 
from embryonic stem cell. Monolayer culture of 
chondrocytes results in the dedifferentiation of 
chondrocytes into a fibroblastic cell type which 
produces fibrocartilage rather than the hyaline 
cartilage required. Re-differentiation of these cells is 
possible through encapsulation within 3D models but 
can have a negative impact on ECM synthesis abilities. 
Mature chondrocytes can also undergo further 
differentiation further into hypertrophic phenotype 
which can then transdifferentiate into an osteoblast 
phenotype. Figure adapted from (Hegert et al., 2002). 
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1.8 Chondrogenic differentiation with human multipotent stem cells 
Table 1.2 summarises in vitro studies investigating chondrogenic differentiation using 
mesenchymal stem cells (MSCs).  MSCs lack both the ethical implications posed by the use of 
embryonic stem cells (ESCs) and the teratogenic potential of induced pluripotent stem cells 
(iPSCs). However, in contrast to the pluripotent potential of ESCs, MSCs are only able to 
differentiate into a select number of cell types. The majority of investigations regarding 
chondrogenic differentiation of stem cells has involved the use of MSCs. In these experiments, 
whilst chondrogenic differentiation is detected it is often associated with hypertrophic and 
osteogenic markers such as alkaline phosphatase (ALP), osteopontin and MMP-13. This of 
course is a significant observation when considering if the cartilage produced by the cells can be 
sustained at a functional level (Pelttari et al., 2008, Pelttari et al., 2006). Another consideration 
for this cell type is the yield of MSCs from tissues. MSC retrieval from tissues within a single donor 
can be extremely limited, requiring extensive in vitro proliferation and a reduction in differentiation 
potential. In addition, the chondrogenic potential of MSCs was previously shown to be more 
limited in comparison to iPSCs and ESCs, most likely a consequence of the reduced 
differentiation potential of these cells in comparison (Ko et al., 2014).  
 
Cell type Model Time  (day) Agents 
Cell 
density Key information Reference 
Human 
MSCs 
implanted 
in SCID 
mice 
Pellet 56 
Dex  
(0.1 µM) 
 
TGFβ3  
(10 ng/ml) 
 
4-5 x 105 
Premature onset of COLX and MMP-13 
expression in pellets at day 7 before 
Col2A1 expression. 
 
Osteopontin and COL1a1 significantly 
upregulated at day 14 and continued to 
day 42. 
 
COLX widely distributed in pellets after 14 
days via immunostaining. 
 
ALP upregulation detected using 
immunostaining. Not observed in 
chondrocyte controls. 
 
MSC pellets mineralised despite producing 
aggrecan and type II collagen. 
(Pelttari et 
al., 2006) 
Human 
MSCs 
and 
HUCPVCs 
Pellet 21 
Dex  
(0.1 μM) 
 
TGFβ3  
(10 ng/ml) 
 
2.5 x 105 
HUCPVCs showed a ↑ proliferative 
potential, similar levels of proteoglycan 
staining and more intense collagen 
staining than MSCs. Statistical differences 
in GAG content only detected at day 7 
(p<0.05). 
(Baksh et 
al., 2007) 
BM- 
MSCs 
Pellet 21 
TGFβ3 
(10 ng/ml) +  
Dex  
(100 nM) 
 
Selected 
cases:  
BMP-2, 
BMP-4 or 
BMP-6 
(500 ng/ml) 
2 × 105 
All BMPs ↑ chondrogenic differentiation. 
BMP-2>BMP-4>BMP-6. 
 
Chondrogenic genes expressed in 
response to BMP-2. 
 
Heterogeneous differentiation in pellet 
observed. 
(Sekiya et 
al., 2005) 
 
Table 1.2: Human MSC in vitro models for chondrogenic differentiation 
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Amniotic fluid derived stem cells (AFSCs), are a broadly multipotent stem cell type 
characterised by expression of OCT3/4 (Prusa et al., 2003), stem cell factor (CD117), vimentin, 
CD90, CD105, SSEA-4 and alkaline phosphatase (Carraro et al., 2008). In particular, OCT3/4 
and SSEA-4 are common markers associated with the undifferentiated state of ESCs. Only 1% 
of the cells found in amniotic fluid derived from amniocentesis samples are referred to as AFSCs. 
The amniocentesis procedure used to extract the fluid is minimally invasive and ultrasound guided 
to provide a relatively safe and painless procedure. While AFSCs have no defining unique marker, 
they are most effectively isolated via immunoselection for the marker CD117 (C-kit). AFSCs have 
been shown to be capable of differentiating into cells derived from all 3 germ layers, but most 
importantly have been shown to be capable of differentiating into chondrocytes using several 
different in vitro models (Zuliani et al., 2018, Resca et al., 2015, Kolambkar et al., 2007, 
Preitschopf et al., 2016). Examples of these studies are included in Table 1.3. Again, this 
successful differentiation is often characterised by the expression of key chondrogenic markers 
such as COL2a1, SOX-9 and aggrecan as well as proteoglycan production and collagen synthesis 
in various culture models including monolayer, pellet and hydrogel. However, when directly 
compared to that of MSCs the robustness of these chondrogenic markers is more limited; 
potentially indicating a more reduced capacity to differentiate into the chondrogenic lineage 
(Kolambkar et al., 2007). 
 
Cell type Model Time  (day) Agents 
Cell 
density Key information Reference 
Human 
AFSCs 
and 
MSCs 
Pellet and 
Alginate 
21 
TGFb1  
(10 ng/ml) 
 
TGFβ3  
(10 ng/ml) 
 
BMP-2 
(500 ng/ml) 
 
IGF-1  
(100 ng/ml) 
Pellet: 
200,000- 
800,000 
 
Alginate: 
2 x 107 
cells/ml 
The growth factors did not affect cell 
proliferation in pellets but TGFβ1 
supplementation alone increased 
GAG/DNA synthesis compared to TGFβ3 
alone or TGFβ3 + BMP-2.  
 
Single factor produced greater staining for 
proteoglycan and type II collagen than 
combined factor. Increasing pellet cell 
density ­ GAG/DNA by 57%. 
 
TGFβ increased Type II collagen 
pericellularly compared to basal control. 
MSCs produced more robust cartilage 
compared to AFSCs.  
(Kolambkar 
et al., 2007) 
Human 
AFSCs 
into AC 
pellet 
Pellet 14 
Dex  
(100 nM) 
 
TGFβ1 
 (5 ng/ml) 
2.5 x 105 
Quantification of chondrogenic marker 
expression showed that knockdown of 
HIF2α reduced SOX-9, aggrecan, and 
COL2a1 gene expression after day 7 of 
differentiation and could not be reversed 
with rapamycin.  
(Preitschopf 
et al., 2016) 
Human 
AFSCs 
Monolayer 21 
Dex  
(100 nM) 
 
TGFβ1  
(10 ng/ml) 
2000 
cells/cm2 
Diffuse positive staining for type II collagen 
detected in ASC (amniotic stem cell) 
compared to AMC (amniotic mesenchymal 
cell). 
(Resca et 
al., 2015) 
Table 1.3: Human AFSC in vitro models for chondrogenic differentiation 
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Human 
AFSCs 
Micromass 21 
Dex  
(100 nM) 
 
TGFβ3  
(10 ng/ml) 
 
5 x 105 
Micromass culture of AFSCs increased 
SOX-9, aggrecan and COL2 gene 
expression after TGFβ3 treatment 
compared to untreated controls cultured in 
monolayer for up to 21 days.  
 
SOX-9 gene expression was greater than 
control, but reduced type II collagen and 
aggrecan expression.  
 
Type II collagen detected in culture 
medium in TGFβ3 treated micromass 
samples at 21 days.  
(Zuliani et 
al., 2018) 
Human 
AFSC 
Agarose 
(2%) 
Starch-
polycaprol
actone 
(SPCL) 
scaffold 
21 
Dex  
(1 mM) 
 
TGFβ1  
(10 ng/ml) 
2 x 106 
Early detection of COL2 at 7 days of 
culture in basal and chondrogenic cultures. 
 
COL2 expression is lost at week 2 but 
reappears at week 3 and increases. 
Agarose gels demonstrate more 
consistent expression over time. 
 
Aggrecan expression is less than that of 
collagen II. Encapsulated AFSCs express 
low aggrecan levels for duration of 
experiment. Viability unaffected in core 
and periphery. 
(Rodrigues 
et al., 2012) 
 
 
However, one of the major problems for the clinical use of MSCs is that they cannot retain 
their stem cell status for longer than five passages without displaying a reduced differentiation 
potential, proliferation and expression of specific cell surface markers (Wagner et al., 2008). In 
contrast, AFSCs have demonstrated the ability to maintain their stemness after 250 population 
doublings without significant telomere shortening which allows them to be cultured for long 
periods from one specific donor (De Coppi et al., 2007). The reduced expression of MHC class II 
or other co stimulatory molecules (CD80, 86) on the surface of AFSCs also indicates that they do 
not initiate a strong rejection response from the host once implanted (Moorefield et al., 2011). 
This has positive implications for evaluating AFSC effectiveness within in vivo models and clinical 
application. This is most likely a result of their development stage between that of an embryonic 
and adult stem cell (Cananzi, 2009). It was also confirmed that AFSCs do not form germ cell line 
tumours in SCID (severe combined immunodeficient) mice which makes these cells a much more 
viable choice for clinical application than embryonic and induced pluripotent stem cells (Resca et 
al., 2015). Whilst ESCs and iPSCs can express chondrogenic markers with less hypertrophic 
gene expression, AFSCs (at least in the short to medium term) are a much easier cell type to 
translate to an in vivo clinical setting due to ethical and safety reasons. 
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1.9 Comparison of in vitro 3D models for chondrogenic differentiation 
Table 1.4 summarises high-density in vitro models involving pellet or micromass culture. 
The principle behind these methods is that by packing the cells together at a high density, there 
are a greater number of cell to cell contacts and gap junction signalling events which reproduces 
the embryonic events that occur during limb development and thus aid the progression of cells to 
the chondrogenic differentiation stage (Augustyniak et al., 2015). Micromass culture differs to 
pellet culture by the fact that the cells are initially suspended within a small volume of liquid, 
typically 10 – 20 µl, to induce the pellet formation instead of using centrifugation. From Table 1.4, 
it is clear that the application of high density cultures, often treated with TGFβ, induces 
chondrogenic gene expression and increased histological staining of either proteoglycans or 
collagens (Johnstone et al., 1998). Comparison experiments between micromass and pellet 
cultures have shown that while both methods lead to chondrogenic differentiation of MSCs, 
micromass cultures demonstrate an enhanced efficiency of MSC chondrogenic differentiation 
compared to pellet culture in terms of specific earlier gene expression including the upregulation 
of cartilage specific COL2a1 and aggrecan in addition to downregulation of fibrocartilage markers 
like COL X and COL 1. Proteoglycan deposition and a reduction in core cell necrosis is also 
clearly evident (Zhang et al., 2010). However, the upregulation in gene expression is not always 
observed for all chondrogenic differentiation genes such as SOX-9. The importance of markers 
such as SOX-9 have been supported in instances whereby decreases in SOX-9 expression 
resulted in decreased aggrecan and collagen II markers (Ruedel et al., 2013). However, whilst a 
downregulation of fibrocartilage markers is evident when comparing pellet to micromass models, 
MSCs used in these models still demonstrate an increased expression of these markers 
compared to controls (Barry et al., 2001, Sekiya et al., 2002, Pelttari et al., 2008). 
Supplementation of culture medium with TGFβ and dexamethasone has actually been shown to 
slow down the hypertrophic progression of MSCs in pellet models and reduce these fibrocartilage 
markers (Mueller et al., 2010). It is therefore possible that the use of high-density culture method 
is conducive to hypertrophic differentiation rather than immature/mature chondrocyte 
differentiation and that the addition of exogenous growth factors is essential to reduce this 
incidence. 
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Model Time (days) Agents 
Cell 
density Key information Reference 
Pellet 21 
Dex  
(1 mM) 
 
TGFβ3  
(10 ng/ml)  
 
BMP-6  
(500 ng/ml) 
200,000 
Increased proteoglycan mRNA, type II, IX, X, XI 
collagen, FGFR-2, PTHrPR, and transcription factors 
SOX-5, SOX-6, and SOX-9. Increased toluidine blue in 
line with culture time. 
(Sekiya et 
al., 2002) 
Pellet 
14 
28 
42 
TGFβ1  
(10 ng/ml) 
 
TGFβ3  
(10 ng/ml) 
200,000 
No statistical differences in GAG synthesis, DNA content 
or histological differences between TGFβ isoforms. Type 
II collagen staining weak at day 14 but positive on day 
28 and localised to central area. Type X collagen in 
periphery at day 28 and 42 in chondrogenic controls 
compared to hypertrophic treated. 
 
TGFβ1 and dex removal required to allow hypertrophic 
expression of type X collagen and ALP. 
(Mueller et 
al., 2010) 
Pellet 21 
TGFβ3  
(10 ng/ml) 
 
Dex  
(100 nM) 
 
BMP-2  
(500 ng/ml) 
 
FGF-2 
 (2 ng/ml) 
200-2000 
x 103 
Single factors did not induce chondrogenesis.  
 
TGFβ3 or dex increased pellet size but no significant 
accumulation of GAG. BMP-2 + TGFβ3 and dex 
increased growth of pellet and ECM production. 
 
DNA content per pellet ↓ during chondrogenesis. Runx2 
expression unchanged with culture period.  
(Shirasawa 
et al., 
2006) 
Micromass 
vs 
pellet 
21 
TGFβ3  
(10 ng/ml) 
 
Dex  
(100 nM) 
2 x 107 
vs 
2 x 105 
Wet weight of micromass tissue larger than pellet. 
 
Increased toluidine blue staining in micromass 
compared to pellet (day 7 - 21). Higher Collagen II in 
micromass with lower collagen I and X compared to 
pellet. TUNEL assay showed positive cells in central 
region of pellet but fewer in micromass. 
 
Micromass: significantly higher collagen II and aggrecan 
(p<0.01) but downregulated collagen I and X (p<0.01). 
SOX-9 expression did not change in either culture 
method, stayed low. 
(Zhang et 
al., 2010) 
Micromass 
vs 
pellet 
33 
Dex  
(1 µM) 
50,000 
cells/ml 
vs 
2.5 x 105 
Hanging drop method showed increased collagen type 
II, SOX-9 and MIA/CD-RAP expression as early as day 
2. Not observed in pellet until day 11. 
 
Collagen X ad AP-2 expression only weakly induced at 
day 7. Addition of TGFβ enhances expression of these 
markers at day 2. siRNA treatment to decrease SOX-9 
expression reduced aggrecan, collagen II, MIA/CD-RAP 
expression also reduced. 
(Ruedel et 
al., 2013) 
 
In general, high density cultures have several advantages compared to other in vitro 
models since they are quick and easy to form and do not require complex enzymatic digestions 
to remove any surrounding structures like hydrogels. In this way, the chondrogenic potential of 
cells can be quickly evaluated along with the investigation of different signalling pathways (Pelttari 
et al., 2008). These models are often used by commercial chondrogenic differentiation kits such 
as STEMPRO (Thermofisher Scientific, UK). However, the production of dense ECM after long 
culture periods by the incumbent differentiating cells can be a problem when trying to isolate cells 
for further investigation, requiring high intensity manual lysis methods which can result in a loss 
of sample or risk of contamination. Another common problem associated with these methods is 
the presence of undifferentiated and necrotized cells within the central regions of the 
Table 1.4: Examples of high-density culture methods for chondrogenic differentiation using MSCs. 
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Figure 1.14 Cell necrosis is reduced in micromass compared to pellet culture for chondrogenic 
differentiation of MSCs. Core regions of pellets show clear differences in staining for specific cartilage 
and fibrocartilage markers indicating a lack of homogenous differentiation within the pellet structure. In 
addition, the results of the terminal deoxynucleotidyl transferase dUTP Nick-End Labelling (TUNEL) 
assay indicate areas of apoptotic cell death within the central region in contrast to that observed within 
the micromass model. Scale bar represents 100µm. Figure from (Zhang et al., 2010). 
pellet/micromass compared to the differentiated outer layer cells (Figure 1.13) (Mueller and Tuan, 
2008, Kafienah et al., 2007). This is due to the way in which the model is formed. By packing the 
cells at a high cell density, a low oxygen tension environment is produced with poor nutrient 
diffusion. Together these constraints increase cellular stress events and cause cells to die within 
the central region of the model. Despite successes some of the main drawbacks for micromass 
culture are the limitations in size, quantity and overall mechanical instability of the constructs once 
implanted in vivo (Tare et al., 2005, Panadero et al., 2016). High density models are therefore 
limited to more investigative roles instead of practical application. 
 
 
 
 
 
 
 
 
 
 
Alginate is an anionic linear polysaccharide composed of alpha-L-guluronic and 1-4 
linked beta-d-mannuronic acid, as detailed in Figure 1.14 (Hernandez et al., 2010, Guo J, 1989). 
Due to the inert nature of alginate, interactions between the hydrogel itself and cells encapsulated 
within it are limited and do not present any toxic products which can affect cell viability allowing it 
to be used for human trials (Tonnesen and Karlsen, 2002). This biocompatibility can be further 
enhanced through the attachment of peptide sequences to the alginate chains itself which allows 
cell integrin interactions e.g. RGD motifs (Shachar et al., 2011). Cells can be distributed 
homogenously within alginate with little impact on cell viability using chelators such as citrates, 
phosphates, carbonates and lactates or incubation in solutions with a reduced calcium 
concentration solutions (Olderoy et al., 2014, Gleghorn et al., 2008). The high permeability 
enables movement of low molecular weight nutrients, oxygen, metabolites and catabolic products 
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(Hernandez et al., 2010). However, porosity is dependent on factors such as the ratio of its 
constituents (guluronic acids to mannuronic acids), temperature, pH and gelation method 
(Lundberg and Kuchel, 1997).   
 
 
 
 
 
 
 
 
Table 1.5 shows examples of MSC chondrogenic differentiation using alginate hydrogels 
as demonstrated by increased safranin O staining and immunostaining for aggrecan and collagen 
(Kolambkar et al., 2007, Xu et al., 2008, Herlofsen et al., 2011). GAG accumulation increases 
were also associated with alginate and fibrin encapsulation compared to monolayer culture. Cell 
proliferation was also shown to be possible within alginate hydrogels but whilst high viability 
values are always noted, a reduction in viability has been observed after prolonged periods of 
culture (Xu et al., 2008). This is a potentially significant issue since chondrogenic differentiation 
typically takes place over a protracted time period of 3 - 4 weeks. Comparisons of alginate bead 
models to monolayer and pellet culture showed that alginate encapsulation initially caused an 
upregulation of hypertrophic markers but after prolonged culture resulted in a significant 
downregulation compared to these other models (Dashtdar et al., 2016). Subcutaneous 
implantation of MSC seeded alginate hydrogels was also associated with significant chondrogenic 
gene expression and histological staining for collagen markers indicating the suitability for 
alginate hydrogels for in vivo application (de Vries-van Melle et al., 2014). 
 
 
 
 
Figure 1.15 Chemical structure of the repeated units of alginate: β-D-mannuronic acid and α-L-
guluronic acid. Divalent cations such as calcium (Ca2+) ions bind to the exposed guluronic acid residues 
creating a solution-gel transition material. Crosslinks between Ca2+ and the guluronic residues forms a 
stiff egg box structure responsible for the viscoelastic behaviour of the hydrogel (LeRoux et al., 1999). 
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Model Time  (day) Agents 
Cell 
density Key information Reference 
Alginate 
(2%) 
24 
TGFβ3 
(10 ng/ml) 
1 x 106 
Cell proliferation increased with culture period (76.5%). 
Cell viability reduced (14 - 18%) at day 24. 
 
Increased safranin O staining with culture period in 
chondrogenic constructs compared to day 0. 
 
Aggrecan and collagen immunostaining observed 
intracellular and pericellularly as early as day 6 in 
chondrogenic constructs whilst increased Type II 
collagen II, X, COMP and aggrecan gene expression 
temporally.  
(Xu et al., 
2008) 
Alginate 
(1%) 
21 
Dex  
(0.1 µM) 
 
TGFβ1  
(10 ng/ml) 
5 x 106/ml 
High viability throughout alginate culture. 
 
COL1 was initially expressed at high levels in monolayer 
culture and decreased slightly over time. 
 
In comparison, COL2, COL10, SOX-5, SOX-6, SOX-9 
and aggrecan ↑ at day 7 while COL1 and versican ↓. 
 
Collagen and aggrecan showed dispersion through the 
ECM after 21 days whilst COL10 showed 
intra/pericellular localisation. 
(Herlofsen et 
al., 2011) 
Alginate 
(1.2%) 
and/or HA 
(1%) 
within an 
OA defect 
28 
Dex  
(100 nM) 
 
TGFb1  
(10 ng/ml) 
1 x 107/ml 
Glycosaminoglycan deposition and chondrogenic gene 
expression (COL2 and aggrecan) significantly ­ in 
alginate hydrogels and fibrin hydrogels. 
Supplementation of HA to alginate did not have an effect. 
 
When implanted subcutaneously, alginate hydrogels had 
significantly ­ cartilage gene expression after 28 days 
than fibrin and significantly ­ safranin O staining after 12 
weeks in vivo. 
 
DNA content ¯ with time in alginate structures. 
 
Expression of COL X and ALP ­ for all materials tested 
compared to negative control. 
(de Vries-
van Melle et 
al., 2014) 
Monolayer 
v 
Pellet  
v  
Alginate 
(1.2%) 
21 
Dex 
(100 nM) 
 
TGFb3  
(10 ng/ml) 
 
2.5 x 105 
per pellet 
 
80,000  
per bead 
Alginate bead encapsulation and pellet culture 
significantly ­ immunohistochemical staining of collagen 
and aggrecan compared to monolayer. 
 
GAG content and expression of aggrecan, SOX-9 and 
collagen II were significantly higher in alginate bead 
samples compared to pellet culture samples at all time 
points tested (p<0.05). 
 
Hypertrophic markers COLX and Runx2 significantly 
higher in alginate samples compared to pellet at early 
point of culture (day 3; p<0.05) but were significantly ¯  
at later time points (days 12 and 21). 
(Dashtdar et 
al., 2016) 
 
 
 
 
 
 
 
 
Table 1.5: Examples of alginate hydrogels for chondrogenic differentiation of human MSCs 
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Alternatively, agarose is a polymer that consists of disaccharide units with variable 
numbers of methoxy groups which stabilise by hydrogen bonding between galactose residue 
hydroxyl groups and water resulting in pores that can range between 10 - 500 nm in diameter for 
a 2% w/v gel as detailed in Figure 1.15.  (Lundberg and Kuchel, 1997).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.6 summarises some examples of agarose models used for chondrogenic 
differentiation of MSCs.  Within these, an increase in type II collagen expression, variable 
proteoglycan content, increased collagen staining and chondrogenic gene expression have all 
been noted using agarose hydrogels when treated with dexamethasone and TGFb (Rodrigues et 
al., 2012, Tangtrongsup and Kisiday, 2016). However, these increases have also been associated 
with an enhancement of hypertrophic/osteogenic markers such as type X collagen and ALP 
(Thorpe et al., 2012). Whilst superior differentiation has been noted in self-assembled polypeptide 
scaffold materials, agarose encapsulation was also shown to be conducive to chondrogenic 
differentiation although more so for bovine MSCs than human MSCs (Florine et al., 2013). In 
contrast, TGFβ3 mediated chondrogenesis within agarose was shown to be superior to fibrin gels 
Sol phase Elastic gel Rigid gel 
Cooled Cooled 
Heated Heated 
37°C Molten 
~100°C 
+ 
Cell 
suspension 
Cooled Mixed 
Figure 1.16: Agarose polymer arrangement in different phases. When heated to high temperature 
(100°C) agarose polymers exist as individual single chains (sol phase). When cooled these chains 
start to combine, generally into a helical structure due to low level cross linking (elastic gel phase). 
When left to cool further these complexes begin to stick together due to the formation of further cross 
links which makes the gel become much more rigid (rigid gel phase). 
37 
 
as shown by enhanced staining for type II collagen, whilst fibrin seemed to support greater 
myogenic differentiation (Thorpe et al., 2012). Markers for hypertrophic chondrocytes were also 
noted to be higher in agarose constructs compared to fibrin. Testing of chondrogenic differentiated 
MSCs within agarose constructs also showed significant accumulation of cartilaginous matrix but 
the mechanical properties were shown to be diminished compared to mature chondrocytes 
cultured under identical conditions (Mauck et al., 2006). However, it was also suggested that 
further optimisation of the model through a longer induction period or the application of 
mechanical loading to differentiated MSCs could potentially overcome these issues and enhance 
the mechanical properties of the resulting cartilage. In support of this, the effect of mechanical 
loading on MSC chondrogenic differentiation has been well examined using agarose hydrogels 
(Mouw et al., 2007, Mauck et al., 2007, Kisiday et al., 2009, Huang et al., 2010). 
 
Cell 
type Model 
Time 
(day) Agents 
Cell 
density Key findings Reference 
Equine
MSCs 
Agarose 
(2%) 
21 
Dex  
(1 or 
100nM) 
 
TGFb1  
(5 ng/ml) 
1.2 x 107 
per ml 
GAG accumulation, toluidine staining, collagen 
II staining, chondrogenic gene expression and 
hydroxyproline content showed no significant 
difference when dex concentration reduced 
from 100 nM to 1 nM. 
 
In dex free, GAG accumulation significantly ↓ 
compared to dex treated. DNA content 
unchanged but type I collagen gene 
expression significantly ­. 
 
Collagen II gene expression ↑ in response to 
100 nM dex with 52-fold increase between 3 
and 15 days. Collagen I expression showed 
2.5-fold increase at day 15. 
 
Type X collagen and alkaline phosphatase ↑ in 
response to 100 nM dex. MMP ↑ in 1 nm dex 
compared to 100 nM. ADAMTS4 ↓ in response 
to 100 nM dex. 
 
Withdrawal of dex caused ↓ in hydroxyproline 
but not GAG relative to controls after 6 days.  
(Tangtrongsup 
and Kisiday, 
2016) 
Human 
and 
Bovine 
BM-
MSCs 
Agarose 
(2%) 
and/or 
V 
RADA 
21 
TGFb1 
(10 ng/ml) 
 
Dex  
(100 nM) 
1 x 107 
cells/ml 
TGFβ1 with dex significantly ↑ GAG 
accumulation compared to TGFβ1 alone in 
agarose hydrogels but ↓ in RAD scaffolds. 
 
DNA content ↑ in response to dex treatment in 
agarose constructs.  
 
TGFβ and dex showed significant 
proteoglycan synthesis ↑ compared to TGFβ 
alone at day 14 and 21. 
 
Hydroxyproline content ↑ over time in both 
scaffolds. In agarose no statistical difference 
between dex and TGFβ alone at any time 
point. 
 
Immunohistochemistry showed collagen II 
staining in RADA but not agarose. More 
collagen type II in TGFβ alone gels compared 
to dexamethasone and TGFβ. Collagen I 
staining not evident in agarose or RADA. 
 
Apoptosis levels ↑ in agarose gels (20-30%) 
compared to RADA gels (2%). TGFβ and dex 
resulted in ↓ apoptosis compared to TGF alone 
in agarose. 
 
(Florine et al., 
2013) 
Table 1.6: Examples of agarose hydrogels used for chondrogenic differentiation 
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RU-486 significantly ↓ GAG synthesis levels in 
TGFβ + dex treated samples in agarose and 
RADA. 
 
Seeding of constructs with human BMSC 
showed minimal GAG increases in agarose 
hydrogels and levels 50% of that of bovine 
cells in RADA. 
Human 
AFSC 
Agarose 
(2%) 
21 
Dex  
(1 mM) 
 
TGFβ1  
(10 ng/ml) 
2 x 106 
Early detection of COL2 at 7 days of culture in 
basal and chondrogenic cultures. 
 
COL2 expression is lost at week 2 but 
reappears at week 3 and increases. Agarose 
gels demonstrate more consistent expression 
over time. 
 
Aggrecan expression is less than that of 
collagen II. Encapsulated AFSCs express low 
aggrecan levels for duration of experiment. 
 
Viability unaffected in core and periphery. 
(Rodrigues et 
al., 2012) 
Porcine 
MSCs 
Agarose 
(2%) 
22 or 
42 
TGFβ3 
(1 or 10 
ng/ml) 
1.5 x 107 
/ml 
Agarose embedded MSCs showed spherical 
morphology compared to spread morphology 
in fibrin matrix. 
 
Free swelling agarose showed positive 
chondrogenic staining but also mineral staining 
indicating a progression towards terminal 
differentiation. 
 
Free swelling fibrin constructs differentiated 
towards myogenic pathway. 
 
Dynamic compression application reduced 
differentiation short-term but long-term 
extrinsic loading supported chondrogenic 
differentiation. 
(Thorpe et al., 
2012) 
 
Overall, the sheer number of growth factor treatments, in vitro models, cell types, scaffold 
materials, gelation methods and cell densities used to achieve chondrogenic differentiation of 
stem cells is vast and confusing. Contradictory findings are rife and has led to a lack of consensus 
in regard to even basic considerations when it comes to approaching the synthesis of a tissue 
engineered cartilage product. As such, any approaches to investigate stem cell chondrogenic 
differentiation or the development of new models requires a step wise evaluation.   
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1.10 Role of C-type natriuretic peptide in bone homeostasis 
In addition to the cells and scaffold materials used to engineer specific tissues, the 
addition of biological agents that can stimulate a desired cellular response is a significant 
determination to be made. One of the most significant small peptides with growing evidence to 
support its role in cartilage and bone homeostasis is that of CNP.  
1.10.1 CNP expression and signalling 
Activation of the Nppc gene, chromosomally located at 2q24-qter. synthesises a 126 
amino acid long pre-pro form of CNP (Figure 1.16). Removal of the N-terminal signal peptide 
allows the cleavage of pro-CNP, via the endoprotease furin into 2 products; a 50 amino acid long 
amino terminal pro peptide (NT-proCNP) and a 53 amino acid long active CNP. These products 
can be excreted from the cell, but ordinarily the 53 amino acid peptide is cleaved again into a 
mature 22 amino acid long product. CNP-22 is much more potent than the uncleaved 53 amino 
acid long peptide (Wu et al., 2003) but has a considerably shorter plasma half-life. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Whilst sharing a similar peptide main structure with a 17 amino acid loop structure to its 
family members, atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP), the 
Figure 1.17: CNP synthesis. The transcription factor TSC22 stimulates the NPPC gene to trigger 
production of a 126 amino acid pre-pro CNP with a signal peptide attached. Subsequent removal of 
this signal peptide forms ‘Pro-CNP’ which then allows cleavage by an endoprotease (furin) into 2 
components: an active 53 amino acid CNP along with an amino terminal pro-peptide. Secretion of these 
out of the cell allows further cleavage of CNP-53 into mature CNP-22.  
40 
 
distribution of CNP within the body is distinct (ANP and BNP are predominantly produced by the 
heart) localised to the CNS and to a lesser extent within vital organs such as the lung, liver, kidney 
and most importantly the growth plate of cartilage (Chusho et al., 2001).  
CNP acts through a membrane bound guanylyl cyclase receptor; natriuretic peptide 
receptor (NPR)2 and another receptor that lacks a guanylyl cyclase functionality called NPR-3. 
These 2 receptors are important for two different reasons. Binding of CNP to the glycosylated 
NPR-2 homodimer triggers the binding of an ATP molecule which acts to instigate a 
conformational change within the guanylyl cyclase domains, bringing them together. This 
movement activates the conversion of GTP to cyclic GMP which can go on to stimulate the 
activation of a host of downstream targets ranging from cGMP dependent kinases (the main 
intracellular cGMP target, such as PKGII), cGMP regulated phosphodiesterases and cyclic 
nucleotide gated ion channels (Pilz and Casteel, 2003). Dephosphorylation of the ATP binding 
domain causes the conformational change to reverse as ATP is released and the initial CNP 
ligand is released from the receptor (Potter, 1998). Breakdown of CNP within the extracellular 
space is performed by matrix membrane metalloendopeptidase, principally neprilysin, resulting in 
CNP’s rapid half-life (Kenny et al., 1993).  
1.10.2 Evidence of the role of CNP in bone and cartilage homeostasis 
The evidence to support the role of CNP during limb development has been indicated 
from several in vivo knockout studies that either disrupt CNP or one of its cognate receptors such 
as NPR-2. For example, dwarfism results with severe growth retardation postnatally due to growth 
reduction in endochondral bones (Chusho et al., 2001, Yasoda et al., 2004). In contrast, 
overexpression of CNP or deletion of NPR-3, which is thought to be responsible for clearance of 
natriuretic peptides from the circulation rescues the phenotype of CNP knockout mice 
(Matsukawa et al., 1999). These effects are not only seen in murine models but also clinically, as 
is the case for acromesomelic dysplasias type Maroteaux (Bartels et al., 2004, Olney, 2006) which 
results from Nppc or Npr2 mutations. It has been suggested that CNP plays a direct role in 
regulating when chondrocytes exit the cell cycle, whereby the proliferative zone of the growth 
plate is directly affected (Chusho et al., 2001, Yasoda et al., 2004). By removing CNP, the length 
of time that these cells are able to remain within the synthesis phase (S phase) of the cell cycle 
is reduced and therefore directly reduces the length of the proliferating zone resulting in growth 
retardation. More significantly, when CNP is removed a shortening of the hypertrophic zone is 
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apparent. Treatment of endochondral long bones with CNP increases the size and number of 
hypertrophic cells without an effect on cell apoptosis (Agoston et al., 2007). In terms of in vitro 
investigations, CNP has been associated with regulating osteoblast activity by increasing 
osteogenic gene expression markers such as ALP and osteocalcin in osteoblastic MC3T3-E1 
cells and osteoblast like cells from foetal rat calvaria (Yeh et al., 2006, Suda et al., 1996). 
Furthermore, CNP was also previously associated with increasing osteoclast bone resorption 
activity in osteoclast containing mouse bone marrow cultures (Holliday et al., 1995). These and 
other investigations suggest that CNP plays an important role in regulating osteoblast activity 
which directly affects bone formation 
Importantly, CNP supplementation has been shown to induce proteoglycan synthesis and 
reduce enzymes associated with ECM breakdown (Krejci et al., 2005, Woods et al., 2007). In 
addition to its local effects, CNP has also been associated with controlling the secretion of pituitary 
growth hormone, known to directly regulate endochondral bone growth (McArdle et al., 1994), as 
well as chondroprotective effects against inflammatory challenge by inflammatory cytokines such 
as IL-1β (Peake et al., 2015), an effect further enhanced by the application of mechanical loading 
(Table 1.7). This increase in ECM synthesis caused by CNP application has been attributed to 
an increase in the activity of the enzymes responsible for chondroitin sulfate synthesis and 
therefore GAG production (Woods et al., 2007). The principle mechanism that drives this 
chondroprotective effect in human chondrocytes has been characterised via cGMP production 
and subsequent activation of PKGII. Therefore, the role of CNP in bone formation and the 
maintenance of healthy articular cartilage is clearly evident and has subsequently driven research 
into its potential role in the chondrogenic differentiation process. 
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Species Model Agents Key findings References 
Human 
Agarose 
(3%) 
/ 
bioreactor 
Il-1b 
10 (ng/ml) 
 
CNP  
(0.1 – 1000 nM) 
CNP reduces IL-1 induced NO + PGE2 release in 
dose dependent manner 
 
Dynamic compression with CNP reduced iNOS 
and COX2 expression at 6 hours of culture 
 
CNP treated unstrained samples show increases 
in aggrecan and collagen type 2 expression -
concentration dependent effect 
(Ramachandran 
et al., 2011) 
Human 
Agarose 
(3%) 
/ 
bioreactor 
CNP (100 nM) 
IL-1b (10 ng/ml) 
Co-treatment of constructs with CNP and IL-1b 
reduced catabolic effects of IL-1 via reduction in 
NO. 
 
Inhibition of NPR2 prevented this effect 
 
Activation of NPR3 reduced NO and PGE2 release 
in co-treated constructs 
 
CNP presence significantly enhanced GAG 
synthesis and cGMP levels 
(Peake et al., 
2013) 
Bovine Pellet 
CNP  
(10 pM – 10 nM) 
Low doses of CNP stimulated proliferation but no 
ECM accumulation 
 
High doses of CNP resulted in significant ECM 
accumulation with no increase in cellularity 
 
CNP stimulated cells more rounded morphology 
than untreated 
 
Dose dependent decrease in Collagen X 
expression when CNP applied 
(Waldman et al., 
2007) 
 
 
Table 1.7: Examples of functional studies looking at the role of CNP in chondrocyte signalling 
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1.11 Aims & Objectives 
This project investigated the chondrogenic potential of human amniotic fluid-derived stem 
cells in alginate and agarose 3D models upon treatment with different TGFb isoforms. AFSCs 
isolated from human amniotic fluid were expanded in conditioned media supplemented with either 
growth factor TGFb1, TGFb3, CNP and/or dexamethasone (Dex). In order to identify which model 
was optimal for long-term differentiation and production of chondrogenic markers, AFSCs were 
either encapsulated in alginate beads or seeded into agarose constructs (Chapters 2 and 3), and 
the differential effects of either CNP, growth factors or Dex on protein synthesis (collagen, GAG) 
and gene expression (aggrecan, type II collagen, SOX-9) were investigated in AFSC/agarose 
constructs (Chapter 4). In a separate study, I explored the potential of CNP containing 
microcapsules to promote GAG synthesis in chondrocyte/agarose constructs (Chapter 5). 
AIM 1: Short-term culture effects of AFSCs either encapsulated in alginate beads or seeded 
into agarose constructs. 
OBJECTIVES: I developed a model to expand AFSCs and culture in either alginate beads or 
agarose constructs for up to 14 days in the presence and absence of either TGFb1 or TGFb3. 
Biochemical assays were used to quantify GAG synthesis and DNA content. Confocal microscopy 
was used to examine cell viability in the centre and edge of AFSC/agarose constructs. 
Epifluorescence microscopy was used to examine cell viability in cross sections of AFSC/alginate 
beads. Fluorescence activated cell sorting (FACS) was also used to examine cell surface markers 
of AFSCs used in these experiments. 
PROJECT OUTCOMES:  AFSC/agarose constructs: Treatment with either TGFb1 or TGFb3 
significantly increased DNA content compared to controls whilst maintaining cell viability in core 
and edge of constructs after culture for up to 14 days. GAG synthesis in AFSC/agarose constructs 
was elevated in TGFb treated samples relative to only basal control samples after 14 days of 
culture. AFSC/alginate beads: Treatment with TGFb  demonstrated statistically significant 
increases in DNA content compared to controls but no statistically significant increases in GAG 
synthesis were detected. Alginate beads were not stable after short-term treatment with growth 
factors and the structure appeared to diminish making it a poor model for cell differentiation.  
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AIM 2: Long-term culture effects of either TGFb1 or TGFb3 in AFSC/agarose constructs. 
OBJECTIVES: Following cell expansion, AFSCs were cultured in agarose constructs for up to 28 
days in the presence and absence of either TGFb1 or TGFb3. Confocal microscopy was used to 
examine cell viability in the centre and edge of the AFSC/agarose constructs. Biochemical assays 
were used to quantify GAG synthesis, collagen synthesis and DNA levels. The differential effects 
of the TGFb isoforms on GAG synthesis and collagen content in AFSC/agarose constructs were 
investigated up to 28 days of culture. 
PROJECT OUTCOMES: Treatment with either TGFb1 or TGFb3 in AFSC/agarose constructs 
significantly increased GAG synthesis, collagen levels, DNA content and maintained 
homogeneous cell viability after culture for up to 28 days when compared to day = 0.  
 
AIM 3: Long-term culture effects of either CNP, TGFb1, TGFb3 or Dex in AFSC/agarose 
constructs.  
OBJECTIVES: Following cell expansion, AFSC/agarose constructs were cultured for up to 28 
days in the presence and absence of either CNP, TGFb1, TGFb3 and/or Dex. At the end of the 
experiment, GAG synthesis, collagen levels and DNA levels were quantified by biochemical 
assay. Histology was used to examine proteoglycan content with alcian blue staining. RT-qPCR 
was used to examine SOX-9, Type II collagen (COL2a1) and aggrecan gene expression. SHG 
imaging and confocal microscopy was used to examine collagen fibre organisation in the centre 
of the AFSC/agarose constructs. 
PROJECT OUTCOMES: Co-stimulation with CNP and either TGFb1 or TGFb3 significantly 
increased GAG synthesis and collagen levels in in AFSC/agarose constructs cultured for up to 
28 days.  I observed greater levels of alcian blue staining and increased SOX-9 gene expression 
in co-stimulated samples when compared to day = 0. Pericellular deposition of collagen was also 
detected in co-stimulated samples according to SHG imaging. 
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AIM 4: Short term culture effects of CNP containing microcapsules in bovine articular 
chondrocyte/agarose constructs. 
OBJECTIVES: CNP microcapsules were made using layer by layer assembly of the alternately 
charged polyelectrolytes poly-L-arginine and dextran sulfate around a dissolvable calcium 
carbonate core with CNP incorporated within. Bovine chondrocytes from articular joints of 18 – 
24-month old steers were isolated from tissue and cultured in 3% agarose constructs in the 
presence and absence of CNP microcapsules for up to 48 hours and compared to treatment with 
exogenous CNP, empty microcapsules and day 0 control. Biochemical assays were used to 
quantify GAG synthesis and DNA content. Confocal and SEM microscopy were used to 
characterise and observe microcapsule distribution in the core of agarose constructs. 
PROJECT OUTCOMES: Treatment with CNP microcapsules resulted in a statistically significant 
increase in GAG synthesis compared to day 0 and exogenous CNP application. CNP containing 
microcapsules were shown to have no morphological differences with empty microcapsules. 
Cellular and microcapsule distribution were shown to be homogeneously distributed in the centre 
of the constructs.  
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Chapter 2: Assessment of alginate and agarose 
hydrogels for early amniotic fluid derived stem 
cell differentiation 
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2.1 Introduction 
This chapter investigates the chondrogenic differentiation of AFSCs embedded within 
alginate beads and agarose constructs using TGFβ1 or TGFβ3. TGFβ1 is typically secreted as a 
290 kDa latent complex whereby a latent binding protein is directly linked via a disulphide bridge 
to the TGFβ1 precursor (latency associated peptide) (Kanzaki et al., 1990). Initial binding of TGFβ 
to type I (TGFβR1) and type II (TGFβR2) serine/threonine kinase receptors on the surface of the 
cell triggers downstream phosphorylation of Smad2/3 to form a hetero-oligomeric complex with 
Smad4 which is then able to migrate into the nucleus and instigate the transcription of target 
genes such as COL2a1, aggrecan, SOX-9 (Figure 2.1). CBP/p300 are then recruited to the 
transcription factor and further increase SOX-9 transcriptional activity. TGFβ1 can also activate 
other non-smad signalling pathways such as the MAPK pathway via TGFβ activated kinase 
(TAK1), ERK1/2 via TIMP-3 and PI3K/Akt–MAPK signalling. These pathways aid in the control of 
wnt mediated signalling through the intracellular β-catenin TCF pathway which in turn controls N-
cadherin expression. N-cadherin upregulation allows the formation of cell adhesion complexes 
during MSC chondrogenesis (Tuli et al., 2003). ERK1/2 controls the anabolic activity of 
chondrocytes and cellular growth as well as expression of AGC1, COL2a1 and cartilage link 
proteins (Vater, 2011).   
 
 
 
 
 
 
 
 
 
 
Figure 2.1: TGFβ signalling canonically and non-canonically. Canonical pathways utilise Smad 
signalling to instigate changes to chondrogenic gene transcription. Non-canonical pathways have 
been associated with determining the functional outcome of TGFb including tissue repair (Mu et al., 
2012, Gilbert et al., 2016, Wang et al., 2014). Figure taken from Mu et al., 2012. 
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Table 2.1 summarises some in vitro examples of the effect of TGFb on MSC 
differentiation. Of the 3 prototypic TGFβ isoforms, most investigators utilise either TGFβ1 (Yoo, 
1998, Johnstone et al., 1998, Bock et al., 2018, Zhu et al., 2018, Bertolo et al., 2015) or TGFβ3 
(Sekiya et al., 2002, Bian et al., 2011, Mahboudi et al., 2018). Most studies have supported the 
use of TGFβ1 for the differentiation of stem cells to a chondrocyte phenotype (Blunk et al., 2002) 
and hypertrophy prevention (Mueller and Tuan, 2008).  
However, contrasting studies have been published suggesting specific TGFb isoforms 
are superior to the others for chondrogenic differentiation of stem cells. For example, Barry et al 
in 2001 suggested that TGFβ3 results in a more rapid differentiation of BM-MSCs than other  TGFb 
isoforms (Barry et al., 2001). Conversely, in 2007 Kolambkar et al suggested the opposite with 
greater GAG synthesis detected in pellet cultures treated with TGFβ1 compared to TGFβ3 
(Kolambkar et al., 2007).  Finally in 2014, Jakobsen et al suggested that at least on a gene 
expression level, no difference in the expression of chondrogenic or non-chondrogenic genes 
was detected when comparing TGFβ1 and TGFβ3 treatment (Jakobsen et al., 2014). 
 
Model Time  (day) Agents 
Cell 
density Key findings Reference 
Pellet 21 
Dex  
(100 nM) 
 
TGFβ3, 
,TGFβ2, 
TGFb1  
(10 ng/ml) 
200,000 
No changes in DNA content for all conditions. TGFβ1 showed 
less GAG compared to TGFβ2 and TGFβ3 at all time points 
(7, 14, 21 days) due to lower synthesis rate per cell.  
 
TGFβ1 showed lowest chondrogenic differentiation at all time 
points and largest distinct difference between core and 
periphery in terms of collagen II staining. 
 
Type I collagen gene expression throughout culture for all 
treatments but type II gradually increased. Type X collagen 
rapidly upregulated and maintained.  
(Barry et al., 
2001) 
PES 
scaffold 
21 
Dex  
(100 mM)  
 
TGFβ3 
(10 ng/ml) 
2 x 105 
Collagen type II and aggrecan markers positive via 
immunocytochemistry at day 21, but also detected in controls. 
 
Chondrogenic gene expression higher for scaffold treated 
cells compared to scaffold free, collagen I expression lower 
in scaffold group at end of culture. 
 
Statistically significant gene expression of aggrecan and 
collagen II at 21 days of culture higher in scaffold compared 
to scaffold free. No significant difference in SOX-9 expression 
for either culture. 
(Mahboudi 
et al., 2018) 
Alginate 
disc 
21 
 TGFβ1, 
TGFβ2, 
TGFβ3 
(10 ng/ml) 
 
Dex 
(100 nM) 
 
BMP-2 
(500 ng/ml) 
 
BMP-4 
(500 ng/ml) 
 
BMP-6 
(500 ng/ml) 
 
FGF-2 
(10 ng/ml) 
 
IGF-1 
(100 ng/ml) 
1.25x106 
or 
2x107/ml 
Wanted genes: aggrecan, biglycan, collagen XI, COL2a1, 
COL9a1, COMP, decorin, fibromodulin. Unwanted genes: 
ALP, COLXa1, osteoglycin, Runx2, osteopontin and 
versican. 
 
TGFβ1, Dex and BMP-2 directly increased wanted markers 
whilst FGF-2 decreased the wanted markers. Dex was 
essential for TGFβ1 induction of wanted markers, TGFβ1 
alone had a much smaller effect. Downregulation of 
osteocalcin also observed. 
 
TGFβ1 with BMP-2 caused a lower increase in wanted marker 
expression compared to TGFβ1 alone. Supplementation with 
all 3 markers decreased the total effect but still increased 
wanted marker expression. Dex alone did not have significant 
effect on markers. TGFβ1 or BMP-2 caused increases in 
unwanted marker expression but when used in combination 
did not further enhance this. In all cases unwanted gene 
expression was evident despite increases in wanted gene 
expression. TGFβ2 and TGFβ3 can replace TGFβ1 positive 
effects of chondrogenic differentiation. 
(Jakobsen 
et al., 2014) 
Table 2.1 Examples of TGFβ isoforms for chondrogenic differentiation using BM-MSCs 
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Given the varied and contradictory findings of the effects demonstrated by previous 
research by other groups, I sought to distinguish if any difference in the effect of TGFb isoforms 
on chondrogenic differentiation could be detected. To achieve this, based on the advantages and 
disadvantages laid out in Chapter 1, I utilised 2 basic hydrogel models to investigate their effects; 
alginate beads and agarose constructs. I also utilised AFSCs as the cell type to undergo 
chondrogenic differentiation since they have been shown capable of undertaking this process, 
are relatively easy to procure and have been less readily researched compared to other more 
commonly used stem cell types. This chapter furthers our understanding of how AFSCs react to 
growth factor stimulation within 3D hydrogel models at an early stage of a chondrogenic 
differentiation protocol (up to 14 days) by investigating common biochemical markers which 
signify ECM synthesis indicative of chondrogenic differentiation. Using this method, I sought to 
determine whether there were any differences in the effect of TGFβ1 or TGFβ3 supplementation 
on this process. 
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2.2 Methods 
2.2.1 Ethics 
Ethical approval was granted by the joint UCL/UCLH Committees on the Ethics of Human 
Research (REC: 14/LO/0863). Human amniotic fluid (N = 8) was collected with informed consent 
from women undergoing elective amniocentesis, amniodrainage or laser procedures for foetal 
karyotyping, polyhydramnios or therapeutic procedures at University College London Hospital 
NHS Foundation Trust. The outlines of the research and what the samples would be used for 
were explained before informed consent was provided. The collection procedure for 
amniocentesis involved ultrasound guided placement of a needle into the amniotic cavity whereby 
amniotic fluid was extracted using sterile syringes (50 - 2000 ml). Cells with an abnormal 
karyotype were excluded from the study. Example consent forms are included in the appendix of 
this thesis. Clinical data was recorded for cells used in all experiments (Tables 2.2 and 2.3). 
Alginate 7- and 14-day experiments 
Code ID Gestational age Source Karyotype Maternal Age 
H0303 15 weeks + 5 days Amniocentesis Normal 38 
H0294 18 weeks + 1 days Amniocentesis Normal 33 
H0318 14 weeks + 2 days Amniocentesis Normal 32 
H0272 20 weeks + 6 days Amniodrainage Normal 23 
H0300 21 weeks + 5 days Amniocentesis Normal 28 
 
Agarose 14-day experiments 
Code ID Gestational age Source Karyotype Maternal Age 
H0344 29 weeks Laser Normal 32 
H0298 15 weeks + 1 day Amniocentesis Normal 38 
H0273 25 weeks + 2 days Laser Normal 33 
H0315 15 weeks + 3 days Amniocentesis Normal 41 
 
*Data retrieved includes the gestational age of the foetus from which the sample was extracted, the 
procedure undertaken to remove the fluid, the resulting karyotype of the cells extracted from the fluid and 
the maternal age. 
Table 2.2: Clinical data pertaining to cells collected for alginate 7- and 14-day experiments* 
Table 2.3: Clinical data pertaining to cells collected for agarose experiments* 
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2.2.2 AFSC isolation and culture 
Fluid samples were provided an identification number to protect the patient’s identity and 
for record keeping (for example H0123). To culture and preserve the stemness of the AFSCs, 
culture medium containing αMEM (Thermofisher Scientific, UK), FBS (Thermofisher Scientific, 
UK), L-glutamine (Sigma-Aldrich Ltd, UK), penicillin with streptomycin (Sigma-Aldrich Ltd, UK), 
Chang B and Chang C supplements (FUJIFILM Irvine Scientific, UK) was used. Of the Chang 
supplements used here, Chang B is a basal medium whilst Chang C is a lyophilised component 
which contains 6% v/v Newborn calf serum, fibroblast growth factors, insulin and no antibiotics. 
This media formulation will hence forth be referred to as Chang medium (Table 2.4). 
Amniotic fluid samples were filtered through a 40 /µm cell strainer into a 50 ml volume Falcon 
tube to remove debris from the sample. Filtered samples were then centrifuged at 300 x g for 5 
minutes and the resulting supernatant removed prior to resuspension in 2 ml of defined Chang 
medium. 500,000 cells were transferred to each sterile non-tissue culture treated bacteriological 
petri dishes containing 10 ml of warm Chang medium and incubated at 37°C with 5% CO2 
(HeraCell Incubator, Thermofisher Scientific, UK).  
 
Reagent Concentration Source 
aMEM n/a Sigma 
FBS 16% Sigma 
L-glutamine 2 mM Sigma 
Penicillin/Streptomycin 1000 U/µg Sigma 
Chang B 18% Irvine Scientific 
Chang C 2% Irvine Scientific 
 
NB: It was noted that upon transfer of the cells between institutes, the cells would struggle to 
adhere to the bacteriological plates that are used for AFSC culture at the Institute of Child Health 
(ICH). As the vials all remained frozen during transit it was thought unlikely to be causing this 
problem. However, the one area where methods differed in culture was in culture medium 
filtration. At ICH, a vacuum pump system was used with a Merck-Millipore Stericup set up to filter 
the solution rapidly within a few seconds. At the Institute of Bioengineering (IOB), without access 
to a vacuum pump system I used hand-made filters using 0.22 µm filter papers, autoclavable filter 
Table 2.4: Chang medium constituents for AFSC culture. 
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holders and syringes. This process took considerably longer to perform and possibly withheld 
some growth factors from transferring through. Due to this, culture of the AFSCs was moved back 
to ICH for all further experiments. 
2.2.3 Cell counting - Trypan blue exclusion principle 
Cells were diluted 1:1 with 0.4% trypan blue solution (Sigma-Aldrich Ltd, UK). 10 μl of the 
cell suspension/trypan blue solution was then placed into the 0.1 mm deep chamber of the 
haemocytometer under the coverslip and visualised using a Leica DM1000 LED microscope at 
10x magnification. The presence of Newton’s rings was checked to ensure the coverslip was 
adequately adhered to the haemocytometer by suction. The cells were then counted within the 
central 5 x 5 grid or 4 x 4 corner grids for high and low cell densities respectively (Figure 2.2). 
Any cells that were blue in colour were counted as dead. Equation A was used to determine cell 
number in 1 ml for low cell densities and equation B was used to determine cell number in 1 ml 
for high cell densities: 
 
 
 
 
 
 
 
 
 
 
 
 
Number of cells counted 
Number of squares counted 
x 2 x 10,000 Number of cells in 1ml = 
Number of cells counted 
5 
x 2 x 25 x 10,000 Number of cells in 1ml = 
A 
B 
1 2 
4 3 
5 
Figure 2.2: Cell counting. Left: A standard haemocytometer grid. Corners labelled 1, 2, 3 and 4 are 
used for low densities whilst grid 5 is used for high densities. Right: Displayed is one of the 4 x 4 grids 
used to count AFSCs on the haemocytometer. AFSCs are in suspension and stained with Trypan blue 
to help with visualisation and to distinguish dead cells. Image taken at x10 magnification. 
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2.2.4 Magnetic activated cell sorting (MACS) 
When cell confluency reached 70 - 80%, Chang C culture medium was removed from the 
petri dish which was then washed using 5 ml PBS (Sigma-Aldrich Ltd, UK) to remove any residual 
culture medium. 3 ml of TrypLE (Thermofisher Scientific, UK) was applied and the dish placed in 
an incubator for 5 minutes to detach the cells. This was checked via observation of the cells in a 
light microscope where the cells should be free floating and have a circular morphology. In 
circumstances where the detachment was incomplete, a further 2 minutes in the incubator was 
possible. TrypLE was deactivated via the application of an equal quantity of Chang C culture 
medium and this mixture was then centrifuged at 300 x g for 5 minutes. While this centrifugation 
took place, the MACS buffer solution was made (Table 2.5). 
 
 
Reagent Concentration Company 
PBS 1x Sigma 
BSA 5 mg/ml Sigma 
EDTA 2 nm Sigma 
 
*Mix and filter using a 0.2 µm filter. Store at 2 - 8°C and keep on ice before use. 
 
Following centrifugation, the supernatant was removed and the cell pellet re-suspended 
in 300 µl of buffer per 108 cells. 100 µl of FcR blocking reagent (Miltenyi Biotec Ltd, UK) and 100 
µl of CD117 microbeads (Miltenyi Biotec Ltd, UK) were then added to the sample and incubated 
on ice for 15 minutes. 1ml of buffer was then used to wash the cells and then centrifuged (300 x 
g, 10 minutes). The supernatant was removed and 500 µl of buffer was added per 108 cells. A 
magnetic bead column ((Miltenyi Biotec Ltd, UK) was placed within an OCTOMACS separator 
(Miltenyi Biotec Ltd, UK) attached to a MACS multistand. Round bottom polypropylene tubes were 
labelled as either waste, CD117 positive and CD117 negative. The tube labelled ‘waste’ was first 
placed beneath the column which was subsequently washed with 500 µl of buffer into the waste 
tube (no physical input was applied). Next, the CD117 negative tube was placed beneath the 
column. The cell suspension was then added and allowed to pass through again with no physical 
input. 500 µl of buffer was added through the column 3 more times. The column was then removed 
Table 2.5: MACS buffer solution* 
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from the OCTOMACS and placed over the CD117 positive tube where 1 ml of buffer was added 
and the syringe applied to the column to forcefully eject the trapped cells into the collecting tube 
(Figure 2.3). The CD117 positive tube was then centrifuged at 300 x g for 5 minutes and 
resuspended in 1ml of Chang medium where the cells were then placed back into monolayer 
expansion whilst the negative cells were discarded. Following selection, Chang culture medium 
was changed every 48 - 72 hours from the day of plating. When the cells reached 70 - 80% 
confluency the cells were passaged, counted and split into 2 new plates in 10 ml culture medium 
(500,000 cells per plate).
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Figure 2.3: Magnetic activated cell sorting (MACS). AFSCs are sorted for the cell surface marker CD117 from a heterogeneous sample population. Cells are incubated with magnetic 
microbeads (    ) specific for CD117. Following incubation, the cells were placed into a MACS column and passed through using gravity to remove the negative cells (    ). Finally a 
plunger was applied to forcefully eject the CD117 positive cells (    ) held within the column. Positive cells are returned to culture while negative cells are either frozen or discarded. Cell 
culture images taken at x10 magnification. 
Cell ejection Cell suspension 
CD117 microbead incubation 
Before MACS After MACS 
20µm 20µm 
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2.2.5 FACS 
AFSCs were incubated in 300 μl MACS buffer solution (Table 2.25). 100 μl of FCR 
blocking reagent (Miltenyi Biotec Ltd, UK) and 1 µg/ml of different fluorophores were then added 
to this solution (Table 2.6) before being incubated on ice for 15 minutes. 1 ml of buffer was used 
to wash the cells, centrifuged (300 x g, 10 mins). 4’6-diamidino-2-phenylindole (DAPI) staining 
was also added to quantify the number of alive cells within the sample. The supernatant was 
removed, washed in 500 μl of buffer and then transferred to the flow cytometer for analysis. For 
each test, 1 x 105 cells were used in 100 µl of buffer. Cells were analysed using LSRII cytometer 
with BD FACSDiva Software v.6.1.3. Subsequent analysis was performed using FlowJo10 
software (Treestar, USA). All fluorophores listed supplied by BD Biosciences. 
 
 
Fluorophore 
Peak 
emission/nm 
Target Target function 
PE-A 578 CD117 
Stem cell marker involved in signalling activation and 
proliferation 
APC-CY7 774 CD34 
Transmembrane glycoprotein expressed on hematopoietic 
stem, endothelial progenitor and foetal stem cells 
APC-A 660 CD73 
Membrane bound enzyme which hydroylses adenosine 
monophosphate (AMP) to bioactive adenosine. Expressed on 
lymphocytes, follicular dendritic cells and marrow stromal cells 
Brilliant 
Violet 421 
421 CD90 
GPI anchored protein of Ig superfamily. Expressed on 
neurons, foetal liver cells and hematopoietic stem cells  
PE-CY5 667 CD105 Endoglin, receptor for growth factors TGFβ1 and TGFβ3  
FITC 520 CD45 
Leukocyte common antigen. Type 1 transmembrane protein 
involved in cell growth, mitotic cycle and oncogenic 
transformation. 
DAPI 461 Dead cells 
Dye that can stain the nuclei of dead cells; live if used at high 
enough concentrations 
Table 2.6: Fluorophores used for cluster of differentiation detection on AFSCs* 
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2.2.6 AFSC encapsulation in alginate 
The working sodium alginate solution was formed using sodium alginate keltone LV (ISP, 
Germany). A 6% alginate solution (0.06 g alginate per ml of sterile Earls balanced salt solution 
(EBSS)) was mixed overnight on rollers at 37°C and sterilised by autoclaving. The 100 mM CaCl2 
gelling solution was made by adding 7.35 g CaCl2 (Sigma-Aldrich Ltd, UK) to 500ml of standard 
chondrocyte growth medium (DMEM + 20% FBS). The solution was then mixed thoroughly and 
filtered through a 0.2 μm filter. An equal volume of cell suspension was added to the sterile 
alginate and placed on rollers for 10 minutes to allow adequate mixing. The cell 
suspension/alginate mixture was then transferred to a new sterile 1 ml syringe with a 21Ga needle 
attached. The calcium chloride solution was then placed into a 25 ml sterile beaker. The cell 
alginate mixture was added dropwise to the calcium chloride solution from a fixed height of 10 cm 
whereby bead structures instantly formed upon impact with the solution. Care was taken to 
prevent the formation of air bubbles within the solution as this would introduce bubbles into the 
beads causing immediate rupture. The beads were then incubated in the calcium/DMEM solution 
for 10 minutes before being washed in EBSS and then added to a 24 well plate and suspended 
in a minimum volume of 3 ml of chondrogenic differentiation medium. Each bead was calculated 
to contain 4 x 106 cells/ml.  Day 0 samples were immediately frozen at -20°C or snap frozen to 
preserve them as control samples. 
2.2.7 AFSC encapsulation in agarose 
6% low gelling agarose (Sigma-Aldrich Ltd, UK) solution was made (0.06 g agarose per 
ml EBSS) and autoclaved for 30 minutes then placed in a 37°C oven to cool down. The cell 
suspension was then added to the sol agarose suspension in a 1:1 ration and mixed on rollers 
inside the 37°C oven. After 5 minutes, the agarose/cell mixture was removed from the oven and 
quickly pipetted into the prepared mould using a Pasteur pipette. Any excess mixture was 
removed from the overflowing mould and a glass cover was then applied to the top of the mould 
to secure the constructs inside. The mould was then transferred a large petri dish, sealed and 
then moved to a 5°C fridge for 5 minutes before returning to the culture hood. A Pasteur pipette 
was then used to push the constructs out from the mould holes and the constructs immediately 
placed inside well plates containing the same volume of culture medium used in alginate bead 
culture. Each construct was calculated to contain 4 x 106 cells/ml. Day 0 samples were 
immediately frozen either at -20°C or snap frozen using liquid nitrogen within a plastic dewar. 
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2.2.8 Chondrogenic differentiation culture 
Chondrogenic differentiation medium consisted of high glucose Dulbecco modified eagle 
medium (HG-DMEM), insulin, transferrin, selenium (ITS), bovine serum albumin (BSA), 
GlutaMAX, penicillin streptomycin, L-proline, sodium pyruvate, L-ascorbic acid and linoleic acid 
sourced from Sigma-Aldrich Ltd, UK (Table 2.7). Each construct or bead was supplied with 3 ml 
of chondrogenic differentiation media and cultured within a 24 well plate. For all differentiation 
experiments in this chapter, samples were treated either with Chang medium (control), basal 
chondrogenic medium (control), 10 ng/ml TGFβ3 (R&D Biosystems, USA) or 10 ng/ml TGFβ1 
(R&D Biosystems, USA). Culture experiments lasted for either 7 or 14 in the case of alginate 
beads and 14 days for agarose constructs. Day 0 samples were immediately frozen and stored 
at -20°C for analysis. 
 
Reagent Concentration Company 
HGDMEM (phenol free) n/a Sigma 
Penicillin/Streptomycin 1000U/100 µg/ml Sigma 
L-proline 40 mg/ml Sigma 
Sodium pyruvate 100 mM Sigma 
BSA 1 mg/ml Sigma 
GlutaMAX 200 mM Gibco 
 
Day of use additions: 
 
Reagent Concentration Company 
ITS+1 liquid media supplement 100x Sigma 
L-ascorbic acid 50 mg/ml Sigma 
 
 
 
 
 
 
Table 2.7: Constituents of basal chondrogenic medium* 
*Standard combination of chondrogenic differentiation components can be added at the same time 
and will last up to 1 month when stored at 4°C.  
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2.2.9 Digestion of AFSC seeded alginate beads 
Constituents of the alginate digest buffer were added to 480 ml of PBS and adjusted to 
pH 6.0 using sodium hydroxide (NaOH, Sigma-Aldrich Ltd, UK) before adding up to a final volume 
of 500 ml (Table 2.8). Constructs were then submerged in 1 ml of digest buffer within an O ringed 
tube then agitated overnight at 60°C. Digested samples were then stored long term at -20°C or 
assayed immediately. 
Reagent Concentration 
Sodium chloride 150 mM 
Sodium citrate 55 mM 
EDTA 5 mM 
Cysteine hydrochloride 5 mM 
Papain 0.56 units/ml 
 
2.2.10 Digestion of AFSC seeded agarose constructs 
Constituents were added to 480 ml PBS and adjusted to pH 6.0 using NaOH before 
making up to final volume of 500 ml (Table 2.9). Constructs were placed within standard 2 ml 
Eppendorf tubes and heated to 70°C for 1 hour within a temperature-controlled oven. The 
samples were then allowed to cool within a 37°C oven before 10 μl of agarose (Sigma-Aldrich 
Ltd, UK) and 5 μl of papain (Sigma-Aldrich Ltd, UK) was added to each sample. The constructs 
were then digested overnight at 37°C to allow for agarase digestion. Once complete the samples 
were returned to the 60°C oven for 1 hour to allow papain digestion of the remaining polymers. 
Samples were then assayed immediately or stored at -20°C. 
 
Reagent Concentration 
PBS 1x 
Cysteine hydrochloride monohydrate 9 µM 
EDTA 2.76 µM 
 
 
Table 2.8: Constituents of alginate digest buffer. 
Table 2.9: Constituents of agarose digest buffer 
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2.2.11 Viability profiling using live dead assay 
Cell viability within the hydrogel specimen was determined using a two-colour assay to 
stain and identify viable or non-viable cells within the hydrogel using Calcein-AM (Molecular 
Probes, UK) and Ethidium homodimer-1 (Calbiochem, UK), respectively. Each hydrogel 
specimen was bisected using a no. 11 scalpel and immersed in 1 ml of DMEM + 20% FBS 
containing 5 µm of Calcein-AM and Ethidium homodimer-1 for 30 minutes at 37°C with gentle 
agitation. Each specimen was then mounted on a glass slide before imaging. Calcein-AM is able 
to permeate cells and upon contact with intracellular ubiquitous esterases is converted into a 
highly fluorescent polyanionic calcein which is retained within the live cell. This fluorescence 
produces an intense uniform green fluorescence emission at ~515 nm when excited at ~495 nm. 
Ethidium homodimer-1enters non-viable cells where the cell membrane has been perforated and 
non-covalently binds to the nucleic acids; producing a 40-fold increase in fluorescence. In non-
viable cells, Ethidium homodimer-1 will bind DNA and emit a fluorescence at ~635 nm when 
excited with green light at 495 nm. Viability was determined using a systematic sampling 
procedure whereby a standard sample area of 0.5 x 0.25 mm under a x20 objective and the 
sampling area was run from the top of the specimen to the base with the number of live cells 
(green) and dead cells (red) were counted (Figure 2.4). Alginate beads and agarose constructs 
were visualised using a Zeiss confocal microscope at x 20 objective. Viability was assessed using 
a systematic sampling procedure for both hydrogels but was localised at edge and core regions 
of the agarose construct due to its size. The percentage viability was then calculated [(viable 
cells/total cells) * 100]. The mean percentage viability was calculated from 3 replicate cell counts 
from different field views and data represented with standard error of the mean. 
 
 
 
 
 
 
 
Figure 2.4: Measuring viability using grid system. Each cell counted within the grid was counted 
using standard exclusion principles through both green and red wavelength excitations. This was 
repeated 6 times through each sample before quantification. 
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2.2.12 Hoechst assay 
The DNA content was measured using the DNA specific fluorometric Hoechst 33258 to 
generate a standard curve. The binding of Hoechst to adjacent adenine thymine pairs of DNA 
results in a fluorescence that can be measured taken at 360 nm excitation and 460 nm emission 
wavelengths. Concentration of DNA was extrapolated from deoxyribonucleic acid sodium salt 
from calf thymus (Sigma-Aldrich Ltd, UK) to establish a standard curve for DNA content. DNA 
standard (1 mg/ml) was first diluted to a working concentration (20 µg/ml) was performed using 
980 µl 2xSSC/digest buffer (Table 2.10 and 2.11) and 20 µl of stock standard. A serial double 
dilution using 2xSSC/digest buffer as the 0 µg/ml standard was performed producing 
concentrations of 20, 10, 5, 2.5, 1.25, 0.666 and 0.333 µg/ml of DNA. Subsequently, 100 µl of 
standard and samples was pipetted into each well of a 96 well plate. Working solution of Hoechst 
was made using 19.98 ml of SSC/digest buffer and 20 µl of Hoechst stock solution. 100 µl of 
Hoechst reagent was then added to all wells. The plate was then transferred to a BMG FLUOstar 
OPTIMA microplate reader to be scanned (FLUOstar, BMG Labtech Ltd, UK). DNA concentration 
of unknown samples was then calculated from the equation of the linear regression line applied 
to the standard concentrations (Figure 2.5). 
Digest buffer 
Reagent Weight/g 
Cysteine Hydrochloride 0.788 
EDTA 0.403 
 
Digest buffer: Make up to approximately 480 ml with PBS and adjust to pH 6.0 with NaOH. Make up to  
500 ml finally and freeze aliquots at -20°C. 
 
 
 
 
 
 
Table 2.10: Digest buffer sodium citrate buffer constituents. 
20x sodium citrate buffer 
Reagent Weight/g 
Sodium Chloride 87.65 
Trisodium Citrate 44.1 
 Table 2.11: Sodium citrate buffer constituents 
20x SSC stock buffer: Make up to approximately 480 ml then pH adjusted to 7.0 using 1 M NaOH/1 M 
HCl. Make up to 500 ml and sterilise by autoclaving. For 2 x working buffer used in the assay, dilute 25 
ml of 20 x SSC buffer in 225 ml of dH2O. 
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Figure 2.5: Example DNA assay standard curve with linear regression applied. The curve 
demonstrates the relationship between the fluorescence intensity and the DNA concentration. Linear 
regression model applied to the data to allow calculation of DNA content of our unknown samples. 
Rearrangement for x allows input of the fluorescence values to provide data regarding DNA concentration. 
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2.2.13 Optimisation of DMMB assay for sulphated glycosaminoglycans 
Principle 
1,9-dimethylmethylene blue (DMMB) is a highly metachromatic dye first introduced for 
the histological detection of glycosaminoglycans (GAGs) by Taylor and Jeffree in 1969, with an 
analytical method for quantitative determination of GAG content proposed by Farndale in 1982 
(Taylor and Jeffree, 1969, Farndale, 1982). In principle, when DMMB forms complexes with 
negatively charged carboxyl groups and sulphate groups which are present on GAGs, this initiates 
a metachromatic shift in the absorbance maximum of the dye (600 nm to 525 nm). As such the 
reduction in absorbance as measured at 595 nm with increasing GAG concentration can be 
measured and GAG concentration accurately determined. One complication for DMMB assay 
application for use in alginate embedded cells is that alginate contains carboxyl groups which also 
bind to the DMMB used in this assay. This can therefore affect the accuracy of the measurement. 
In 1996, Enobakhare et al. demonstrated that acidification of the DMMB preparation to below pH 
2 retains the high affinity binding of the sulphate groups present on sulphated GAG but blocks 
binding of it to the carboxyl groups present on the alginate polymer (Enobakhare et al., 1996). 
However, despite following this protocol accurately, it was frequently observed that positive 
values would be registered in control day 0 samples in which there should have been no GAG 
present. This observation was present for both alginate and agarose hydrogels. Therefore, I 
investigated the use of different pH DMMB reagents on day 0 samples for both agarose and 
alginate samples to assess which pH DMMB would produce the weakest false positive result from 
day 0 samples. 
Optimisation method 
Day 0 samples of alginate beads and agarose constructs were stored and digested using 
the standard enzymatic protocol. Following digestion, samples were stored at -20°C or analysed 
immediately. DMMB solutions were prepared within a fume hood following standard procedures. 
Firstly, 0.016 g of DMMB (Sigma-Aldrich Ltd, UK) was added to ethanol (5 ml, Sigma-Aldrich Ltd, 
UK) and allowed to dissolve into solution. 2 grams of sodium formate (Sigma-Aldrich Ltd, UK) 
was subsequently added to deionised H2O (850 ml). The two solutions were then mixed and made 
up to 1 litre using deionised H2O. Finally, the pH was adjusted to pH 3.0 or 1.5 using formic acid 
for the purposes of optimisation. Due to light sensitivity, the solutions were covered in foil and 
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kept in the dark prior to use. Standard concentrations of chondroitin sulphate (Sigma-Aldrich Ltd, 
UK) were used to create a standard curve based on the absorbance at 525 nm which could then 
be used to compare and determine the GAG concentration of the unknown samples, within the 
range of 0 - 50 μg/ml (Figure 2.6A). In brief, 1 mg/ml of standard was diluted 1:10 with digest 
buffer before preparation of the dilution series. Prior to plating within a clear 96 well plate, all 
samples and standards were vortexed. Samples and standards were run in triplicate (40 µl/well) 
before a multichannel pipette was used to add DMMB reagent to the wells (250 μl/well). For 
detection, a SpectrostarNano system (BMG Labtech Ltd, UK) was used whereby plates were 
initially shaken at 360 RPM, orbital for 10 seconds prior to measurement at 595 nm. A 95% 
confidence limit of GAG concentration is maintained due to the minimal deviations for the standard 
from a linear fit. R2 values close to 1 were used. 
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Optimisation results 
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Figure 2.6: Results of DMMB assay optimisation. A: Lowering of DMMB pH results in a reduced 
gradient standard curve but maintains distinction between each standard concentration. B: A distinct 
colour change is associated with increasing concentration of chondroitin sulphate standards typically 
associated with DMMB assay at both concentrations investigated. C+D: Lowering of pH completely 
removes false positive GAG concentration readings in digested cell free agarose samples but retains 
positive reading in alginate samples. N = 3. Error bars = ± SEM. 
66 
 
Reduction of DMMB pH from 3.0 to 1.5 resulted in an expected flattening of the standard 
curve associated with increasing GAG concentration used for the assay (Figure 2.6A). This is 
attributed to a reduction in the metachromatic shift associated with the interaction between DMMB 
and sulphated GAG (Figure 2.6B).The presence of digested alginate exposed to DMMB reagent 
at pH 3.0 was certainly unsuitable for this assay, in line with previous observations made by 
Enobakhare et al (Figure 2.6C). At the same pH, agarose samples registered smaller amounts 
of GAG even in blank constructs, but at much lower levels in comparison to the alginate. 
Reduction of the DMMB pH to 1.5 reduced the DMMB reaction significantly in regard to alginate 
samples (a 5 - fold decrease in GAG concentration) but still registered a positive GAG value at 
levels comparable to that of agarose constructs observed at pH 3.0 (Figure 2.6D). In regard to 
agarose, the reduction in pH to 1.5 greatly reduced positive day 0 control readings in the sample, 
as should be expected from a blank control construct. Therefore, for the biochemical analysis of 
digested alginate and agarose constructs a reduced pH DMMB of 1.5 was used.  
 
Final DMMB method used for analysis following optimisation 
Standard solutions of chondroitin sulphate (Sigma-Aldrich Ltd, UK) were used to create 
a standard curve based on the absorbance at 525 nm which could then be used to compare and 
determine the GAG concentration of the unknown samples, within the range of 0 - 20 μg/ml. A 
SpectrostarNano system (BMG Labtech Ltd, UK) was used for this detection. A 95% confidence 
limit of GAG concentration was maintained due to the minimal deviations for the standard from a 
linear fit. R2 values close to 1 were observed. The concentration of unknown samples was 
determined by rearranging the equation of the trendline in terms of x. Total GAG synthesis in each 
digest and its corresponding medium was then calculated and normalised to its DNA 
concentration to provide GAG synthesis. 
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2.2.14 Statistics 
To determine which statistical test to use, all biochemistry data was checked for normal 
distribution using a Shapiro-Wilk normality test in SPSS (SPSS version 10, IBM, USA). A QQ plot 
was included in this analysis (Figure 2.7). 
 
 
 
 
 
 
 
The histogram and QQ plots of the raw GAG synthesis data demonstrated a non-normal 
distribution with the Shapiro-Wilk test giving a statistically significant value of 0.000095. This 
reduces the number and strength of statistical tests that can be performed on the data. In order 
to circumvent this, the raw data was transformed to its natural log and log10.  Following the 
transformation of the data the resulting QQ plot changed significantly from before (Figure 2.8): 
 
 
 
 
 
 
 
 
However, despite the log transformations performed, the Shapiro-Wilk test still retained 
statistically significant results (p<0.05) indicating that the data was not normal. Normal distribution 
assumption is a requirement for standard t tests and ANOVA statistical tests. Because of this, a 
non-parametric test was used on the raw biochemistry and viability data. The statistical test 
Figure 2.7: Representative histogram and QQ plot of abnormal data. Clear kurtosis and skewness 
present within the dataset, therefore the data fails the first assumption required for parametric testing. 
Figure 2.8: Natural log transformation of raw GAG synthesis data. Despite transformation of the data, 
there is still an inherent skew that still makes the data follow a non-normal distribution. 
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selected for analysis was the Mann-Whitney U test. All results in this study were shown as the 
mean from replicates and individual experiments with error bars representing the standard error 
of the mean (SEM). The number of patients and replicates are indicated in figure legends. In all 
comparisons, p<0.05 was considered statistically significantly for tests comparing treatment 
conditions vs controls and inter-treatment comparisons.  
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2.3 Results 
2.3.1 FACS analysis of CD117 selected AFSCs following 3 passages and MACS selection. 
A sample of AFSCs (source: H0315) post CD117 MACS selection and prior to culture 
experiments was investigated to look at the expression of common stem cell surface markers. 
Analysis of the sample showed a high expression for the markers CD73, CD90, CD117 indicative 
of common stem cell features (Figure 2.9). Further analysis of the cell sample showed positive 
expression of CD34 and CD105 (88 and 93.8% respectively) but showed negative expression of 
the non-stem marker CD45 (<3%) (Figure 2.10). 
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Figure 2.9: Flow cytometry analysis of stem cell marker expression following 3 passages and 
MACS selection. Analysis of human AFSCs demonstrated that the cells were strongly positive for the 
stem cell markers CD73 and CD90 (Figure 2.9B and D; >90% of population expressed the markers) 
including the selected marker CD117 (Figure 2.9C; 88.1%). DAPI staining indicated that the majority of 
cells were alive post MACS selection and prior to encapsulation (Figure 2.9A; viability of 88.8%). N = 1, 
independent experiments, representative examples shown in figure). Percentages of positive cells for 
the specific marker displayed based on histogram plot. 
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Figure 2.10: Further analysis of stem cell and non-stem cell markers prior to hydrogel 
encapsulation. MACS selected AFSCs from the same sample group were negative for the non-stem 
cell marker CD45 (Figure 2.10F; <3% of population) but positive for CD34 and CD105 expression 
(Figure 2.10E and G; 88 and 93.8% respectively).  N = 1, percentages of positive cells for the specific 
marker displayed based on histogram plot. 
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2.3.2  Temporal effect of hydrogel encapsulation on AFSC viability in alginate and agarose 
materials. 
The viability of AFSCs/alginate beads treated with either TGFb1 or TGFb3 was performed 
at 7 and 14 days of culture using a live-dead assay. AFSC/agarose constructs treated with TGFb1 
or TGFb3 were also assessed for viability using this method but only for constructs cultured at 14 
days. All samples were compared to Chang, basal chondrogenic medium and day 0 samples.  
Viability of AFSC/alginate beads was initially detected at > 90% at day 0 with good 
distribution of cells within the bead. No statistical differences were detected when comparing day 
7 TGFb treated AFSC/alginate beads with day 0 controls (Figure 2.11; p>0.05). The same 
situation was observed when comparing day 14 TGFb treated AFSC/alginate beads with day 0 
controls also (Figure 2.12; p>0.05). No obvious differences were detected between TGFb treated 
samples and Chang/Basal chondrogenic medium controls (p>0.05). No clear difference was 
detected between TGFb isoform treatments (p>0.05). 
Viability of cells within the core and edge of AFSC/agarose constructs was initially 
detected at >80% and 70% respectively at day 0 (Figure 2.13). No differences were detected 
when comparing TGFb treated samples with day 0 controls (p>0.05). Similarly, no obvious 
differences were detected between all treatment options at 14-days of culture (p>0.05). No 
marked differences were detected between core and edge viability indicating homogenous cell 
viability throughout the constructs. No statistical differences were also detected between TGFb 
isoform treatments (p>0.05). 
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Figure 2.11: Viability of AFSCs within alginate beads is not affected by short term 7-day culture. No 
statistical differences detected between different treatment conditions and controls after 7 days in culture.  
Error bars represent ± SEM. N = 3. White bar in images indicates 1 mm scale bar. 
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Figure 2.12: Viability of AFSCs within alginate beads is not affected by 14-day culture. Quantification 
of viable cells after 14 days of treatment indicated. Error bars represent ± SEM. N = 3. White bar in images 
indicates 1 mm scale bar. 
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Figure 2.13: Viability of cells is unaffected after 14 days of culture compared to control. A: Agarose 
constructs maintained a high level of cellular viability after 14 days of culture in core and edge of the 
constructs (>80 and >70%). B: The size of the agarose constructs required the use of a confocal 
microscope to assess the number of viable cells in core and edge images. C + D: No statistical differences 
were observed between treated samples and controls at edge and core (p>0.05). No statistical 
differences were also detected between TGFb isoform treated samples also at edge and core sections 
(p>0.05). Error bars represent ± SEM. N = 3. White scale bar represents 1 mm. 
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2.3.3  Effect of TGFb treatment on GAG synthesis and DNA content of AFSC/alginate and 
AFSC/agarose constructs. 
 
AFSC/alginate beads 
AFSC/alginate beads treated with 10 ng/ml of exogenous TGFb3, showed no statistically 
significant increases in GAG synthesis compared to Chang medium, basal chondrogenic medium 
and day 0 controls (p>0.05; Figure 2.14A). Samples treated with TGFb1 or TGFb3 showed no 
differences compared to control samples (p>0.05). Control samples demonstrated marked 
decreases in GAG synthesis compared to day 0 samples (p<0.01). DNA content significantly 
increased when comparing samples treated with exogenous TGFb1 or TGFb3 to all controls at 
day 7 and at day 14 (Figure 2.14B). No obvious differences were detected between TGFb1 and 
TGFb3 samples in terms of GAG synthesis or DNA content changes (p>0.05). 
AFSC/agarose constructs 
Treatment of AFSC/agarose constructs with 10 ng/ml of exogenous TGFb1 or TGFb3, showed a 
statistically significant increase in GAG synthesis relative to basal control medium treatment but 
not Chang medium (Figure 2.15A). Only exogenous application of TGFb1 or TGFb3 samples 
showed an increase in DNA content compared to all control samples (Figure 2.15B). No marked 
differences in DNA content were detected between control samples. Further to this, no statistical 
differences were detected between TGFb1 and TGFb3 within AFSC/agarose constructs in terms 
of GAG synthesis or DNA content changes (p>0.05). 
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Figure 2.14: Alginate encapsulation of AFSCs and treatment with TGFb results in significant DNA 
content increases. Statistically significant decreases in GAG synthesis were detected between basal, 
Chang control groups compared to day 0 control with no differences detected with the TGFb1/3 treated 
samples (A). DNA quantification demonstrated statistically significant differences following TGFb1/3 
treatment after 7 days compared to day 0 controls, basal and Chang treatments (B). No statistical 
differences are detected between treatment of each TGFb isoform in terms of GAG synthesis and DNA 
content. * = p<0.05 and *** = p<0.01. Error bars represent ± half range. N = 8 for each condition. Samples 
sourced from 2 different patients. *** indicates sample compared to day 0, +++ indicates sample 
compared with Chang, $$$ indicates sample compared with basal control. Day 0 data included to indicate 
effect of alginate presence on assay. 
*** *** *** 
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Figure 2.15: AFSCs embedded within agarose constructs initiates GAG synthesis increases in all 
treatment conditions but cell proliferation only observed in TGFb treated samples. For GAG 
synthesis, statistically significant differences were detected when comparing the average of TGFb1 and 
TGFb3 treated samples to the average of basal chondrogenic medium treated samples. Treatment of 
samples with either TGFb1 or TGFb3 isoforms resulted in a statistically significant increase in DNA content 
compared to all control samples. No significant differences were detected between TGFb isoforms detected 
in terms of GAG synthesis and DNA content increases. Error bars represent SEM. N = 12 for each condition. 
Samples sourced from 3 different patients. +++ indicates sample compared with Chang treatment (p<0.01), 
$$$ indicates sample compared with basal medium treatment (p<0.01). All data normalised to day 0. 
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2.3.4 Alginate beads demonstrate fragility and failure after 14 days of culture 
 
AFSC/alginate beads become increasingly fragile as time in culture increases resulting 
in a splitting of the alginate bead structure after 14 days (Figure 2.16A). This phenomenon is also 
associated with an increase in AFSC/alginate weight over time in culture (Figure 2.16B). This 
observation is independent of the treatment applied to each culture. Agarose constructs did not 
demonstrate any structural failings at the same culture time points.  
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Figure 2.16: AFSC/alginate bead structures begins to rupture or disintegrate after prolonged 
culture up to 14 days. A: AFSC/alginate beads after 14 days of culture begin to split demonstrating 
structural weakness of the structure after prolonged culture. B: Positive correlation between 
AFSC/alginate bead weight and time in culture is present, suggesting a swelling of the bead structure. 
N = 6 per time point. Error bars indicate ± SEM. 
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2.4 Summary of results 
• AFSCs used for the chondrogenic differentiation experiments within alginate and agarose 
hydrogels demonstrated high expression of stem cell markers and low expression of non-
stem markers. 
• AFSCs embedded within alginate hydrogels maintained cellular viability with no statistical 
differences detected up to 7 days of chondrogenic differentiation culture. 
• AFSCs embedded within alginate hydrogels showed statistically significant decreases in 
viability after 14 days of culture for all treatments and controls compared to day 0 samples 
but was most significant for TGFb treated samples. 
• AFSC/agarose constructs demonstrated no statistically significant changes in viability 
after 14 days of culture for all treatments and controls. 
• A statistically significant increase in GAG synthesis was detected in TGFb1 treated 
sample after 14 days of culture in AFSC/alginate beads compared to day 0 but not in 
TGFb3 samples. 
• DNA content of AFSC/alginate beads statistically increased in TGFb1 or TGFb3 treated 
samples compared to all controls at day 7. 
• DNA content of AFSC/alginate beads showed only a statistically significant increase 
when comparing TGFb3 treated samples and Chang medium control sample after 14 
days. 
• GAG synthesis statistically increased in agarose constructs treated with either TGFb or 
control medium compared to day 0. 
• DNA content statistically increased in only TGFb1 or TGFb3 treated samples compared to 
all controls. 
• No differences between TGFb isoforms in terms of GAG synthesis and DNA content 
increases in AFSC/agarose constructs. 
• AFSC/alginate beads rupture following 14 days of culture. 
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2.5 Discussion 
This aspect of my thesis set out to investigate the effect of TGFb1 and TGFb3 on the 
chondrogenic differentiation of AFSCs within the first 14 days of culture. GAG synthesis, DNA 
content and viability were examined and compared to control samples of non-growth factor 
supplemented medium (basal), stem cell medium (Chang) and day 0 samples. Furthermore, the 
study used here optimised the methods for examining GAG synthesis in the different hydrogels 
used which can be applied for further investigations. 
2.5.1 AFSCs are heterogeneous cell population with mesenchymal surface markers. 
AFSCs are heterogeneous cell population derived from all three germ layers; ectoderm, 
endoderm and mesoderm. As such the key markers which characterise AFSCs are typically 
associated with mesenchymal marker expression; CD90, CD105, CD44 etc. In addition, 
haematopoietic markers such as CD34 and 45 are absent from this population of cells as well as 
the lack of HLA-DR antigen which contributes to the immunologic properties of the cell type. 
FACS analysis AFSCs used in these experiments was performed in order to confirm that 
after passaging, the cells retained the surface marker profile associated with AFSCs and had not 
differentiated prior to encapsulation. Expression levels observed from FACS analysis were 
consistent with the literature for AFSCs with strong mesenchymal marker expression and weak 
haematopoietic expression. CD117 expression was also confirmed to be high following the MACS 
selection process. 
Since AFSCs are a heterogenous population of cells, this has potential implications for 
differentiation experiments as cells from different donors or different surface expression markers 
could have an impact on the level of differentiation into specific lineages. Since the FACS 
performed here was for informative purposes only, this could have an impact on the cellular 
responses to the chondrogenic differentiation protocols employed in later chapters of this thesis. 
In order to circumvent this in the future, it would be beneficial to utilise FACS to sort the cells on 
their expression profile more selectively, to produce a more homogeneous clonal cellular 
population and therefore eliminate any variation between cells from different populations. Given 
the time/cost constraints and labour intensiveness of such a procedure however this was not 
performed for these experiments. Previous experiments by other groups have indicated that 
AFSCs from different subpopulations express the same markers as each other but may differ in 
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terms of the level of expression. This could therefore have an impact of a particular AFSCs ability 
to differentiate into a specific lineage compared to another. The extent to which this effects 
chondrogenic differentiation has not previously been investigated but could be a potential area of 
future work. 
2.5.2 TGFb1 or TGFb3 treatment does not affect GAG synthesis in AFSC/alginate and 
AFSC/agarose hydrogels at 14 days of culture. 
The findings establish that in AFSC/alginate beads supplementation of TGFb1 to culture 
medium results in a statistically significant decrease in GAG synthesis at day 7 of culture when 
compared to day 0 values, but no other statistically significant observations are made at either 
time point investigated for both TGFb1 and TGFb3 treated samples (Figure 2.14). Furthermore, 
this investigation determines that for AFSC/agarose constructs, all treatment conditions 
investigated increase GAG synthesis relative to day 0 control but only TGFb3 treatment presents 
an increase relative to Chang medium control at day 14 of culture (Figure 2.15). 
The observation that GAG synthesis values did not statistically differ between TGFb1 or 
TGFb3 treated samples is demonstrated in this study. However, the study documents that the 
application of either TGFb isoform did constitute an obvious increase in DNA content compared 
to control samples within both agarose and alginate hydrogels. This suggests that TGFb plays a 
role in instigating in vitro proliferation in the early stages of the chondrogenic differentiation 
protocol used here. This observation is consistent with groups such as Awad et al that 
demonstrated that TGFb is a potent instigator of cellular proliferation during the early stages of 
chondrogenic differentiation but an initiator of chondrogenesis in vitro at later time points (Kim et 
al., 2014, Awad et al., 2004). The level of GAG synthesis achieved here is slightly lower than what 
was reported by Awad et al, although this could simply be due to the increased number of cells 
used in that study (1 x 107 cells/ml) relative to my study (4 x 106 cells/ml) (Awad et al., 2004). 
Furthermore, Dexheimer et al previously suggested from their study that proliferation was 
positively associated with chondrogenesis of MSCs within a pellet culture model (Dexheimer et 
al., 2012). In contrast, Florine et al. identified no changes to DNA content when culturing bovine 
BM-MSCs in agarose constructs but did confirm no statistically significant changes in terms of 
proteoglycan synthesis when culturing BM-MSC/agarose constructs supplemented with TGFb1 
within the first 14 days (Florine et al., 2013).  
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This then poses a question of why control conditions of basal chondrogenic medium (HG-
DMEM with no growth factors added) and Chang medium (stem cell culture medium) caused an 
increase in GAG synthesis compared to day 0 in alginate and agarose hydrogels. One explanation 
for this may be due to the suspension of the cells within a 3D environment. The actin cytoskeleton 
is an integral part of chondrocyte differentiation, so much so that in dedifferentiated chondrocytes 
the addition of actin polymerisation inhibitors (such as cytochalasin D) results in a return to 
rounded morphology and return of chondrogenic gene expression and GAG production (Daniels 
and Solursh, 1991, Loty et al., 1995). By maintaining the stem cells in a rounded morphology as 
opposed to the one they maintain when cultured in 2D, the rearrangement of the actin 
cytoskeleton may instigate different signalling pathways associated with chondrogenesis resulting 
in the cells trying to generate their own microenvironment to enable cell survival. In doing so, 
lower levels of GAG synthesis are observed. 
An alternative explanation is that the optimisation of the DMMB assay to detect the 
presence of sulphated GAGs is still not sufficient. The reduced pH used for the DMMB assay 
makes the binding of DMMB to sulphated GAGs more likely given the higher pKa compared to 
that of alginate. However, by reducing the pH so significantly it is possible that the reduction in 
pH reduces the sensitivity of the assay to sulfated GAGs present in the sample. Given the fact 
that levels of GAG synthesis are very low in the early stages of the chondrogenic differentiation 
protocol, this could result in the decreases observed in my study. 
2.5.3 Viability is not affected in TGFb1 or TGFb3 treated AFSC/agarose constructs or 
AFSC/alginate beads after 14 days of culture. 
In further in vitro studies I determined that the encapsulation of AFSCs within alginate 
beads resulted in no loss of viability over the first 14 days of culture (Figures 2.11 and 2.12). The 
same observation was made in AFSC/agarose constructs which also maintained a high viability 
of cells throughout the 14 days of culture with no statistically significant increases or decreases 
(Figure 2.13).   
The only major difference between the two hydrogel materials is the initial viability of day 
0 samples. In AFSC/alginate bead samples, the initial percentage viability recorded at day 0 was 
in excess of 90% indicating a minimal loss of cells during the encapsulation process. In contrast, 
AFSC/agarose constructs showed an initial viability of between 70 – 80%. A possible explanation 
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for this is the difference in the construction of the hydrogel structures. Since alginate bead 
construction simply requires addition of cells to a sterile alginate solution and then into a cation 
gelling solution, the cells are not stressed by the procedure, provided that the temperature of the 
solutions is maintained at a constant 37°C. In contrast, agarose encapsulation requires the 
agarose to be in a liquid state which can only be achieved by first melting the agarose at a high 
temperature. Whilst the solution is allowed to cool before addition to the cells, the only method of 
temperature evaluation available was through the use of a thermometer. If the solution was 
allowed to cool down too much, the agarose would set requiring the solution to be heated once 
again into its sol state. Once the AFSC/agarose solution is added to the mould, it is then 
transferred to a fridge for 5 minutes in order to speed up the gelling process. The cells are 
therefore exposed to a variety of temperatures through the construct assembly process which 
could potentially cause cellular stress and the activation of an apoptotic response in some cells 
resulting in a reduced initial viability compared to those of alginate beads for example.  
However, the maintenance of viability in agarose constructs observed in my experiments 
is in agreement with that of Rodrigues et al who demonstrated no loss of viability when using 
AFSCs in agarose hydrogels also (Rodrigues et al., 2012). My findings also indicate no loss of 
viability when treated with TGFb isoforms in agarose constructs or alginate beads.  
2.5.4 AFSC/alginate bead rupture occurs after 14 days of culture 
Despite successful culture of AFSCs within alginate beads up to 14 days, there were 
significant issues regarding their utility for a long term chondrogenic differentiation model. 
Between days 12 and 14 of culture, alginate beads began to display increasing fragility 
culminating in either rupture or eventual disintegration of the beads themselves (Figure 2.16A). 
Measurements of the bead volumes as they were cultured indicated a positive correlation 
between the time in culture and the volume of the beads with bead volume increasing by more 
than 35% of their initial volume as early as 3 days of culture (Figure 2.16B). Given the amount of 
GAG synthesis detected by the GAG assays performed (Figure 2.14), it was unlikely that these 
weight changes were due to proteoglycan deposition. This is a finding common to hydrogel cell 
culture and is sometimes used for specific applications (Ehrenhofer et al., 2018).  
In terms of cellular culture, softening of hydrogels following prolonged culture has 
previously been noted by several groups who demonstrated that the compressive modulus of 
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alginate hydrogels decreases over time possibly due to the loss of cross linking calcium ions in 
the case of alginate (LeRoux et al., 1999, Shoichet et al., 1995, Awad et al., 2004). Awad et al 
noted that the compressive moduli of the hydrogels did decrease over the first 2 weeks of culture 
but began to increase between 15 and 28 days of culture; an increase associated with greater 
matrix synthesis. Unfortunately for the alginate beads used in this experiment, further culture was 
impossible as the constructs themselves were too fragile and began to split upon replacement of 
the culture medium. 
A possible explanation for the changes in bead volume during culture is due to differences 
in osmolarity between the culture medium supplied and the fluid of the hydrogel; resulting in an 
influx of fluid into the bead. Using an osmometer, the osmolarity of the alginate used to 
encapsulate the cells was measured at 234 mOsm whereas the osmolarity of the HG-DMEM used 
was measured at around 90 mOsm. Whilst this effect may be beneficial for cells within the 
construct to enable adequate delivery of cellular nutrients vital for cell metabolism, it also puts an 
increased strain on the delicate alginate structure. As culture medium requires removal and 
replacement every 48 - 72 hours, this consistent change in osmolarity may cause excessive influx 
and efflux of fluid from the hydrogel resulting in a weakening of the structure and a loss of calcium 
ions from the alginate structure. As calcium ions are removed from the structure, the complex egg 
box arrangement of the alginate polymers become disrupted and begins to dissociate. This may 
also explain why the agarose constructs did not appear to weaken as much as the alginate 
structures since agarose constructs utilise thermal crosslinking which is unaffected by the change 
in medium as long as the temperature is consistent. Since the culture medium was always heated 
to 37°C, any weakening of the agarose structure was minimised. The size of the structures may 
also play a role in this difference, since a larger structure will inherently possess more crosslinks 
between polymers, conferring greater structural strength. Alternatively, the composition of the 
alginate itself in terms of mannuronic and guluronic acid could also play a role since other alginate 
structures have been used successfully by other groups. Therefore, further investigation using 
other alginate sources might be warranted to clarify the suitability of alginate for stem cell 
differentiation purposes. Ultimately, since alginate beads presented a poor hydrogel for prolonged 
chondrogenic differentiation culture, agarose was selected for further investigation instead. 
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2.6 Summary 
In conclusion, this chapter reports novel findings which indicate that at the early stages 
of human AFSC chondrogenic differentiation, limited GAG synthesis but significant differences in 
cell division were detected upon TGFβ1 or TGFβ3 stimulation relative to controls in AFSC/agarose 
and AFSC/alginate hydrogels. This investigation also suggests that there are minimal differences 
between the use of either TGFβ1 or TGFβ3 at such an early stage of the chondrogenic 
differentiation process in terms of GAG synthesis or DNA content changes. To my knowledge, no 
direct comparison of TGFβ isoforms has been performed previously in regard to the chondrogenic 
differentiation of AFSCs within a hydrogel model in the first 14 days of culture. This study therefore 
provides an optimised method and a basic examination of the initial biochemical and viability 
events that occur during chondrogenic differentiation of AFSC within alginate and agarose 
hydrogels over a time course of 14 days. Characterisation of the changes associated with these 
processes provides an important foundation for the further investigation of AFSC differentiation 
and TGFb’s effect on this process. 
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3.1 Introduction 
This chapter outlines the investigation of AFSC/agarose hydrogels using TGFb1 or TGFb3 
over a 28-day period to achieve chondrogenic differentiation. The results of this chapter highlight 
the effectiveness of TGFb1 and TGFb3 on enhancing the chondrogenic differentiation of AFSCs, 
the lack of differences between the isoforms on this process and finally the possibility of applying 
other treatments to this model for further investigation. 
3.1.1 Importance of culture duration on chondrogenic differentiation 
Since my previous findings outlined in Chapter 2 indicated that there were no statistically 
significant differences when comparing TGFb1-treated sample with TGFb3-treated samples after 
14 days of culture, I determined that this was likely to be a consequence of the short culture time 
employed. Whilst groups such as Barry et al have successfully been able to observe differences 
in TGFb isoform mediated chondrogenic differentiation as early as 7 days of differentiation, albeit 
within a pellet culture model, the majority of investigations regarding stem cell chondrogenic 
differentiation utilise culture durations in excess of 21 - 28 days or even longer (Barry et al., 2001, 
Mauck et al., 2006). Findings by Awad et al also support this requirement for a prolonged 
differentiation culture as they demonstrated that after an initial stage of proliferation within the first 
14 days of culture, proliferation began to subsequently decrease while collagen and proteoglycan 
deposition began to increase at  later stages of culture when using adipose derived stem cells 
(Awad et al., 2004).  I therefore hypothesised that differences in the chondrogenic differentiation 
capacity of TGFβ isoforms within our model might be time dependent and would be more evident 
if the time in culture was extended, allowing cells to move from the proliferation stage of 
differentiation to ECM synthesis. This would also enable determination of whether the agarose 
model I investigated would be sufficiently durable enough to remain intact over a prolonged 
culture time since alginate beads had already demonstrated significant instability after only 14 
days of culture resulting in a diminishment of the structural properties of the gel that prevented 
further culture (Figure 2.16A). 
3.1.2 Approach 
In addition to the optimised DMMB and Hoechst assays used previously, a hydroxyproline 
assay was necessary to further assess the effect of TGFb1 and TGFb3 on the chondrogenic 
differentiation of AFSCs in terms of their ECM synthesis capabilities over 28 days. Furthermore, 
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I included a brief investigation that utilised SEM characterisation of AFSCs within agarose 
constructs to provide high resolution imaging at 2 different time points (day 7 and day 28) to 
identify any morphological changes that might be occurring during the culture process.  
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3.2 Methods 
3.2.1 Chondrogenic differentiation experiment 
Chondrogenic differentiation medium was identical to that described in Chapter 2.2. Each 
construct was supplied with an identical volume of differentiation medium and growth factor 
concentrations as previously stated also. Culture time was altered to an endpoint of 28 days. 
Culture medium was exchanged every 3 days as previously performed. 
3.2.2 Biochemical assays 
DMMB and Hoechst assay protocols were identical to that described in Chapter 2.2. 
Each construct was also processed identically to the methods stated previously.  
3.2.3 Hydroxyproline Assay 
Digested agarose hydrogel samples within microcentrifuge tubes (100 µl) were initially 
digested in a 1:1 ratio with concentrated HCl (Sigma-Aldrich Ltd, UK), vortexed, centrifuged briefly 
and then incubated at 110°C for 18 hours within a temperature-controlled heating block. Samples 
were then cooled down to room temperature, centrifuged at 11.5 x g for 5 minutes and then dried 
in a heat block within a fume hood for approximately 48 hours at 50°C with the microcentrifuge 
lids removed. 250 µl of ultra-pure ddH2O was used to dissolve the sample and vortexed until re-
suspended completely then spun briefly. Samples were stored at 4°C until required.  
Fresh solutions required prior to assay included the following: 
Hydroxyproline stock solution: 1 mg/ml trans-4-hydroxy-L-proline (Sigma-Aldrich Ltd, UK). 
Citrate stock buffer: 5.04 g of citric acid monohydrate (Sigma-Aldrich Ltd, UK) was added to 11.98 
g of sodium acetate trihydrate (Sigma-Aldrich Ltd, UK), 7.22 g of anhydryous sodium acetate 
(Sigma-Aldrich Ltd, UK) and 3.4 g sodium hydroxide (Sigma-Aldrich Ltd, UK) and dissolved in 80 
ml of ultra-pure H2O. Following this, 1.26 ml of glacial acetic acid (Sigma-Aldrich Ltd, UK) was 
added to the solution and pH adjusted to 6.1. The solution was then made up to 100 ml and 
filtered using Whatman filter paper. 
Assay buffer: 1.5 ml of 1-propanol (Sigma-Aldrich Ltd, UK) was added to 1 ml of ultra-pure H2O 
and made up to 7.5 ml using citrate stock buffer. 
Chloramine T reagent: 141 mg of chloramine T reagent (Sigma-Aldrich Ltd, UK) was added to 
0.5ml of ultra-pure H2O and heated at 60°C for 10 minutes until completely dissolved. 0.5 ml of 
92 
 
1-propanol and 4 ml of assay buffer was then added. The solution was light sensitive so was 
wrapped in foil prior to use. 
DMBA reagent: 4.5 g of 4-dimethylamino-benzaldehyde (DMBA, Sigma-Aldrich Ltd, UK) was 
dissolved in 6 ml of 1-propanol and 3 ml of 70% perchloric acid (Sigma-Aldrich Ltd, UK). The 
solution was light sensitive so was wrapped in foil prior to use. 
Hydroxyproline standard: 1 mg/ml hydroxyproline standard was diluted 1 in 20 in PBE solution, 
vortexed. 
Using the 50 µg/ml hydroxyproline standard solution, a standard curve was made using 
the following concentrations: 0, 15, 60, 120, 210 and 300 ng (Figures 3.1 and 3.2). 60 µl of 
samples and standard were added in triplicate to wells of a clear 96 well microtest plate (Sarstedt 
Ltd, UK). 20 µl of assay buffer (1-propanol, citrate stock buffer) and 40 µl of chloramine T reagent 
were then added to each well containing standard and samples. Plates were covered in tinfoil and 
allowed to incubate at room temperature for 20 minutes to allow hydroxyproline oxidation. 80 µl 
of DMBA reagent (1-propanol, perchloric acid, DMBA) were subsequently added to each well 
using a multichannel pipette until mixed well and the solution clear. Plates were sealed and 
incubated at 60°C for 20 minutes then allowed to cool for 25 minutes. The sealplate was removed 
and plates read using the SpectroNano Star plate reader at 570 nm optical density. 
Hydroxyproline content of collagen has been determined as 13% therefore hydroxyproline 
samples were multiplied by 7.69 to provide an estimation of collagen content of each sample 
(Ignat’eva et al., 2007).  
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Figure 3.1: Example hydroxyproline assay curve with linear regression model applied. Linear 
regression provides the equation of the trendline which can then be rearranged to calculate the 
hydroxyproline content of unknown samples simply by inputting the absorbance values. 
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Figure 3.2: Colour change associated with increasing concentration of hydroxyproline content 
in standards. Low concentrations of hydroxyproline show no reaction to the DMBA reagent added and 
maintain a yellow colour. Presence of hydroxyproline initiates a colour change, changing from yellow 
to dark brown with increasing concentration. 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.4 Optimisation of hydrogel sample preparation for SEM 
Principle          
 For SEM visualisation, the removal of water from the specimen is essential as it can disturb the 
vacuum used by the microscope to produce detailed images. For some samples simple air drying 
is suitable to achieve this. Unfortunately for delicate structures such as hydrogels, air drying of 
specimens can result in severe deformation of the structure leading to its collapse and an inability 
to visualise cells within the construct. This is primarily due to the effect of surface tension as water 
moves between its phase boundaries during evaporation. Therefore, the high surface tension of 
water (72 Nm-2 at 20°C) needs to be substituted for a liquid with a much lower surface tension. 
One typical method of water removal uses a solvent series such as ethanol to replace the majority 
of water within the sample. However, the surface tension of ethanol is still too high (22 Nm-2 at 
20°C) and would result in the same effect. Because of this, 2 different methods have been 
developed in order to remove water without damaging the delicate specimens needed to be 
imaged; freeze drying and critical point drying (CPD). 
              CPD works on the principle that when a liquid is contained in a sealed volume it will 
expand and evaporate at the same time as temperature is increased. As kinetic energy increases, 
more molecules enter the gaseous phase resulting in a decrease in the density of the liquid and 
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Figure 3.3: The different states of a fluid. At point X, water exists as a solid. As pressure and 
temperature increase sublimation begins (blue). Subsequently, the water can either melt (red) or 
vaporise (green) depending on the pressure and temperature used. Anything below Ptp cannot exist 
as a liquid. Anything above Pcr and Tcr is known as supercritical. When the triple point is reached 
(orange) the sample is said to exist in all three states. For freeze drying, the entire process occurs 
below the triple point, where water moves directly to vapour phases. 
a simultaneous increase in the density of the gas. When the densities of both phases are equal 
(the critical point) surface tension effectively becomes zero (Bray, 2000) (Figure 3.3). Dehydration 
of samples containing water using critical point drying is unfeasible as the critical point itself lies 
at 374°C and 229 atm of pressure which would cause the destruction of the sample (similarly with 
ethanol; 241°C at 60 atm). Therefore, replacement of the fluid within the construct with one that 
has a lower surface tension than water and ethanol but at a reasonable critical point is required. 
In this case, carbon dioxide is used due to its realistic pressure (73 atm), practical temperature 
(31.1°C) and miscibility with ethyl alcohols. By replacing the water with liquid CO2, when the 
temperature is raised above critical temperature the CO2 changes to vapour form without a 
change in density thereby avoiding the surface tension affects seen in water dehydration. The 
gas can then be released slowly, drying the sample without distorting it. 
In contrast, freeze drying offers a simpler method of water removal. Freeze drying works 
by removing specimen water through sublimation. Initially the samples are prepared within loosely 
capped tubes to allow water vapour to escape, then the samples are frozen to a temperature that 
results in complete solidification of the contents. Following this the chamber is evacuated in order 
to reduce the pressure to below the vapour pressure of ice at the temperature of the item. Heat 
is then applied to provide energy for sublimation of the ice present in the sample (primary drying). 
The samples are then provided further drying time to allow any adsorbed water to be removed 
(secondary drying). 
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Therefore, to ascertain whether CPD or freeze drying should be used for SEM sample 
preparation I investigated the use of both methods for AFSC/hydrogel structures.  
Optimisation of method 
Critical point drying  
Fixed bead samples underwent critical point drying following the standard protocol. 
Briefly, hydrogel samples were fixed in 4% PFA for 1 hour at 4°C. Fixed samples were then 
dehydrated in an ethanol series for 10 minutes at each concentration (50%, 75%, 96% and 100%) 
before being placed in the CPD machine (EMS 850, Quorum Technologies, UK). The CO2 was 
vented into the machine to cool temperature down to around 5°C (taking care to avoid excessive 
flow and freezing of the system). Specimens were loaded into the chamber insert and tightened 
into the machine. The chamber was checked to ensure it was depressurised prior to starting the 
process. The chamber was then filled by allowing more CO2 into the system ensuring the 
meniscus was visible before purging. The heater was applied to increase the temperature up to 
35°C (critical point of CO2) and the pressure was checked to have reached 1250 psi. Following 
this, the chamber was depressurised slowly (100 psi per minute) then samples removed and 
stored in a 24 well plate dish sealed with parafilm prior to sputtering. 
Freeze drying  
Samples were simply inserted into an Eppendorf inside a 50 ml Falcon tube with parafilm 
wrapped around the exterior of the screw cap, then inserted into the freeze drier overnight at a 
temperature of -70°C. 
Sputter coating  
To improve topographical contrast and minimise damage to the specimens, all samples 
were glued onto standard aluminium stubs using carbon tape and sputter coated (EMITECH 
Sputter Coater SC7620) with a 5 nm thick layer of gold to allow dissipation of charge.  
SEM imaging 
Samples were analysed using a 10 - 20 kV electron beam (FEI Inspect F, Oxford 
Instruments, Netherlands). Voltage was selected at between 10 and 20 kV in order to produce 
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sufficient resolution whilst providing enough small structural detail. A scalpel was used to cut the 
constructs in half for an interior look at the specimen.  
Optimisation result 
 
 
 
 
 
 
 
 
 
 
 
 
 
             
 From SEM imaging of the bisected samples it was clear the sample prepared using the 
freeze-drying method was much weaker structurally compared to the construct prepared using 
CPD method. This may be due to the preservation of the natural porosity of the structure which 
become empty when water is removed. Upon bisection using a scalpel, I could not identify any 
cells within the interior of the constructs. In contrast, CPD offered a more rigid material that upon 
bisection allowed visualisation of multiple cells embedded within the constructs. However, it is 
likely that the CPD process altered the structure since there is an evident lack of porosity within 
the structure in comparison to the freeze-dried sample. To what degree the method affects the 
cells visualised requires further investigation but for simple visualisation of the cell structures, 
CPD offered a clear advantage over the freeze-drying. 
Figure 3.4: Comparison of freeze-dried and CPD prepared hydrogel samples. Whole hydrogel 
samples showed small differences between the structures with the freeze-dried sample showing a 
much rougher surface compared to the CPD prepared sample. Upon bisection, cells could be 
visualised within the structures but were conspicuously absent from the freeze-dried sample. 
CPD Freeze dried 
Whole 
sample 
Bisected 
sample 
2 mm 2 mm 
2 mm 300 µm 
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3.3 Results 
3.3.1 TGFb1 or TGFb3 treatment of AFSC/agarose constructs enhanced GAG and collagen 
synthesis up to 28 days of culture 
The ability of TGFb1 or TGFb3 to influence GAG synthesis in AFSC/agarose constructs 
was compared to that of Chang and Basal chondrogenic medium controls over a period of 21 and 
28 days. Treatment of constructs with exogenous TGFb1 or TGFb3 resulted in marked increases 
in GAG synthesis, DNA content and hydroxyproline synthesis compared to Chang and Basal 
medium controls after 21 and 28 days of culture (Figure 3.5A and B, Figure 3.6A and B, Figure 
3.7 A and B;  p<0.01). Further to this, no statistical differences were detected between TGFb1 
and TGFb3 treated AFSC/agarose constructs in terms of GAG synthesis, DNA content changes 
and hydroxyproline synthesis (Figure 3.5A and B, Figure 3.6A and B, Figure 3.7 A and B; 
p>0.05).  
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Figure 3.5: Extracellular matrix synthesis is enhanced in response to time in culture and TGFb1 or 
TGFb3 supplementation. Each column indicates a different patient. +++ indicates significant comparison 
with Chang treatment, $$$ indicates significant comparison with Basal medium +++ = p<0.01, $$$ = p<0.01. 
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Figure 3.6: Extracellular matrix synthesis is enhanced in response to time in culture and TGFb1 or 
TGFb3 supplementation. +++ indicates significant comparison with Chang treatment $$$ indicates 
significant comparison with Basal medium treatment. +++ = p<0.01, $$$ = p<0.01. 
$$$ 
$$$ 
$$$ $$$ 
+++ 
+++ 
+++ +++ 
A 
B 
100 
 
0
1
2
3
4
5
6
Chang Basal TGFβ1 TGFβ3
D
N
A
 c
o
n
te
n
t 
µ
g
/m
l
Treatment conditions
Day 28 Patient 1 Day 28 Patient 2 Day 28 Patient 3
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
1
2
3
4
5
6
7
Chang Basal TGFβ1 TGFβ3
D
N
A
 c
o
n
te
n
t 
µ
g
/m
l
Treatment conditions
Day 21 Patient 1 Day 21 Patient 2 Day 21 Patient 3
Figure 3.7: Extracellular matrix synthesis is enhanced in response to time in culture and TGFb1 or 
TGFb3 supplementation. +++ indicates significant comparison with Chang treatment, $$$ indicates 
significant comparison with Basal medium treatment. +++ = p<0.01, $ = p<0.01. 
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3.3.2 Scanning electron microscopy imaging of TGFb1 treated AFSCs embedded within 
agarose hydrogels suggests morphological changes over 28 days. 
Macroscopic observation of the CPD dehydrated AFSC/agarose sample demonstrated 
maintenance of the general structure of the construct after the drying and sputtering procedures 
(Figure 3.7A). Indeed, bisection of the construct showed a varied polymer fibre network in some 
areas of the construct demonstrating some of the porosity of the agarose hydrogel (Figure 3.7B). 
SEM is a poor indicator of cellular distribution considering we can only observe the exposed 
surface, but it does suggest that some cells are in close proximity to each other within the small 
section of the gel observed (Figure 3.7C). Electron micrographs of the cells at the beginning of 
encapsulation show the cell surface contains filopodia-like projections (Figure 3.7E). Of the cells 
imaged later on in the differentiation process, these projections are seemingly lost, with a 
smoother surface evident (Figure 3.7F). The size of the cells is maintained throughout culture 
between 5 - 10 µm. 
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Figure 3.8: Electron micrograph of AFSC/agarose constructs and cells within. Following CPD 
processing, the agarose construct remains intact and well preserved (A). In some sections, the fibrous 
polymer nature of the agarose is evident at 26,000 magnification (B). Bisection of the construct to look at 
the cells within is not always successful with overlying gel preventing closer inspection of the AFSCs (C), 
but some AFSCs are exposed and visible within their microenvironment (D). Of the exposed cells, AFSCs 
appear to express finger like projections at day 7 which appear to interact with the environment around 
them (E), whereas in the later stages of culture at 28 days these projections are noticeably absent (F). 
Image A taken at 70x mag., B at 26,000x magnification, C at 914x magnification, D at 9208x magnification, 
E at 12,000 magnification and F at 23,123 magnification. 
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3.4 Summary of results 
• GAG synthesis, DNA content and hydroxyproline synthesis of AFSC/agarose constructs 
statistically increased in all conditions compared to day 0. 
• Treatment of AFSC/agarose constructs with TGFb1 or TGFb3 resulted in statistically 
significant increases in GAG synthesis, DNA content and hydroxyproline synthesis after 
21 and 28 days of culture. 
• No differences in GAG synthesis, DNA content and hydroxyproline synthesis were 
detected when comparing TGFb1 treated sample to TGFb3. 
• Statistically significant increases in hydroxyproline synthesis were detected when 
comparing day 28 TGFb1 or TGFb3 treated samples with day 14 TGFb1 or TGFb3 samples. 
• SEM imaging of cells shows rounded morphology and loss of cellular extensions over 28 
days of culture compared to day 7. 
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3.5 Discussion 
3.5.1 TGFb treatment enhances GAG and collagen synthesis in AFSC/agarose constructs 
up to 28 days. 
Following on from my initial 14-day investigation, further culture up to 28 days resulted in 
a greater deposition of chondrogenic biochemical markers in terms of GAG and hydroxyproline 
synthesis (Figure 3.31A and C). This finding was consistent not only for TGFb1 and TGFb3 treated 
samples but also controls when comparing to day 0 values. This was also observed in Chapter 
2 and supports the idea that encapsulation of AFSCs within a 3D environment can contribute to 
a degree of ECM deposition independent of growth factor stimulation. This observation correlates 
with recent research carried out by Tuan et al who demonstrated that chondroinductive growth 
factor independent differentiation of MSCs could be achieved. In that case, graphene oxide was 
incorporated into a poly-d-l-lactic acid/polyethlyene glycol hydrogel whereby the stiffness of the 
supportive hydrogel and the graphene oxide (GO) incorporated within it stimulated the production 
of ECM molecules as well as chondrogenic gene expression (Shen et al., 2018). Even without 
GO incorporation, which was hypothesised to sequester endogenous growth factors to aid in the 
chondrogenic differentiation of the cells, hydroxyproline and GAG synthesis was still achieved 
without growth factor supplementation indicating a level of ECM production similar to that seen in 
my experiments. However, the application of chondrogenic growth factors still significantly 
enhances this process. This is shown when TGFb1 or TGFb3 is applied to the AFSC/agarose 
constructs whereby a statistically significant increase in GAG synthesis, DNA content and 
hydroxyproline synthesis is detected compared to Basal and Chang medium controls after 21 and 
28 days of culture. 
Collagen synthesis was substantially upregulated relative to the effect seen in GAG 
synthesis when TGFb is supplemented to the culture medium (Figure 3.5C). Increases in 
collagen synthesis are typically observed during chondrogenic differentiation processes however 
much more significant increases are usually seen in regard to GAG synthesis also. This potentially 
could indicate that the AFSCs within my model are not only differentiating to a chondrogenic 
phenotype but also other lineages. Supplementation of TGFb has been associated with collagen 
synthesis increases in cardiac fibroblasts, skeletal muscle fibrosis, tendon fibroblast and even 
dental pulp cells. Given the broadly multipotent lineages that can derive from AFSCs and the lack 
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of substantial increases in GAG synthesis there is the potential for the differentiation observed 
here to be progressing towards a non-chondrogenic phenotype/genotype of either osteogenic, 
fibroblastic or myogenic. To further investigate this, histological or immuno staining of cells within 
the hydrogel could be performed to confirm if alternative differentiation is occurring. This could be 
achieved thorough immunostaining for markers such as a-actin for myogenic lineage detection 
whilst histological staining using alizarin red could be used to indicate if osteogenesic 
differentiation is occurring. From a genetic perspective, analysis of markers such as Osx, Alp and 
Bsp could also be used to determine osteogenic differentiation. If cells could be harvested from 
within the hydrogel structures, FACS analysis of surface markers such as CD10 and CD92 could 
also give an indication of osteogenic differentiation. However, the ease with which to extract intact 
live cells from within agarose hydrogels is challenging requiring optimisation. 
In terms of DNA content, the lack of statistically significant increases in the case of TGFb3 
treated samples from day 21 to day 28, and statistically significant decreases in DNA content 
following TGFb1 treatment within the same time period could indicate the fulfilment of the 
phenomenon suggested by Awad et al that the cells had essentially switched priorities from cell 
proliferation to ECM synthesis. This could also indicate that AFSCs require a specific cell density 
to increase cell to cell contacts. Upon reaching the required cell per volume ratio cells then can 
withdraw from the proliferative phase of the cell cycle and establish chondrogenic nodule 
formation. Thus, I may have observed the cells within the model system adjusting to the lack of 
sufficient cellular contacts by increasing proliferation to meet this requirement. In a way, this could 
be evidence of the cell attempting to initiate the events of embryonic development whereby 
mesenchymal stem cell proliferation and condensation to achieve chondrogenic differentiation is 
seen at early development. 
Overall, the basic hydrogel model of AFSCs embedded within agarose constructs shown 
herein supports a level of ECM deposition. However, when we look at the level of GAG synthesis 
achieved from these cells is very low. I observed GAG synthesis levels between 2.5 and 3 µg/µg 
of DNA when treated with either TGFb1 or TGFb3. In contrast Vinardell et al found GAG synthesis 
levels of 20 µg/µg DNA after 21 days of culture (Vinardell et al., 2011). Similar comparisons can 
be made in regard to collagen synthesis, whereby the levels achieved in my investigation were 
between 0.3 and 0.9 µg/µg DNA after 21 and 28 days of culture. These values are significantly 
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lower than that shown by Vinardell et al who noted collagen synthesis levels of 20 µg/µg DNA 
when investigating BM-MSCs in agarose constructs. Whilst the cell density must be taken into 
consideration (Vinardell et al used 1.5 x 107 cells/ml in comparison to 4 x 106 cells/ml herein), my 
data was significantly lower in comparison. This might further indicate the importance of cell 
seeding density in relation to chondrogenic differentiation of stem cells. Also, while AFSCs are 
described as having broadly multipotent potential, their chondrogenic differentiation capability has 
been shown not to be as robust as BM-MSCs (Kolambkar et al., 2007). Therefore, the lack of 
GAG synthesis in my model could potentially be simply a limitation of the AFSCs ability to 
differentiate to the chondrogenic lineage.  
3.5.2 No differences in GAG and collagen synthesis is detected between TGFb1 and 
TGFb3 treated AFSC/agarose constructs 
 No biochemical differences in TGFb1 or TGFb3 treated AFSC/agarose constructs were 
detected. Crystallisation studies by Huang et al demonstrate that TGFb1 or TGFb3 share 
considerable homology in terms of structure; they share 71 - 79% identity, similar 3D structures 
consisting of two cysteine monomers tied by a disulphide bond and similar solution structures. 
The only way in which they do differ is when placed in solution whereby TGFb3 favours an open 
state whilst TGFb1 favour a closed state. These isoforms are typically indistinguishable in many 
cell-based reporter gene assays, growth inhibition assays and, importantly, Smad 
phosphorylation assays. The only major differences are typically seen in chemo-regulated 
migration assays whereby TGFb3 is an active promoter of migration whilst TGFb1 is inactive. 
TGFb1 and TGFb3 also show very similar overall affinities and kinetics with only small differences 
in dissociation rate from TGFbRI binding by the TGFb:TGFb3RII complex. They also share similar 
association rates but TGFb3 has a slightly slower dissociation rate indicating a slightly greater 
affinity. Results by Huang et al indicate that the closed or open state of the particular TGFb isoform 
causes the difference in function (albeit in absence of intrinsic dissimilarities) (Huang et al., 2014). 
Therefore, any differences observed in published chondrogenic differentiation experiments 
previously may be due to the differences in this dissociation rate, but not directly by the cell 
signalling pathways activated. In my studies, since TGFb isoforms were re-supplemented to 
culture medium after every medium change the likelihood is that this small difference in 
107 
 
dissociation becomes attenuated and could therefore contribute to the lack of a statistical 
difference observed at all time points investigated. 
3.5.3 Morphological changes of AFSCs occur between beginning and end of chondrogenic 
differentiation protocol 
Observation of AFSCs within the agarose construct was important to understand fine 
detail morphological changes the cells undergo through the chondrogenic differentiation process.  
The specific cases pictured in Figure 3.7 show cells imaged within agarose constructs at day 7 
and 28. Electron micrographs of the cells at the beginning of the chondrogenic differentiation 
protocol shows that the cell surface of AFSCs contain filopodia-like projections that are likely the 
cell’s attempt to interact with the surrounding structure or other nearby cells (Figure 3.7E). In this 
way the cells could be exploring their surrounding environment as is often seen in ECM 
development and migration to identify appropriate adhesion sites. Of the cells imaged later on in 
the differentiation process, these projections are seemingly lost, with a smoother surface evident 
(Figure 3.7F). Since filopodia are dynamic structures which can rapidly extend and retract this 
could be a transient observation or an indication that the cell had already suitably altered its 
surrounding ECM to its requirements. Given the level of GAG and hydroxyproline synthesis 
detected, it is more likely that this is a transient observation. Further investigation into this 
phenomenon would be required for a definitive answer.  
3.5.4 Implications 
Although I have successfully demonstrated that TGFb supplementation to AFSC/agarose 
constructs constitutes statistically significant increases in proteoglycan and hydroxyproline 
synthesis compared to control samples over a period of 28 days, TGFb treatment alone is rarely 
used in the majority of chondrogenic differentiation experiments that have been published. 
Frequently, supplemental factors are utilised to enhance this process with the most common of 
these being the synthetic glucocorticoid dexamethasone. However, whilst the supplementation of 
dexamethasone to TGFb mediated chondrogenic differentiation protocols has been associated 
with an enhancement of ECM synthesis and chondrogenic gene expression, it is also 
accompanied with an increase in hypertrophic/osteogenic gene expression and in some cases 
an inhibitory effect on the chondrogenic differentiation process in some stem cell types. This has 
resulted in some calls for its omission from this process and investigation into other alternative 
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agents (Buxton et al., 2011, Shintani and Hunziker, 2011). Since the level of ECM synthesis 
detected in my preliminary experiments is significantly lower than other established work in this 
field, I thought it essential to investigate other supplemental factors that could potentially replace 
or at least recapitulate the effect of dexamethasone in terms of enhancing the chondrogenic 
differentiation of human AFSCs. Therefore, my next steps in regard to this differentiation model 
were to characterise the effect of new supplemental factors on TGFb1 and TGFb3 mediated 
chondrogenic differentiation of AFSC/agarose constructs. One promising supplemental factor for 
this purpose is CNP. 
3.6 Summary 
This chapter reports the biochemical and morphological changes that occur in AFSCs 
embedded within agarose constructs over a full 28-day culture cycle following an established 
chondrogenic differentiation protocol. Further to my previous work, no statistically significant 
differences in the effect each TGFb isoform had on GAG and hydroxyproline synthesis were 
detected suggesting a shared mechanism of effect and a transition away from cellular 
proliferation. These data therefore build upon the work established in Chapter 2 of this thesis and 
present a foundational model that can be used for the characterisation of novel treatments for the 
chondrogenic differentiation of AFSCs over a 28-day period. 
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Chapter 4: Effect of CNP on amniotic fluid 
derived stem cell differentiation embedded 
within agarose constructs 
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4.1 Introduction 
This chapter investigates the effect of the peptide CNP on the chondrogenic 
differentiation of human AFSCs within agarose constructs over 28 days of culture. To my 
knowledge, the application of CNP for the chondrogenic differentiation of human AFSCs has not 
previously been investigated. Biochemical (GAG, DNA, collagen), histological (Alcian blue 
staining) and gene expression changes to SOX-9, aggrecan and COL2a1 are studied here. By 
identifying the effect of CNP on this process with human AFSCs, it potentially provides a target 
for developing future differentiation protocols for cartilage tissue engineering applications. 
4.1.1 Effect of CNP on chondrogenic differentiation 
While TGFb is a critical determinant of stem cell differentiation to chondrocyte 
phenotype/genotype, it has also been associated with upregulating CNP/NPR2 expression in BM-
MSCs (Tezcan et al., 2010). Table 4.1 summarises some of these in vitro investigations regarding 
the effect of CNP on TGFb-mediated chondrogenic differentiation. Within these examples, alcian 
blue staining for proteoglycans was shown to be influenced by the presence of CNP during TGFb 
mediated chondrogenic differentiation of MSCs. Specifically, CNP supplementation to TGFb1 
treated MSCs demonstrated a dose dependent increase in alcian blue staining (Tezcan et al., 
2010), whilst blocking of CNP and its receptors resulted in a reduction in alcian blue staining 
(Kocamaz et al., 2012). Moreover, TGFb1 supplementation in rat chondrocytes has also been 
associated with an increase in CNP secretion (Hagiwara et al., 1994). Further links between TGFb 
and CNP can be seen when looking at the genetics of CNP production. The gene, Nppc, that 
codes for CNP possesses an enhanced binding site for the TGFβ early response inducible gene 
TSC22 (Transforming growth factor B stimulated clone-22) within its promoter region, potentially 
suggesting a close role between TGFβ signalling and CNP synthesis (Kawamata et al., 2004, 
Ohta et al., 1996, Olney, 2006). 
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Cell 
type 
Time  
(days) Agents 
Cell 
density Key findings Reference 
Chicken 
BM-
MSCs 
21 
TGFb1  
(10 ng/ml) 
 
CNP  
(100 nM) 
3 x 105 
TGFb1 treatment ↑ CNP-3 mRNA in monolayer culture 
but ↓ NPR-2 mRNA compared to control. 
 
CNP addition ­ chondrogenesis compared to control 
(p<0.01). Effect removed when antibodies targeting NPR-
2 and CNP were used. 
 
TGFb1 supplementation resulted in spheroid shaped 
pellets after 21 days which stained positive for Alcian 
blue. When CNP antibody inhibitors used staining and 
pellet size ↓. 
 
Pellet culture resulted in collagen II mRNA expression but 
hypertrophic chondrocytes in peripheral regions 
compared to central regions of pellet. 
 
CNP and NPR-2 specific antibodies did not affect 
collagen II mRNA expression compared to TGFb1 treated 
but alcian blue staining significantly ↓. 
(Kocamaz et 
al., 2012) 
Human 
MSCs 
21 
Dex  
(0.1 µM) 
 
TGFβ1  
(10 ng/ml) 
 
CNP  
(10-6, 10-7 
or 10-8 M) 
3 x 105 
per 
pellet 
TGFβ1 induction of chondrogenesis resulted in ↑ of CNP 
mRNA and NPR-2 precursor at day 4, 10 and 21 
compared to control. 
 
TGFβ1 chondrogenic induction with 10-7 M CNP 
significantly ↑ alcian blue uptake in comparison to TGFβ1 
only at day 10 and 21. 
 
Similar effects seen with 10-8M CNP with TGFβ1 
compared to TGFβ1 only but not as strong as 10-8 M CNP 
effect. 10-6M CNP diminished this effect, showing 
comparable results to TGFβ1 only. 
 
Gene expression analysis of aggrecan, SOX-9 and 
collagen II did not differ statistically among treatment 
groups. 
(Tezcan et 
al., 2010) 
 
Phenotype instability is a common problem associated with the differentiation of MSCs to 
chondrocytes and diseases such as OA. Loss of the chondrocyte phenotype results in cells 
progressing towards a hypertrophy like phenotype characterised by an abnormal production of 
matrix proteins and matrix degrading enzymes (Singh et al., 2019). Therefore, maintenance of 
the chondrocyte phenotype is of utmost importance in order to produce the hyaline cartilage 
required for tissue engineering endeavours. CNP has been associated as a key regulator of this 
process for MSC derived chondrocytes, potentially through the downregulation of RANK and 
Collagen type X expression, in addition to inhibiting calcification formation under an inflammatory 
environment caused by OA (Shi et al., 2017). In addition, CNP has been shown to downregulate 
the Tnfs11 gene which encodes RANKL; a key marker of hypertrophic cartilage. CNP has also 
been suggested to participate in the Indian hedgehog / parathyroid hormone related protein loop 
that inhibits pre-hypertrophic chondrocytes from entering the hypertrophic phase (Yamashita et 
al. 2000, Olney, 2006). Furthermore, while the application of dexamethasone inhibits the 
longitudinal growth of tibial explants, this effect can be reversed by CNP addition (Ueda, 2016). 
This potentially signifies a substantial area of improvement over the traditional dexamethasone 
Table 4.1: Examples of CNP involvement in chondrogenic differentiation in pellet models. 
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mediated method of chondrogenic differentiation which is commonly associated with hypertrophic 
progression.  
So, the question that follows these investigations is how CNP affects this process from a 
signalling perspective. Overall, the underlying mechanism is thought to be through the modulation of 
RAF-1 activation (Figure 4.1). In brief, activation of NPR-2 through CNP binding to its extracellular 
domain triggers cGMP generation which can activate a host of different intracellular machinery including 
phosphodiesterases (PDE), cGMP gated ion channels and cyclic GMP dependent protein kinases I 
and II (PKGI and PKGII). Activation of PKGII directly activates p38 which can directly interact with RAF-
1 resulting in inhibition. Preventing RAF-1 activation directly affects MEK1/2 and ERK1/2 signalling 
which are known to reduce chondrocyte proliferation, ECM synthesis and differentiation (Krejci et al., 
2005). While TGFb primarily uses its Smad-dependent signalling pathway to trigger cellular response, 
it also utilises p38 through its non-Smad dependent pathway. Therefore, it can be hypothesised that 
TGFb and CNP together can inhibit RAF-1 and thus enhance the chondrogenic differentiation process. 
However, p38 activation is also noted to be involved in activating MAPK which can directly affect the 
phosphorylation of the hypertrophic gene Runx2. Therefore, activation of p38 and subsequent inhibition 
of RAF-1 could also actually be enhancing the expression of hypertrophic genes as well as 
chondrogenic ones. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Intracellular signalling 
schematic showing areas of potential 
crosstalk between TGFb and CNP 
signalling pathways. While TGFb primarily 
signals through a Smad dependent 
pathway, non-canonical signalling also 
takes place that can affect chondrogenic 
differentiation. Meanwhile CNP signalling is 
able to inhibit RAF-1, which directly impacts 
on MEK and ERK and effectively reduces 
SOX-9 inhibition. 
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 In addition to CNP and its close association with TGFβ for chondrogenic differentiation, 
Agoston et al demonstrated that Dex regulates the expression of CNP and its receptors in 
chondrocytes (Agoston et al., 2006). Since Dex is consistently used in concert with TGFb isoforms 
to achieve chondrogenic differentiation and CNP has been shown to help enhance the effect of 
TGFb1 in this process, it stands to reason that CNP could potentially play a role in the 
chondrogenic differentiation of AFSCs and should therefore be investigated in comparison to Dex 
+ TGFb1 treatment for this purpose. In addition, no evidence exists to the effect that CNP 
application without TGFb has on chondrogenic differentiation of AFSCs. Given the complexity of 
interaction of these two agents, further work is required to elucidate the nature of this association. 
Taken together, I sought to determine the effect of CNP on the chondrogenic 
differentiation of human AFSCs within agarose constructs over a period of 28 days. Using the 
established basic agarose model, I performed my standard optimised biochemical analysis in 
terms of DMMB, hydroxyproline and DNA assays. In addition to my previously stated controls, I 
included a dexamethasone + TGFb1 treatment to compare the effect of CNP with the most 
commonly used method of stem cell differentiation in the literature, plus a CNP only treatment to 
distinguish if CNP itself had potential as a chondro-inductive agent like TGFb. Furthermore, I 
optimised a method for alcian blue staining of AFSC/agarose constructs, optimised primer binding 
efficiency for 3 chondrogenic genes (SOX-9, aggrecan and COL2a1) and optimised a method for 
imaging of collagen deposition using SHG microscopy. In this way, I was able to visualise 
proteoglycan and collagen deposition by cells while also determining any differences in gene 
expression depending on treatment. To my knowledge, no other group has investigated the use 
of CNP as a chondro-inductive or chondro-supportive agent in the differentiation of AFSCs within 
an agarose construct model over 28 days. 
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4.2 Methods 
4.2.1 RNA extraction optimisation methods 
 For all methods of RNA isolation investigated, extraction was performed within a Class 
II fume hood that had been thoroughly wiped down and sprayed liberally with RNase away to 
remove any RNA degrading RNases from the work area. Only essential instrumentation such as 
a mini centrifuge, heat block, pipettes and sterile filter tips were allowed within the setup area 
once wiped with RNase away. Gloves were worn at all times when handling RNase away as it 
can be a skin irritant and to prevent contact of RNases on the skin from contaminating the 
samples. Surgical masks were also worn as an extra precaution. All constructs used for the 
extractions were identical in terms of the dimensions (5 x 5 mm), cell seeding density (4 x 106 
cells/ml) and amount of time in culture (21 days). A simplified overview of methods investigated 
is depicted in Figure 4.2. 
Method 1: Buffer QG expired 
 Buffer QG (Qiagen Ltd, UK) was preheated within a heat block at 42°C for 10 minutes. 
AFSC/agarose samples were taken directly from a Heracell incubator (Thermofisher, Scientific, 
UK), removed from their well plates, rinsed briefly in D-PBS and then inserted into the heated 
Buffer QG (600 µl per construct) within an RNase free 1 ml Eppendorf tube. The tubes containing 
buffer QG and constructs were then placed within the heat block for a further 10 minutes to ensure 
adequate digestion of the agarose construct and lysis of the cell membranes present in the 
samples. Sample tubes were then transferred to a dry rack within the hood whereby 100 µl of 
isopropanol was added, mixed briefly by pipetting and then the total volume added to a RNeasy 
spin column. The spin columns were then centrifuged at maximum speed (12,225 x g) for 1 minute 
at room temperature. Following this the flow through was discarded and the spin column placed 
back in the same collection tube. 500 µl of the Buffer QG was again inserted into the spin column 
to ensure the complete removal of agarose from the spin column and centrifuged once again at 
12,225 x g for 1 minute. Flow through was again discarded, then 750 µl of Buffer RPE (Qiagen 
Ltd, UK) was added to the spin column. The spin column was centrifuged again at 12,225 x g for 
1 minute, flown through discarded and then the spin column was placed within a fresh microfuge 
tube. To elute the RNA, 400 µl of RNase free H2O was added to the centre of the spin column 
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and then centrifuged at 12,225 x g for 1 minute. The spin column was then removed from the tube 
and the sample kept on ice immediately.  
Method 2: Tilwani method 
 Many of the steps here were shared with that of Method 1 but a few simple changes 
were made. Firstly, each construct was incubated with 750 µl of buffer QG in order to digest the 
agarose and cell membrane rupture. 125 µl of isopropanol was then added instead of the 100 µl 
stated previously, with the resulting fluid yield requiring 2 centrifugation steps since the maximum 
volume contained within a RNeasy mini spin column is 700 µl. Centrifugation steps were also 
altered to reduce the speed and time of the table top centrifuge to 4293 x g for 15 seconds only. 
Following this, the addition of 700 µl of RW1 buffer (Qiagen Ltd, UK) was added to remove any 
proteins present within the sample. The samples were then treated with RPE buffer as in the other 
method with the addition of an extra centrifugation step with the empty RNeasy spin column to 
remove any excess solution that might still be present within the column. Elution was repeated in 
same way as Method 1. 
Method 3: TRIzol extraction 
 Chloroform, TRIzol and 70% ethanol solutions were all pre-chilled on ice before the 
extraction was started. Isopropanol was kept at room temperature within a dry rack. Samples 
were removed from their well plates, placed within 1 ml cryovials and immediately snap frozen 
using liquid nitrogen within a dewar for 5 minutes. A sterile ball bearing was then placed within 
each cryovial which were then inserted into a Qiagen tissue lyser (Qiagen Ltd, UK). 50 oscillations 
per second for 1 minute was performed to grind the snap-frozen sample into powder format. 500 
µl of TRIzol was then added to each cryovial and left to thaw for 5 minutes at room temperature. 
All homogenised sample were then transferred to an RNase free microfuge tube and placed on 
ice. 200 µl of chilled chloroform was added to each tube containing TRIzol and mixed thoroughly 
using a vortex. Samples were then centrifuged for 5 minutes at 12000 x g at 4°C. Hereby 3 layers 
were observed and the top layer (aqueous phase) was transferred to a fresh RNase free 
microfuge tube (approximately 300 - 400 µl total). Care was taken not to disturb the other layers 
present as these contained contaminants such as DNA, proteins and lipids. 500 µl of isopropanol 
was then added to the extracted layer and left at room temperature for 10 minutes to allow 
precipitation of the RNA from the sample. This was followed by centrifugation at 12,000 x g for a 
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further 10 minutes whereby an RNA pellet would form at the base of the tube. Once the 
supernatant was removed, the sample was washed in 1 ml of 70% ethanol, mixed by gentle 
inversion so as to not disturb the pellet and centrifuged again for 5 minutes at 7500 x g. The 
supernatant was then removed once again and inverted to air dry for a further 10 minutes. 100 µl 
of RNase free water was then used to resuspend the pellet prior to further purification steps. 
 Purification was achieved using the Qiagen RNeasy minikit (Qiagen Ltd, UK). Briefly, 
350 µl of buffer RLT and 250 µl of 100% ethanol was added to the sample and transferred to a 
RNeasy mini spin column. Samples were then centrifuged for 1 minute at 8000 x g. The follow 
through was then discarded and 700 µl of RW1 buffer added before repetition of the centrifugation 
step again. DNase treatment was applied here by adding 80 µl of DNase 1 solution to the sample 
and incubating for 30 minutes. Following this 350 µl of buffer RW1 was added, centrifuged and 
removed before adding 500 µl buffer RPE. RPE buffer was incubated with the sample for 5 
minutes then centrifuged as prior. Finally, 500 µl of 75% ethanol was added to the spin column 
and centrifuged for 2 minutes at 8000 x g before discarding and air drying the spin column.  The 
column was then centrifuged with no additional liquid to help facilitate the removal of trace ethanol. 
The spin column was then transferred to a fresh microfuge tube and then 50 µl of RNase free 
water added to the tube before final elution (1 minute at 10,000 x g).  
Method 4: Ogura method 
 Following the initial TRIzol method until the 70% ethanol wash step, the precipitant was 
dissolved in 200 µl of potassium thiocyanate buffer (NTC buffer, Macherey-Nagel, Germany) and 
incubated at 50°C for 10 minutes. Afterwards, the sample was then mixed with 70% ethanol and 
transferred to a silica spin column (Nucleospin Gel and PCR Clean up column, Macherey-Nagel, 
Germany) and centrifuged at 4293 x g for 1 minute. The follow through was then discarded and 
replaced with NT3 buffer (Macherey-Nagel, Germany) to wash the column, discarded again and 
then the RNA was eluted by the addition of low ionic strength NE buffer (Macherey Nagel, 
Germany). 
Method 5: Buffer QG fresh 
 This method is identical to Method 1 except fresh Buffer QG, RPE and spin columns 
were purchased and used. 
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Figure 4.2: Overview of the different methods investigated for RNA extraction from agarose 
constructs. 
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DNase treatment 
For all procedures, DNase treatment was carried out by adding 1 μl of DNase I enzyme 
and 10x DNase buffer to the RNA sample and incubating it for 20 minutes at 37°C. Another 
incubation period then followed for 2 minutes at room temperature, after adding 4 μl of DNase 
inactivating reagent to the tube. The resulting slurry was pelleted by carrying out centrifugation at 
14,000 x g for 1 minute at 40°C. The RNA containing solution was then transferred into a new 
microfuge tube and kept on ice prior to RNA quantification or stored at -70°C. This procedure is 
summarised in Figure 4.3. 
 
 
 
 
 
 
 
 
  
 
 
 
Nanodrop quantification 
To quantify the RNA present, a Nanodrop One spectrophotometer (Thermofisher 
Scientific, UK) was used. In brief, the pedestal was wiped over using Kimwipes (Sigma-Aldrich 
Ltd, UK) before loading 1 µl of RNase free water to the pedestal to blank the Nanodrop system to 
allow quantification of only the RNA within the sample. 1 µl of RNA containing solution was then 
added to the pedestal whereby yield and purity were quantified. For long term storage samples 
were kept in -80°C, otherwise samples were immediately converted to cDNA format. Nanodrop 
analyses of samples were recorded and displayed in Figures 4.4, 4.5 and 4.6. 
 
 
RNA 10x DNase buffer DNase I enzyme 
DNase inactivating reagent 
Final RNA 
20-minute incubation at 37°C 
2-minute incubation at RT 
Centrifuge 14,000 x g 
Nanodrop analysis 
Figure 4.3: DNase treatment of samples. 
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Result of optimisation 
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Figure 4.4: Comparison of RNA yield and purity between different extraction methods.  
A: Average RNA yield extracted from AFSC/agarose samples using various RNA extraction methods. 
B: Average DNA yield from AFSC/agarose constructs harvested from the same population of those 
tested for RNA extraction. C: Average 260/280 ratio from AFSC/agarose samples using the different 
extraction methods D: Average 260/230 ratio from AFSC/agarose samples using the different extraction 
methods. (N = 8 - 25 replicates). Error bars: ± SEM. 
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Figure 4.5: Representative Nanodrop plots from each RNA extraction method. 
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 In summary, the use of fresh buffer QG, buffer RPE and spin columns provided the 
highest yields and purity of RNA for cDNA synthesis and PCR analysis compared to all other 
methods investigated (Figure 4.4, 4.5 and 4.6). However, it must be noted that this method still 
was not effective 100% of the time suggesting that extraction of RNA from cell seeded agarose 
hydrogels is still difficult to achieve. This difficulty has also been noted by several other groups 
who indicate that the formation of ionic complexes between negatively charged RNA and 
positively charged regions of the matrix often results in a low yield of RNA. 
B 
A 
Figure 4.6: An example of a contaminated RNA sample. A: Nucleic acid peak at 230 nm greatly 
outweighs the peak seen at 260 nm indicating that the substantial yield is an overestimation of the 
actual content. Purification of this sample is required. B: Sample A following purification. Note the 
improved 260/280 ratio and much improved 260/230 ratio. The peak at 230 nm has decreased 
significantly indicating a removal of contaminants that absorb at that absorbance. This sample is 
therefore suitable for cDNA synthesis. 
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4.2.2 First strand cDNA synthesis by reverse transcription 
 Conversion of total RNA into high-quality full-length cDNA was performed using the 
Enhanced Avian Reverse Transcription First Strand Synthesis Kit (Sigma-Aldrich Ltd, UK). 
Nuclease free water and 1 µl of Oligo (dT)23 primer was first added to a 100 µl thin walled PCR 
microcentrifuge tube before 50 - 200 ng of total RNA was transferred into the tube. The 
constituents were then mixed and immediately placed on ice making a total volume of 10 µl. The 
tube was then placed into a Techgene thermal cycler (Techne, UK) for 5 minutes at 70°C to 
denature the total RNA. While this was performed, a mastermix was prepared using 10x buffer 
for eAMV-RT (1x final concentration), enhanced avian RT enzyme (1 unit/µl), RNase inhibitor (1 
unit/µl), deoxynucleotide mix (500 µM each dNTP) and water. Once the RNA denaturation was 
complete, the tube was immediately placed on ice to prevent RNA from aggregating. 10 µl of the 
mastermix was then transferred to the tube containing denatured RNA to make a 20 µl total 
reaction volume and mixed with gentle pipetting. The reaction mixture was then centrifuged briefly 
in a minicentrifuge to make sure that the volume was at the bottom of the tube. Finally, the tube 
was transferred to the thermal cycler again and heated for 1 hour at 42°C. Following this step, the 
resultant cDNA was stored at -20°C until required. 
4.2.3 RT-qPCR primer optimisation 
 Optimal hybridisation and priming are an essential part of PCR assay development as 
they concentration can enhance sensitivity, reproducibility and specificity. Each primer/target 
structure has a unique optimal thermodynamic stability, therefore identifying the optimum stable 
combination of primer to cDNA will produce the most repeatable experiments. A cDNA serial 
dilution series was therefore performed (1 in 5) which extended beyond both highest and lowest 
levels of target expected in order to calculate the primer binding efficiency. Dissociation/melt 
curves were included to analyse the PCR specificity and check for the formation of primer-dimers 
in the sample during final analysis. 
Optimisation Method  
 To ensure uniform mixture of PCR reaction components, qPCR mastermixes were 
produced for each sample and primer pair containing Kapa SYBR green I fluorescent dye (2x) 
(Kapa Biosystems, USA), specific primer pairs (Sigma-Aldrich Ltd, UK), ROX high standard (Kapa 
Biosystems, USA), nuclease free water and cDNA sufficient to produce triplicate reactions (Table 
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4.2). ROX high was included as a reference dye to normalise the fluorescent reporter signal as 
an internal reference for non-PCR related fluctuations in fluorescence especially in terms of 
background noise and machine excitation and detection variations. All mastermixes were made 
in thin walled PCR microcentrifuge tubes before plating. Template free controls were produced 
by replacing cDNA with H2O.  
 
 
 
  
  
 Forward and reverse human primers were purchased from Sigma-Aldrich at 100 μM 
stock concentration for the genes SOX-9, COL2a1, beta actin and aggrecan. For primer 
optimisation, these primers were diluted to 50, 25 and 12.5 µM concentrations in preparation for 
their addition to PCR mastermixes. When added to the mastermix they produced concentrations 
of 500, 250 and 125 nM concentrations of primers in each mastermix. Stock cDNA prepared from 
AFSC containing samples were prepared at concentrations of 200 nM and serially diluted 1 in 5 
to produce concentrations of 200, 40, 8, 1.6 and 0.32 nM. When added to the mastermixes, these 
would produce concentrations of 20, 4, 0.16 and 0.032 nM concentrations of cDNA. cDNA 
template free controls were included for each reaction performed. Each mastermix was mixed 
thoroughly before pipetting 25 µl of mixture into each well of a clear 96 well PCR plate. The plate 
was then briefly centrifuged for 1 minute at 50 x g. Following the plate preparation, thermal cycling 
was performed using the StepOnePlus PCR system (Thermofisher Scientific, UK) with the 
following thermocycling conditions for quantitative PCR: 
• 1 cycle 95°C for 10 minutes 
• 40 cycles: 95°C for 15 seconds, 60°C for 1 minute  
• 1 cycle: 95°C for 15 seconds, 60°C for 1 minute, 95°C for 15 seconds 
Table 4.2: qPCR mastermix recipe* 
Reagent Volume/µl 
SYBR green 45 
Forward primer 0.9 
Reverse primer 0.9 
Water 32.76 
ROX high 1.44 
cDNA 9 
*Mastermixes are made 1.2x excess to ensure sufficient volume for plating. Total volume sufficient 
for 3 replicates. 
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Threshold cycle (Ct) values produced were analysed using StepOne v2.3 software. 
Amplification plots were generated for each reaction with fluorescence (dRn) against cycle 
number. The threshold remained unchanged for all experiments within the lower third of the linear 
phase of the amplification plot. Mean Ct values were normalised to day 0 beta actin endogenous 
control data whereby the Pfaffl method was used to calculate gene expression fold changes. 
Primer efficiency calculation 
A plot of Ct versus the log of nucleic acid input levels was performed and a linear 
regression applied. The reaction efficiency from the slope of the line was calculated using the 
following equation: 
Efficiency = 10 (-1/slope)-1 
The correlation coefficient of the line (R2 value) is used to show how well the data fits on 
a straight line with R2 values of 0.99 desirable. For a 100% PCR reaction the amount of PCR 
product from each reaction will double following each cycle, resulting in a standard curve of 
gradient -3.33. Any slope between -3.9 and -3.0 is acceptable for determining efficiency. 
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Result of optimisation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
 
 
 
 
 
 
Primer name Forward Sequence Reverse Sequence 
Beta Actin ACTCTCCCTCCTCCTCTT AAGGCAACTTTCGGAACG 
y = -3.3277x + 40.592
R² = 0.9912
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C Figure 4.7: Primer optimisation for beta actin.  
A: Standard curve indicating initial copy number of 
template versus threshold cycle (Ct). Real time PCR of 
5-fold serial dilutions of human AFSC cDNA was 
performed using 500 nM of a beta actin forward and 
reverse primer. Reactions (3 replicates per dilution). 
Primer reaction efficiency = 0.99. B: Amplification plot of 
serial dilution. C: A rise in absorbance intensity in the 
melt curve indicates the dissociation of double stranded 
DNA during heating. The single amplification peak 
indicates a high standard of primer specificity without 
primer-dimer formation. 
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Primer name Forward Sequence Reverse Sequence 
Aggrecan AACAGTGCCATCATTGCC CTCATCCTTGTCTCCATAGC 
y = -3.619x + 37.369
R² = 0.9994
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C Figure 4.8: Primer optimisation for aggrecan.  
A: Standard curve indicating initial copy number of 
template versus threshold cycle (Ct). Real time PCR 
of 5-fold serial dilutions of human AFSC cDNA was 
performed using 250 nM of aggrecan forward and 
reverse primer. Reactions (3 replicates per dilution). 
Primer reaction efficiency 0.91. B: Amplification plot 
of serial dilution. C: A rise in absorbance intensity in 
the melt curve indicates the dissociation of double 
stranded DNA during heating. The single 
amplification peak indicates a high standard of 
primer specificity without primer-dimer formation. 
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Primer name Forward Sequence Reverse Sequence 
COL2A1 GGAGTCAAGGGTGATCGT CTTGTGCACCAGCTTCTC 
y = -3.569x + 39.267
R² = 0.9956
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C Figure 4.9: Primer optimisation for COL2A1.  
A: Standard curve indicating initial copy number of 
template versus threshold cycle (Ct). Real time 
PCR of 5-fold serial dilutions of human AFSC cDNA 
was performed using 250 nM of COL2A1 forward 
and reverse primer. Reactions (3 replicates per 
dilution). Primer reaction efficiency 0.89. B: 
Amplification plot of serial dilution. C: A rise in 
absorbance intensity in the melt curve indicates the 
dissociation of double stranded DNA during 
heating. The single amplification peak indicates a 
high standard of primer specificity without primer-
dimer formation 
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Primer name Forward Sequence Reverse Sequence 
SOX-9 GTACCCGCACTTGCACAAC GTAATCCGGGTGGTCCTTCT 
y = -3.468x + 39.426
R² = 0.9709
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C Figure 4.10: Primer optimisation for SOX-9.  
A: Standard curve indicating initial copy number 
of template versus threshold cycle (Ct). Real time 
PCR of 5-fold serial dilutions of human AFSC 
cDNA was performed using 500 nM of SOX-9 
forward and reverse primer. Reactions (3 
replicates per dilution). Primer reaction efficiency 
0.93. B: Amplification plot of serial dilution. C: A 
rise in absorbance intensity in the melt curve 
indicates the dissociation of double stranded 
DNA during heating. The single amplification 
peak indicates a high standard of primer 
specificity without primer-dimer formation 
, 
B 
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Following primer optimisation performed in Figures 4.7, 4.8, 4.9 and 4.10, we 
distinguished the following optimal concentrations of primer for use with AFSCs: 
Beta actin: 500nM 
Aggrecan: 250nM 
SOX-9: 500nM 
COL2a1: 250nM 
 
4.2.4 Pfaffl method analysis of PCR data 
For gene expression analysis, relative quantification of the target gene against a 
reference gene (beta actin) was performed in order to obtain the relative expression ratio, which 
incorporates the PCR efficiency values calculated in Figures 4.7, 4.8, 4.9 and 4.10. Relative 
quantification of the target gene was estimated by normalising the target to the reference gene 
(Beta actin) and to the calibrator sample (patient matched day 0 control) by a comparative Ct 
approach. For each sample, the ratio of target Ct and reference Ct was calculated using the Pfaffl 
method which uses the equation below. Ratios were expressed on a logarithmic scale (arbitrary 
units). 
 
  
Whereby GOI = gene of interest and HKG = housekeeping gene. 
 
 
 
 
 
 
 
Primer efficiency of GOI dCt GOI 
Primer efficiency of HKG dCt HKG 
Gene expression ratio = 
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4.2.5 Optimisation of hydrogel embedding and histological staining procedures 
Principle 
Histology from hydrogel samples is typically not shown in many papers due to the 
difficulty in producing high quality histological staining and preservation of the structure for 
analysis. Samples for histology can be prepared in 2 ways; paraffin embedding or cryo-
embedding. Prior to embedding, samples require a period of fixation in order to preserve cell 
morphology and hydrogel architecture, inactivate proteolytic enzymes and prevent microbial 
contamination before undergoing any histological treatments and this is typically achieved using 
fixatives such as paraformaldehyde (PFA) or glutaraldehyde. Fixation works by forming covalent 
cross links such as methylene bridges between functional groups present in the sample and the 
formaldehyde itself. This crosslinking thereby acts to preserve the sample by producing an 
insoluble network without altering the cell structure too greatly. Following this, the constructs can 
be embedded in either paraffin or a cryoembedding compound such as optimal cutting 
temperature compound (OCT). When embedding for cryosectioning an issue can arise with the 
formation of ice crystals (similar to the problem of cryopreservation of cells). In order to reduce 
this incidence and preserve how the cells appear within the construct, cryoprotectants are 
employed. In this case, a hypertonic sucrose series is employed in order to gradually replace the 
water content found within the cells. By doing this, the formation of ice crystals is avoided and 
hence the cells are preserved so that they can be observed when stained. Paraffin embedding 
and cryo-embedding procedures were investigated. 
Optimisation method 
AFSC/agarose constructs were initially bisected using a no.10 scalpel to expose mid sagittal and 
axial sections prior to fixation (Figure 4.11A and B). 
Fixation method: Based on previous method by (Bernstein et al., 2009). In brief, hydrogels were 
transferred to autoclaved glass vials and fixed with acetone for 5 minutes at -20°C (Sigma-Aldrich 
Ltd, UK). Acetone was replaced with methanol (5 minutes, -20°C) followed by an isopropanol 
extraction series (75% for 15 minutes, 96% repeated twice for 30 minutes, 100% repeated twice 
for 30 minutes and xylene for the final 20 minutes.  
Paraffin embedding - Following fixation, samples were the beads were then embedded in paraffin 
by an automated series of formalin (1 hour at 37°C), 70% ethanol (2 x 45 minute washes at 37°C), 
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100% industrial methylated spirits (2 x 60 minute, 1 x 90 minute and 1 x 120 minute at 37°C) and 
xylene (1 x 90, 1 x 150 and 1 x 120 minutes) for hand embedding within paraffin wax. A small 
amount of molten wax was placed into the mould and allowed to cool slightly then a sample was 
placed in the centre. Paraffin was allowed to solidify to hold the sample in position. The tissue 
cassette was then placed on top of the mould and hot paraffin added from the dispenser and 
allowed to cool for 30 minutes. 
OCT cryoembedding - Following fixation methods, each sample was rinsed briefly in ddH2O and 
suspended within sucrose solutions of 5% (30 minutes to 1 hour), 15% (overnight) and 30% 
(overnight) concentrations. Samples were then transferred into a prepared flexible mould and 
coated in OCT compound until suitably covered so that the sample was completely immersed. 
The samples were then transferred to a prepared dewar containing liquid nitrogen, flash frozen 
and then stored at -80°C for long term storage or dry ice for transfer to a cryostat. 
Sectioning of paraffin samples 
All optimisation samples were sectioned at 10 µm thickness using a ThermoScientific 
Microm HM325 microtome and mounted on standard microscope slides. In brief, the paraffin 
embedded samples were stored on ice to cool the sample and aid sectioning. The sample was 
placed into the microtome and orientated to the inserted blade. Sections of 10 - 30 µm were first 
cut to ensure correct orientation of the blade to the sample and to expose the surface level of the 
embedded sample before being reduced to 6 µm. Sections were then cut sequentially and picked 
up by tweezers. Sections were then introduced to the surface of a preheated water bath at 40°C 
before being applied to microscope slide and dried overnight at 37°C. 
Sectioning of OCT samples 
Setup is displayed in Figure 4.11C. All optimisation samples were sectioned at 6 µm 
thickness using a Leica CM3050 S cryostat and mounted on Superfrost slides. Slides were then 
stored on ice prior to staining. Sections were stained with either Haematoxylin & Eosin (H&E), 
picosirius red or alcian blue for the presence of GAGs.  
Microscopy 
Sections were visualised using a Zeiss Axioskope microscope with Infinity3s camera and 
Infinity capture software. Images taken at x 1.25 and x 20 magnifications.  
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Figure 4.11: Preparation of agarose constructs within cryostat. Following fixation and sucrose 
cryoprotection, samples were placed upright and bisected centrally to produce 2 exact halves of the 
construct (A + B). Subsequently one edge was then placed flat on its horizontal plane prior to OCT 
embedding. Secondly constructs were placed on their side and bisected centrally again. This produced 2 
parts of the construct with the core and longitudinal sections of the construct exposed. Following snap 
freezing, samples were placed within cryostat pedestal for sectioning (C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B C 
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Histological staining 
For all paraffin embedded sections prior to staining the following steps were undertaken. 
Firstly, the samples were rehydrated by placing the microscope slides into histoclear baths for 5 
minutes and repeated once more. Following this, the samples were added to an ethanol series of 
baths including 100%, 95% and 70% with each bath repeated twice for 3 minutes to ensure 
rehydration before rinsing in water.  For cryoembedded samples, sections were allowed to air dry 
within a fume hood for 20 minutes prior to any staining procedure. All stains were kept at room 
temperature for 30 minutes prior to staining commencement. 
H&E staining: This staining method is commonly used to identify cell types and cellular 
components in tissue. Haematoxylin is used to stain the cell nucleus blue while eosin stains the 
cytoplasm of the cell red producing a characteristic purple colour to the stained section. Since 
haematoxylin (Sigma-Aldrich Ltd, UK) and eosin solutions were premade, the following procedure 
was followed: 
 Sections were exposed to haematoxylin stain first for 8 minutes then placed under running 
water to remove any excess stain for a period of 5 minutes. Sections were then placed into the 
eosin solution for 2 minutes before being placed into an ethanol series of 96% ethanol for 30 
seconds and 2 washes in 100% ethanol for 30 seconds. Finally, slides were placed in histoclear 
for 10 seconds. Moisture was allowed to evaporate from the surface of the slide in addition to 
gentle wiping of excess histoclear from the slide, before a drop of distyrene, plasticiser and xylene 
mounting solution (DPX, Sigma-Aldrich Ltd, UK) was applied without any air bubbles and a 
coverslip (24 mm x 60 mm) placed above the samples. The DPX was allowed to spread under 
the coverslip and over the samples.  
Picosirius red: a strong, linear, anionic dye comprised of six sulfonate groups which are able to 
associate with cationic collagen fibres. This dye is typically used to stain muscle tissue sections. 
The following procedure was followed for both paraffin and OCT embedded samples: 
Solution A: 0.5 g of Direct Red 80 was added to 500 ml of picric acid solution.  
Solution B: 5 ml glacial acetic acid was added to 1 litre of tap 
Sections were exposed to solution A for 60 minutes, solution B for 30 seconds twice, deionised 
water for 30 seconds twice. Ethanol series was then used including 95% (twice for 20 seconds 
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each), 100% ethanol (twice for 20 seconds) and histoclear for 3 minutes. A drop of DPX was then 
added before coverslip attachment. 
Alcian blue: a dark blue copper containing dye used to stain acidic polysaccharides such as 
glycosaminoglycans and other types of mucopolysaccharides. 
Alcian blue solution (pH 1.0): 400 ml of 0.1 M hydrochloric acid was first made by adding 3.3 ml 
of 38% HCl to 395 ml of deionised water and topped up to 400 ml. 4 grams of alcian blue powder 
was then added to this solution and filtered using Whatman paper. The prepared solution was 
viable for up to 6 months and stored at room temperature. 
Nuclear Fast Red solution: 20 grams of aluminium sulphate was dissolved in 400 ml of deionised 
water followed by 0.4 grams of nuclear fast red. The solution was then boiled on a heat plate and 
allowed to cool. Once cooled the solution was filtered using Whatman paper and a grain of thymol 
added as a preservative. The prepared solution was viable for up to 6 months and stored at room 
temperature. 
Sections were loaded into a slide holder and introduced to the alcian blue solution for 5 
minutes at room temperature. Afterwards, the slides were removed and washed 3 times with 
deionised water before adding to the nuclear fast red solution for a further 5 minutes at room 
temperature. Following this, the slides were removed and washed with tap water 4 times. Slides 
were then dried carefully, DPX applied to the surface of the microscope slide and coverslip 
mounted. Coverslip edges were again covered with nail varnish to secure coverslip to the slide 
and protect the sample. 
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Result of optimisation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The sectioning procedure of paraffin embedded agarose samples caused a significant 
shrinkage of the hydrogel (Figure 4.12). During sample sectioning, the hydrogel expands creating 
the wrinkled appearance in each section. This directly affects the appearance of the section and 
the ability to discern useful information regarding the cells embedded within the sample. In 
contrast, cryoembedded samples demonstrated much clearer sections with no wrinkling as seen 
in the paraffin embedded samples (Figure 4.13). However, sectioning of the cryoembedded 
samples required a large amount of care and delicacy as the sections could easily split.  Another 
problem associated with the histology process was the widespread non-specific background 
staining apparent in all the stains used (Figure 4.12). H&E and picrosirius staining in particular 
showed complete background staining of the gel itself making it difficult to distinguish any cellular 
architecture or collagen deposition. 
 
Paraffin 
H&E 
Paraffin 
Picosirius 
red  
200µm 
200µm 2mm 
2mm 
x1.25 x10 
Figure 4.12: Paraffin embedding of hydrogel construct resulted in severe folding hydrogel 
samples. Intense background staining of the hydrogel and extensive folding of the sample was apparent 
post paraffin embedding and sectioning, obscuring any specific staining attributed to the cells or ECM 
components and was unsuitable as a method of processing hydrogel samples. 
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 However, the alcian blue staining protocol with nuclear fast red counterstain offered the 
least amount of non-specific background staining and allowed the observation of pericellular 
proteoglycan deposition. Therefore, for histological staining AFSC/agarose samples were OCT 
embedded, cryo-sectioned and stained using alcian blue with a nuclear fast red counterstain 
(Figure 4.13). 
 
 
 
 
 
 
 
OCT 
Alcian 
blue 
OCT
H&E 
x1.25 x20 
2mm 100µm 
100µm 2mm 
Figure 4.13: OCT embedding of hydrogel construct eliminates the severe folding seen in paraffin 
embedded samples. While still showing some non-specific staining, the alcian blue staining protocol 
used showed specific staining of cells via nuclear fast red counterstain and specific positive staining of 
proteoglycans (alcian blue). H&E staining showed cell specific staining only. 
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4.2.6 Histology analysis 
To perform image analysis and quantification, the image processing package Fiji was 
used (Schindelin, 2012). The following plugins were used to perform analysis of the prepared 
histological sections: Plot profiling: Dynamic ROI Profiler (Clojure) by Albert Cardona and Analyse 
Particles: Quick PALM by Ricardo Henriques. In brief, the histology collage was opened in the Fiji 
program and the area of the construct was selected using a circular area selection whereby it was 
converted into a 16 bit black and white image and threshold adjusted to isolate the cells within 
the image from the background (Figure 4.14B). This processed black and white image was then 
analysed using the ‘Analyse Particles’ plugin to count the individual number of cells within the 
processed image (Figure 4.1C and D). Smaller particles were excluded by applying 200-infinity 
and the fill hole parameter applied to avoid double counts. Further information including the 
number of counts and average size of each point read was also recorded. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14: Key steps in image processing for cell count within AFSC/agarose constructs 
using Fiji software. 
A B 
C D 
Grayscale conversion 
Binary conversion Particle analysis 
Original image 
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4.2.7 Second Harmonic Generation Microscopy (SHG) 
SHG microscopy was performed using two photon confocal imaging on a Leica TCS SP8 
AOBS multi photon confocal laser scanning microscope equipped with Coherent Chameleon 
Ultra, Ti Sapphire mode locked femtosecond IR laser. Collagen was excited at 900 nm and SHG 
signal detected using a non-descanned transmitted light detector with a 435 - 455 nm bandpass 
filter with a pump wavelength of 880 nm at 80 femtosecond pulse width and a 25 x 0.95 NA water 
immersion objective. The pinhole was set to maximum throughout imaging. Images were 
collected with a 25x objective. DAPI staining was also performed to label cell nuclei. Samples 
were acquired at 2 µm z-section intervals using the data acquisition system and Leica LAS X 
software; which can control the motorized stage containing the sample. The parameters for laser 
power, detector gain and offset remained constant for each sample so that direct comparisons 
could be made per treatment option. Data was collected at a resolution of 1024 x 1024 at a speed 
of 600 Hz with bidirectional mode enabled to allow scanning in both directions. A line average of 
3 was used in order to reduced background noise. 
4.2.8 Chondrogenic differentiation experiment 
Chondrogenic differentiation medium was identical to that described in Chapter 2.2. Each 
construct was supplied with an identical volume of differentiation medium and growth factor 
concentrations as previously stated also. The end point of culture was maintained at 28 days. 
Culture medium was exchanged every 3 days as previously performed. In addition to the previous 
treatments and controls utilised, I included CNP only treatment (100 nM, GenScript, USA), CNP 
+ TGFb1 (100 nM + 10 ng/ml respectively) treatment, CNP + TGFb3 (100 nM + 10 ng/ml 
respectively) treatment and finally Dex + TGFb1 (100 nM + 10 ng/ml respectively). 
4.2.9 Biochemical assays 
DMMB, Hoechst and hydroxyproline assay protocols were unchanged from Chapters 
2.2.12, 2.2.13 and 3.2.3. Each construct was also processed identically to the methods stated 
previously.  
4.2.10 Statistics 
All results in this study were shown as the mean from replicates and individual 
experiments with error bars representing the SEM. Shapiro Wilk normality test was used to 
determine statistical significance of non-normally distributed data between means (determined 
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using SPSS software, version 10, IBM, USA). The number of patients and replicates are indicated 
in figure legends. In all comparisons, p<0.05 was considered statistically significantly for tests 
comparing treatment conditions vs controls and inter-treatment comparisons.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
140 
 
4.3 Results 
4.3.1 Temporal effect of CNP supplementation on GAG synthesis, hydroxyproline 
synthesis and DNA content of AFSC/agarose constructs suggests positive effect when 
applied in concert with TGFb. 
The statistical differences observed were based on comparing the averages of different 
treatment conditions. The ability of CNP to influence GAG synthesis in AFSC/agarose constructs 
was compared to that of Chang, Basal medium, TGFb1, TGFb3, CNP + TGFb1, CNP + TGFb3 and 
Dex + TGFb1 over a period of up to 28 days. Treatment of constructs with exogenous CNP did 
not result in any clear differences to control samples at all time points in terms of GAG synthesis, 
DNA content and collagen synthesis (Figure 4.15, 4.16 and 4.17; p>0.05). Treatment with either 
TGFb1 or TGFb3 resulted in significant increases in GAG synthesis and collagen synthesis relative 
to controls and CNP treated samples (Figure 4.15B and C, Figure 4.16B and C; p<0.01). Further 
to this, no obvious differences were detected between CNP + TGFb1 and CNP + TGFb3 treated 
AFSC/agarose constructs in terms of GAG synthesis, DNA content changes and hydroxyproline 
synthesis (p>0.05; Figure 4.15C). Direct comparisons between TGFb1 or TGFb3 treated samples 
with CNP + TGFb1 and CNP + TGFb3 counterparts for GAG synthesis, showed statistically 
significant differences between CNP + TGFb1 and CNP + TGFb3 treatments compared to TGFb1/3 
treated samples (Figure 4.15C). After 28 days of culture, combination treatment samples were 
all significantly higher compared to single factor treatments. No statistical differences were 
observed after only 14 days of culture between these groups in terms of GAG and collagen 
synthesis.  
For collagen synthesis, statistically significant differences were only detected after 21 and 
28 days of culture in TGFb isoform treated samples and combination treated samples (CNP + 
TGFb1, CNP + TGFb3, Dex + TGFb1) No differences were detected when comparing the 
combination treatments with single TGFb isoform treatment (Figure 4.16A, B and C). 
DNA content changes were detected as early as 14 days of culture whereby samples 
treated with either TGFb isoform alone or combination treatments resulted in statistically 
significant increases relative to control samples. This trend continued at 21 and 28 days of culture. 
No differences in DNA content were observed between single factor TGF treatment and 
combination treatments either (Figure 4.17A, B and C; p>0.05). 
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Figure 4.16: CNP alone does not stimulate collagen synthesis. +++ indicates with Chang, $$$ with Basal, 
£££ with CNP. Brackets indicate the same statistical differences appear at the different time points. N = 3 per condition 
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Figure 4.17: CNP addition does not significantly enhance DNA content. +++ = significantly different to 
Chang treatment, $$$ = significantly different to basal medium, £££ = significantly different to CNP. N = 3 per condition 
and time point with 12 replicates. Error bars indicate ± SEM. Data normalised to day 0. 
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4.3.2 Exogenous treatment of Dex + TGFb, CNP + TGFb1/TGFb3 or CNP alone does not 
affect chondrogenic gene expression in AFSC/agarose constructs after 28 days of culture 
relative to day 0. 
SOX-9 gene expression increased for all treated constructs compared to day 0 control 
(Figure 4.17A). However, the only statistically significant change in gene expression was 
detected when comparing CNP + TGFb1 to day 0 control (p<0.001). 
Similarly, COL2a1 gene expression increased in all treatment conditions compared to 
control (p<0.01, Figure 4.17B). The greatest increase was observed in Dex + TGFb1 treated 
sample, showing 146 times increase in gene expression relative to day 0 control. In contrast, CNP 
treatment alone only resulted in a 25-fold increase in COL2a1 expression. However, no 
statistically significant differences were detected when comparing all treatment conditions to day 
0 control and also when comparing treatments (p>0.05). 
In the case of aggrecan expression, whilst treatment with CNP + TGFb1, CNP + TGFb3 
and Dex + TGFb1 all resulted in increased aggrecan gene expression relative to day 0 control, 
treatment with CNP did not (Figure 4.17C). No statistically significant differences were detected 
between day 0 and treated samples 
Analysis included 4 patients’ cells (N = 3 replicates) where error bars represent the 
standard error of the mean. Gene expression was normalised to patient matched day 0 control 
samples and presented as relative gene expression to day 0 untreated samples with gene 
amplification efficiency values taken into account during the calculation. 
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Figure 4.18: Relative gene expression for SOX-9, aggrecan and COL2a1 with y-axis presented as 
a logarithmic scale. Analysis included 4 patients, with 3 replicates performed during analysis per patient. 
Error bars represent the standard error of the mean. The only statistically significant difference detected 
was observed when comparing CNP + TGFb1 treated sample to day 0 when measuring SOX-9 expression 
(p<0.05). *** indicates statistically significant difference with day 0 (p<0.01). 
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4.3.3 Histological analysis of AFSC/agarose constructs treated with CNP +TGFb1, CNP + 
TGFb3, indicates weak positive pericellular proteoglycan deposition 
Following cryo-preparation and cryo-sectioning of AFSC/agarose day 0 control and 
treated constructs, alcian blue staining with nuclear fast red counterstain was performed on axial 
and mid-sagittal sections of 6 µm thickness. Day 0 controls demonstrated no positive alcian blue 
staining with only cell nuclei stained due to the counterstain used (Figure 4.18). Homogenous 
cell distribution was identified using the Image J plugin and visual confirmation. AFSCs clearly 
displayed strong positive alcian blue staining around the cells when treated with dexamethasone 
and TGFb1 after 28 days of culture (Figure 4.21). This strong staining was evident in both axial 
and mid-sagittal sections (Figure 4.421A and C). Positive staining was also evident in CNP + 
TGFb1 and CNP + TGFb3 treated samples but to a much lesser extent than in the dexamethasone 
+ TGFb1 treated sample (Figure 4.19 and Figure 4.20 respectively). All treated samples 
demonstrated more positive alcian blue staining compared to the day 0 control. The distribution 
of cells throughout the treated constructs was determined by counting the number of individual 
dots of a specific minimum and maximum size which would indicate a cell as the image was 
scanned from left to right. For all sections scanned, the distribution of cells appeared 
homogenously distributed (Figure 4.18C and F, Figure 4.19C and F, Figure 4.20C and F, 
Figure 4.21C and F).  
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Figure 4.19: Alcian blue staining of AFSC/agarose day 0 control are negative for proteoglycan 
deposition. Day 0 controls sections demonstrate largely homogenous distribution of cells within the 
constructs but show no positive alcian blue staining of proteoglycan deposition with only nuclei stained. A 
+ D: Collage of x20 images taken of construct axial (A) and mid sagittal (D) sections of AFSC/agarose 
construct from day 0. B + E:  x20 magnification image of sample negative for proteoglycan. C + F: Pixel 
count of collage image scanning from left to right to demonstrate cellular distribution through construct. 
Steep changes in distribution are attributed to the folding of the section on the slide. N = 1. 
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Figure 4.20: Alcian blue staining for proteoglycans within AFSC/agarose constructs treated with 
CNP + TGFb3 is positive. CNP + TGFb3 histological sections demonstrate homogenous distribution of 
cells within the constructs and weak positive alcian blue staining of proteoglycan deposition. A + D: 
Collage of x20 images taken of construct axial (A) and mid-sagittal (D) sections of AFSC/agarose 
construct cultured with CNP + TGFb3. Axial section stains more positive for proteoglycan compared to 
the mid-sagittal sections. B + E: Example images x20 magnification of positive alcian blue staining of 
cells within the treated construct. C + F: Pixel count of collage image scanning from left to right to 
demonstrate cellular distribution through construct. N = 1. 
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Figure 4.21: Alcian blue staining for proteoglycans within AFSC/agarose constructs treated with 
CNP + TGFb1 is positive. CNP + TGFb1 histological section demonstrated a generally homogenous 
distribution of cells within the constructs and positive for alcian blue staining of proteoglycan deposition. 
A + D: Collage of x20 images taken of construct axial (A) and mid sagittal (D) sections of AFSC/agarose 
construct. Stronger alcian blue staining was observed in axial section compared to mid-sagittal. B + E: 
Example images x20 magnification of positive alcian blue staining of cells within the treated construct. 
C + F: Pixel count of collage image scanning from left to right to demonstrate cellular distribution 
through construct. N = 1. 
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Figure 4.22: Alcian blue staining of AFSC/agarose constructs treated with dexamethasone and 
TGFb1 is strongly positive. The dexamethasone + TGFb1 treated construct demonstrates largely 
homogenous distribution of cells within the constructs and shows clearly strong positive alcian blue 
staining for proteoglycans. A + D: Collages of x20 images taken of the construct at axial (A) and mid 
sagittal (D) orientations. B + E: x20 magnification of positive alcian blue staining of cells within the treated 
construct. C + F: Pixel count of collage image scanning from left to right to demonstrate cellular 
distribution throughout the construct. N = 1. 
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4.3.4 SHG imaging indicates collagen deposition in AFSC/agarose constructs but levels 
are significantly less than positive control samples. 
The ability of AFSCs to produce collagen in response to growth factor stimulation was 
assessed using SHG imaging of AFSC/agarose constructs across an area of 500 µm x 500 µm 
sample region (Figure 4.22). A positive control containing bovine chondrocytes cultured for 48 
hours was used as a comparator. Imaging of the constructs in all treatment conditions did not 
produce clear widespread production of collagen fibres. Rather, areas where cells were in 
extremely close proximity often correlated with more evident collagen fibre deposition. The 
amount of collagen deposition appeared similar in all treatment conditions investigated for 28 
days but was significantly lower compared to the positive control. Cell nuclei showed rounded 
morphology in all cases. 
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Figure 4.23: Second harmonic generation imaging of collagen deposition in day 28 treated 
samples compared to a bovine chondrocyte positive control cultured for 48 hours. At 28 days, 
pericellular deposition of collagen is noted around clusters of cells in all treated samples. The collagen 
detected showed no specific orientation or organisation in AFSC/agarose constructs as well as in bovine 
chondrocyte/agarose constructs. Collagen detection was less distributed throughout the entire area of the 
construct scanned in AFSC/agarose constructs regardless of treatment compared to bovine 
chondrocyte/agarose constructs. Representative of N = 2 experiments. 
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4.4 Summary of results 
• CNP + TGFb and Dex + TGFb demonstrate collagen deposition according to SHG 
imaging of day 28 constructs but is lower than that of tissue derived bovine chondrocytes. 
• CNP alone does not enhance chondrogenic differentiation of AFSC/agarose constructs 
in terms of GAG synthesis, hydroxyproline synthesis or DNA content. 
• CNP with TGFb1 or TGFβ3 enhances GAG synthesis, hydroxyproline synthesis and DNA 
content over 28 days compared to single factors. 
• Weak positive alcian blue staining for proteoglycans is present in CNP + TGFb1 or TGFβ3 
treated samples but is more evident in Dex + TGFb1 treated sample compared to day 0 
control. 
• Statistically significant SOX-9 gene expression changes detected only when comparing 
CNP + TGFb1 treated sample to day 0. 
• No statistically significant changes in terms of aggrecan and COL2a1 gene expression 
when comparing treated samples to day 0 or inter-treatment comparisons. 
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4.5 Discussion 
The work described in this Chapter set out to investigate the effect of CNP on human 
AFSC chondrogenic differentiation over a period of 28 days. Specifically, I examined the effect of 
CNP alone or in combination with TGFb1 or TGFb3 on GAG synthesis, hydroxyproline synthesis 
and DNA content over 28 days of culture compared to day 0 control, non-growth factor treated 
controls (Basal, Chang) and the traditional differentiation method which utilises Dex and TGFb1. 
Furthermore, the study developed a simple in vitro hydrogel model by optimising protocols for 
sectioning of AFSC/agarose constructs, SHG imaging of collagen within AFSC/agarose 
constructs, RNA extraction from AFSC/agarose constructs and primer efficiency optimisation for 
the genes aggrecan, SOX-9, COL2a1 and beta actin when using AFSCs. 
4.5.1 CNP enhances TGFb mediated GAG synthesis of human AFSCs 
CNP alone was insufficient to enhance chondrogenic differentiation of AFSCs within 
agarose constructs (Figure 4.15A-C). This was specifically shown by the lack of statistical 
differences when comparing GAG synthesis, collagen synthesis and DNA content relative to 
control samples (all p>0.05). To my knowledge this is the first study to directly test this using 
AFSCs. In contrast, when supplemented with the chondrogenic growth factor TGFb, the GAG 
synthesis of AFSCs treated with CNP became greatly enhanced compared to control and single 
factor treated samples (Figure 4.16A, p<0.01). This effect was independent of the TGFb isoform 
used, with no statistically significant differences observed between CNP + TGFb1 and CNP + 
TGFb3 (p>0.05). The finding that CNP enhanced TGFb mediated chondrogenic differentiation is 
congruent with that of Tezcan and Kocamaz who also associated this effect when investigating 
MSC chondrogenic differentiation (Tezcan et al., 2010, Kocamaz et al., 2012). 
Patient 3’s cells in Figure 4.16A, showed that GAG synthesis was attenuated when 
treated with combination treatments especially dexamethasone + TGFb1 relative to single factor 
treatment at 14 days of treatment (Figure 4.16A). However, the effect of the treatment was 
recovered after 21 and 28 days of culture. An explanation for this could be due to patient variation 
but this wouldn’t explain the recovery of the positive effect at the later time points investigated. 
Most likely an error occurred during analysis. However, to confirm this a repeat of the sample 
analysis or the overall experiment would be required ideally using more samples/biological 
repeats. In contrast, DNA content increases were statistically significantly higher in CNP + TGFb1 
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and CNP + TGFb3 treated samples compared to Dex + TGFb1 treatment. This suggests that Dex 
+ TGFβ supplementation confers a greater enhancement to chondrogenic differentiation in terms 
of ECM synthesis, whilst CNP + TGFb confers a benefit to cellular proliferation. This observation 
could be dependent on the concentration of CNP applied to this culture, since low concentrations 
of CNP have been associated previously with increase proliferation in chondrocytes (Woods et 
al., 2007). 
Combination treatment of CNP + TGFβ1 or CNP + TGFβ3 or Dex + TGFβ1 achieved GAG 
synthesis levels of 5.4, 5.3 and 5.5 µg/µg DNA respectively. Collagen synthesis levels were 
measured at 0.79, 0.75 and 0.75 µg/µg DNA for CNP + TGFβ1 or CNP + TGFβ3 or Dex + TGFβ1 
treated samples respectively. When put into context with other published work, these values are 
significantly lower. Partly this is due to the differences in cell seeding density used, but even when 
that is taken into account, the sheer scale of difference is quite vast and indicates that this model 
is unsuitable for a practical application but more useful as a method to study different treatments 
of stem cells within a 3D model. 
Importantly when compared to the single factor treatments of TGFβ1 or TGFβ3 
treatments, no statistically significant differences in collagen synthesis were observed when 
compared against the combination treatments, indicating that CNP has no effect on this part of 
ECM deposition (Figure 4.15C and 4.16C). This correlates with findings by Kocamaz et al who 
demonstrated that inhibition of CNP or its receptor did not affect type II collagen mRNA expression 
(Kocamaz et al., 2012). If CNP does not directly affect the expression and therefore transcription 
of collagen, the lack of differences between single factor treatment and combination treatments 
could be explained in this way.  
4.5.2 SHG imaging and histological staining are positive for ECM deposition in CNP + 
TGFb isoform treated samples 
Following the biochemical investigation, SHG imaging indicated that the collagen 
deposition was of a pericellular localisation and did not appear to be different when comparing 
the treatment options assessed, at least from a visual perspective (Figure 4.22). However, when 
compared to tissue derived chondrocytes embedded within agarose constructs for 48 hours, the 
amount of collagen deposition is much lower. This suggests that while ECM synthesis may be 
occurring, the cells are still unable to produce ECM molecules to the same extent as native cells 
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derived from tissue at least at this stage of the differentiation protocol. The lack of any fibrillar 
structures or any directionality in the SHG signal suggests that the collagen deposited here does 
not bear resemblance to the tissue structure of articular cartilage. The limited penetration depths 
of SHG from only 100 - 300 µm using the laser excitation used here, means that imaging of entire 
constructs is extremely difficult, expensive and logistically impractical given the size of the 
hydrogel construct used here (5 mm x 5 mm). Each scan performed in this experiment required 
over 1 hour of imaging time to complete. As such, the areas scanned here offers only a small 
glimpse regarding collagen deposition within the core of these constructs but not a full 
representation of the entire construct. Given the sheer cost of using this equipment due to the 
Ti:Sapphire laser source, and the inability to distinguish between fibrillar collagen types, 
techniques such as immunolabelling of specific collagens may be a more suitable method of 
determining collagen deposition in this particular model.  
In terms of proteoglycan deposition, alcian blue staining of 6 µm histological sections of 
CNP + TGFb1 or CNP + TGFb3 constructs demonstrated weak positive staining for proteoglycans 
especially in mid-sagittal sections (Figure 4.19 and 4.20). This suggests a homogenous 
differentiation is occurring in the samples after 28 days. This level of proteoglycan staining in 
agarose constructs was also observed by Ahearne et al who showed after 21 days a similar level 
of pericellular accumulation of GAG was achieved compared to my study after 28 days. Given 
that the cell density used in Ahearn’s study was much higher than the one used herein (1.5 x 107 
cells/ml) this could explain why similar levels of alcian blue staining are observed in separate 
studies (Ahearne and Kelly, 2013). Alcian blue staining appears to be stronger in Dex + TGFb1 
treated sample compared to CNP + TGFb1 or CNP + TGFb3 treated samples, especially when it 
comes to mid-sagittal sections (Figure 4.21). This is in agreement with the biochemical analysis 
of GAG synthesis performed earlier whereby statistically significant increases were observed in 
Dex + TGFb1 treated samples compared to CNP + TGFb isoform treatments (Figure 4.15A). 
4.5.3 CNP supplementation does not affect chondrogenic gene expression of human 
AFSCs after 28 days of culture 
The finding that no statistically significant changes in gene expression for aggrecan and 
COL2a1 was surprising given the identification of proteoglycan and collagen deposition via 
biochemical, histological and SHG analysis (Figure 4.17A-C). However, the lack of statistical 
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power in terms of limited sample size, difficulties in terms of RNA extraction and the sheer amount 
of time required to perform the culture experiments mean this is not wholly unexpected. Aggrecan 
expression in particular has been associated with a transient expression over time, reliant on 
mechanical stimulation (Palmer et al., 2001). In addition, Greenbaum et al demonstrated that 
there are likely 3 significant mechanisms that explain differences between mRNA expression and 
detectable protein levels; 1) post transcriptional mechanisms that convert the mRNA to protein, 
2) in vivo half-lives of the translated proteins and 3) experimental error and noise (Greenbaum et 
al., 2003). In terms of post transcriptional regulation occurring, many of these mechanisms are 
poorly defined but could explain the discrepancy observed here. Alternatively, experimental error 
is also potentially likely but would require further repeats of the experiment to confirm.  
Gene expression as a measure of stem cell differentiation is a notoriously difficult and 
potentially unreliable method of assessment.  Whilst gene expression changes might not be 
observed at the time point that I extracted my mRNA sample, it might have been upregulated at 
an earlier time point explaining the deposition of proteoglycans observed in the histological 
samples. In addition, aggrecan has previously been disputed as a good marker of chondrogenesis 
as some groups have found its expression to be constitutive event in MSCs (Cho et al., 2004). 
However, this event has not been noted when using AFSCs or agarose hydrogels previously. It 
should also be noted that patient variability is likely to result in some differences but cannot be 
avoided, therefore expansion of the number of samples and replicates would be required during 
analyses to minimise this concern.  
4.6 Summary 
In summary, for the first time I have identified that CNP is not a suitable enhancer of 
chondrogenic differentiation of human AFSCs on its own, but the evidence supports the use of 
CNP to support chondrogenic differentiation of stem cells mediated by TGFb1 or TGFb3 
supplementation. However, further clarification of the effect that CNP has on TGFb meditated 
differentiation is required in terms of the expression of further target chondrogenic genes and 
hypertrophic genes to fully characterise the effect of the peptide on this process compared to 
other established treatments. 
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Chapter 5: The effect of CNP microcapsules on 
ECM synthesis of bovine chondrocyte 
embedded within agarose constructs. 
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5.1 Introduction 
In recent years, the use of tailorable vesicles for the release of bioactive molecules to 
stimulate a biological effect has been increasing. Several different carrier systems have been 
developed from nanoparticles (Boisselier and Astruc. D, 2009), dendrimers (Palmerston Mendes 
et al., 2017, Madaan et al., 2014) and even liposomes (Sercombe et al., 2015), each having 
unique characteristics suitable for practical applications such as drug delivery, chemical synthesis 
and even catalysis. Out of all of these technologies though, layer by layer assembled multilayer 
capsules have been intensively studied for use as a multifunctional system that is capable of 
stimuli responsiveness, stability and a broad range of novel functionalisation. Like many inventive 
technologies, layer by layer (LbL) assembly is based on a simple idea. Basic electrostatic 
interactions between two oppositely charged electrolytes, as proposed first by Decher et al and 
later built upon by Sukhorukov et al, around a spherical dissolvable core template results in the 
formation of reproducible, hollow shell formations referred to as microcapsules (MC) (Decher et 
al., 1992, Decher, 1997, Sukhorukov et al., 1998). The ability to tailor the size, composition and 
surface functionality has resulted in a truly amenable technology for a host of purposes. By 
altering the composition of these microcapsules using different polyelectrolytes, the resulting 
microcapsule can be biodegradable or non-biodegradable (Loca et al., 2014). This can directly 
affect the fate of microcapsules if engulfed by cells; biodegradable microcapsules will be broken 
down and release their contents whilst synthetic polymer microcapsules can remain intact and 
release their payload over time (Luo et al., 2016). The functional groups and structures present 
on different polyelectrolytes as well as environmental factors such as pH and salt concentration 
can directly affect the properties of the resultant polyelectrolytes produced. 
Arguably the most important consideration in terms of microcapsules is the entrapment 
of cargo substances within the capsule’s cavity which can be achieved in a multitude of ways. 
Proteins, polymers, DNA, enzymes and even small inorganic molecules can be incorporated into 
the core template of the microcapsules through co-precipitation (Volodkin et al., 2004) or following 
the removal of the template itself via diffusion through the microcapsules porous shells (Shchukin 
and Sukhorukov, 2003). The native conditions in which the microcapsules are formed allows the 
incorporation of these bioactive molecules (Luo et al., 2016) and the multilayer structure of the 
microcapsule essentially protects the cargo from degradation such that the microcapsule can be 
delivered to the site of action and released. Whilst in some microcapsules this release can be 
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mediated by the application of external stimuli such as physical (e.g. magnetic fields), chemical 
(e.g. pH) and biological (e.g. biodegradation) approaches, the porous network structure of 
microcapsules allows the permeability of molecules less than 5 kDa in size. 
The ECM tightly regulates cell behaviour though its major components such as water, 
structural proteins and glycoproteins but also possess cell surface immobilised proteins and 
proteoglycans capable of binding and sequestering growth factors. In doing so, the ECM is 
capable of regulating the effect of these growth factors either by preventing overstimulation of the 
cells by sequestering them or through release of sequestered growth factors by enzymatic 
degradation of the ECM (Ferrara, 2010). The context and method of presentation of growth factors 
to the cells is itself an important factor. The ECM therefore plays a pivotal role in dictating growth 
factor activity and cellular response.  One of the previous major criticisms for tissue engineered 
scaffold materials was viewing the scaffolds as simply a structure to place the cells when in reality 
the scaffold material acts as a surrogate for the inherent ECM of tissue and plays a much more 
significant role. Due to this, there has been growing interest in the incorporation of bioactive 
molecules within scaffold materials of tissue engineered products for the purpose of enhancing 
cell behaviour regulation or stem cell homing (Wu et al., 2018). The most obvious example of this 
is the use of RGD motifs which allow greater cell interaction with their surrounding material 
thereby affecting stem cell behaviour (Tahlawi et al., 2019). However, the incorporation of 
biomolecules into scaffold materials is costly due to the technical challenge of incorporating such 
molecules and sometimes the lack of appropriate materials in which these molecules can be 
attached. Even if growth factor incorporation into the scaffold material is possible, enzymatic 
degradation of these materials by the cells is sometimes difficult, resulting in a reduced release 
of the growth factor to stimulate the cells and therefore a reduced effect.  
In terms of in vitro research, the application of exogenous growth factors to culture 
medium in order to affect the cellular response of cells within 3D materials is commonly performed 
and routinely effective. However, since the exogenous application of bioactive molecules is reliant 
on passive diffusion of the agent through culture medium and scaffold materials to the cells within, 
this has several implications. Firstly, most bioactive molecules used to elicit cellular responses 
possess short half-lives when free in solution. As such the bioactivity of these agents could be 
affected by this process. For example, CNP has a half-life of just under 2.6 minutes when in 
humans (Hunt et al., 1994). In addition, the fact that growth factors are not directly applied to cells 
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in cases of encapsulated systems requires much higher doses of growth factor to be applied to 
the culture medium in order to allow sufficient active growth factor to stimulate the cells. From a 
financial perspective, the use of high doses of growth factors to elicit cellular responses in these 
systems when much lower doses are required on a local level to facilitate the effect is a significant 
limitation. It is here that microcapsule technology offers a potential solution. Due to the low cost 
of the materials required, the ease with which synthesis can be performed and the vast range of 
functionalities possible; microcapsules offer a unique and versatile way to locally release a 
bioactive compound. Gradual release of a bioactive molecule such as a growth factor or peptide 
from microcapsules incorporated into a scaffold, could mimic the turnover events that occur in 
vivo which allows the release of sequestered growth factors from the ECM. In this way, a tissue 
engineered construct can more closely replicate what occurs in vivo and potentially enhance 
cellular response for example in terms of ECM synthesis.  
The established model of differentiation in the previous chapters of this thesis utilises low 
gelling agarose as the means to provide a 3D environment for AFSC chondrogenic differentiation. 
Therefore, it would make sense to investigate the application of microcapsule technology to 
determine if local release through this method can instigate a positive effect on the cells in terms 
of differentiation. Ideally, microcapsule release of a growth factor such as TGFb would be a good 
way of investigating this theory. However, given the relative molecular weight of TGFb is 25 kDa, 
its size precludes passive release from simple microcapsule structures. In contrast, since CNP is 
a biological molecule of ~2.2 kDa size, it has potential as a candidate for passive release from 
LbL microcapsules. However, from the differentiation investigation in the previous chapter I noted 
that CNP alone does not constitute any effect on ECM synthesis in AFSC/agarose constructs. 
Therefore, to test the use of microcapsules within agarose hydrogels to enhance cell ECM 
synthesis, I sought to first test this technology on an alternate readily available cell type that has 
a previously demonstrated response to CNP; bovine chondrocytes. Bovine chondrocytes have 
previously been shown to be responsive to CNP microcapsule release when applied to the 
surface of a cartilage explant (Peake et al., 2015). By manufacturing and supplying CNP 
containing microcapsules to bovine chondrocyte/agarose constructs, I sought to determine 
whether the passive release of CNP from these structures enhances the ECM synthesis derived 
from these cells (Figure 5.1). If successful, this research would then pave the way for further 
investigation into the use of CNP microcapsules on AFSC differentiation, encapsulation of other 
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bioactive agents into the microcapsule structures or the development of more complex stimuli 
activated microcapsules to deliver larger more complex growth factors to stem cells within an 
agarose construct such as this. 
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Figure 5.1: Localised passive release of CNP from polyelectrolyte microcapsules to stimulate 
proteoglycan synthesis of bovine chondrocytes. 
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5.2 Methods 
Materials used: Poly-L-arginine hydrochloride (PLA, 15 - 70 kDa), dextran sulphate sodium salt 
(DS, 100 kDa), calcium chloride, sodium carbonate and all other salts were purchased from Sigma 
Aldrich Ltd, UK. Other reagents including tetramethylrhodamine (TRITC) were purchased from 
Thermofisher Scientific, UK). 
5.2.1 CNP preparation and labelling 
Fluorescent labelling of CNP was performed using the Pierce FITC Antibody Labelling Kit 
(Thermofisher Scientific, UK) according to the manufacturer’s instructions. A 2 mg/ml solution of 
CNP (purity 95.1%) in 50 mM PBS was added to NHS-fluorescein isothiocyanate (FITC) and then 
incubated with FITC for 1 hour at room temperature. To purify the protein, the FITC labelled CNP 
was mixed with purification resin within a spin column and centrifuged for 30 - 45 seconds at 1000 
x g to remove unbound dye. To measure the degree of labelling, fluorescence readings were 
taken at excitation 480 nm and emission 520 nm using a microplate reader (Fluostar, BMG 
Labtech, UK) and CNP concentration was determined using a Nanodrop ND-1000 
Spectrophotometer at absorbance 280 nm and 495 nm (LabTech, UK). From this, the total 
amount of labelled CNP available was deduced. FITC labelled CNP was then stored at -20°C 
prior to use. 
5.2.2 TRITC labelling of poly-L-arginine (PLA) 
Poly-L-arginine was first dissolved in 0.1 M borate acid buffer at pH 8 - 9 (titrated with 
NaOH) at 2 mg/ml concentration. Separately TRITC was dissolved in ethanol at 1 mg/ml (5 ml).  
The TRITC solution was slowly added to the polymer solution while stirring with a magnetic stirrer, 
and then left to stir for 24 hours. After that, the solution obtained was transferred to into 25 kDa 
cut-off dialysis membrane and dialysed against deionized water for 1 week or until the water 
outside showed fluorescence traces. Water was changed at least twice a day during this process. 
TRITC labelled PLA was then stored at 4°C.  
5.2.3 Microcapsule synthesis and characterization 
All microcapsules used within these experiments were prepared using the layer by layer 
assembly technique using well established protocols of depositing alternately charged 
polyelectrolytes (poly-L-arginine hydrochloride and dextran sulfate onto CaCO3 templates. To 
successfully load CNP into the microcapsule cores, 100 µg was co-precipitated into the sacrificial 
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0.33M CaCl2 + 
CNP (100µm)
0.33M Na2CO3
CaCO3
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Adsorption Washing
AdsorptionWashing
Figure 5.2: CNP microcapsule synthesis process. Incorporation of CNP inside of a microcapsule 
structures requires early addition during the sacrificial core formation step where it is incorporated and 
protected during the layer by layer assembly process. Adsorption of a positive polyelectrolyte layer 
(PLA) was always initiated first and finished with a negatively charged polyelectrolyte layer (DS). EDTA 
was used to dissolve the calcium carbonate core and liberate the bound CNP within. 
CaCO3 templates formed by vigorous agitation of 0.33 M CaCl2 AND 0.33 M Na2CO3. Oppositely 
charged 2 mg/ml polyelectrolytes PLA (positively charged) and DS (negatively charged) in 0.15 
M NaCl were alternately adsorbed for 15 minutes before agitation with the calcium cores, 3 
washing steps using ddH2O and centrifuged briefly before the next polyelectrolyte added (Figure 
5.2).  After a triple bilayer was formed the calcium carbonate cores were dissolved using 0.2 M 
EDTA (pH 6.5) twice for 15 minutes followed by washing in EDTA and H2O and centrifugation 
steps. Microcapsules were stored at 4°C for a maximum of 1 week due to their inherent leakiness. 
CNP free microcapsules were kept for up to 1 month at 4°C. For fluorescent visualisation, the 
second positive layer was replaced with TRITC-PLA. Six layers were deposited for all the 
capsules before dissolving the templates with 0.2 M EDTA solution.  
 
 
 
 
 
 
 
 
 
 
 
 
 
5.2.4 Microcapsule counting 
To count the number of microcapsules the stock volume was diluted 1/100 in H2O. 10 μl 
of microcapsule suspension was placed on a disposable C-Chip haemocytometer (NanoEnTek 
Inc, USA) and counted using a Leica DMI4000B Epifluorescence microscope using its brightfield 
capacity at magnification of x 20 (Figure 5.3). FITC labelled CNP microcapsules were also 
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Figure 5.3: Counting microcapsules. Representative image of microcapsule counting within 
disposable haemocytometer grid at x20 magnification. 
visualised under the microscope at emission 525 nm. TRITC labelled empty microcapsules were 
visualised at emission 630 nm.  
 
 
 
 
 
 
 
 
5.2.5 Estimating CNP content of microcapsules and release profile 
Each wash fraction throughout the microcapsule synthesis phase was collected and 
stored at -20°C during synthesis steps. CNP concentration in each wash fraction was then 
measured by comparing the signal from each wash fraction against a standard curve generated 
using known concentrations of CNP - FITC (0 - 20 µg/ml, Figure 5.4). Fluorescence was 
measured using a fluorescence spectrometer (FLUOstar, BMG Labtech, UK) at excitation 485 
nm and emission 520 nm. The amount of CNP in each wash fraction was calculated by multiplying 
the CNP concentration measured in the sample against the volume of the wash fraction solution. 
The values from each wash fraction were then collated and subtracted from the initial quantity of 
CNP used to make the microcapsules to calculate the encapsulation efficiency of CNP within the 
CNP microcapsules.  
To determine release profile in solution, supernatant samples were taken periodically 
from CNP-FITC loaded microcapsule stock solutions (N = 3) every 12 hours for 4 days and 
analysed using a Nanodrop Spectrophotometer.  The CNP-FITC standard curve was then used 
to calculate the release profile at each time point and expressed as a mean value. 
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Figure 5.4: CNP standard curve. Representation of standard curve to derive concentration of CNP 
in wash fractions. 
 
 
 
 
 
 
 
 
5.2.6 Culture medium 
The culture medium used for experimental work involving bovine chondrocytes was 
prepared using the following reagents (Table 5.5). Dulbecco’s Modified Eagle’s Medium (DMEM), 
was supplemented with 20% FCS, penicillin/streptomycin, 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) buffer, L-glutamine and L-ascorbic acid (all components 
from Sigma-Aldrich Ltd, UK).  The resulting solution was filtered using a 0.22 µm pore sized 
cellulose acetate filter for sterility. The prepared culture medium was then aliquoted into 50 ml 
sterile universal containers (Sterilin, UK) and stored at 4°C or at -20°C. Immediately prior to use, 
the culture medium was heated within a water bath for 25 minutes at 37°C. Constructs were 
cultured in a standard Heracell incubator at 37°C at 5% CO2. The culture medium of constructs 
was changed every 48 hours.  
 
Reagent Final concentration Quantity 
DMEM N/A 500 ml 
FCS 20% (w/v) 125 ml 
HEPES 20 mM 10 ml 
L-glutamine 2 µM 5 ml 
Penicillin/streptomycin 5 µg/ml 5 ml 
L-ascorbic acid 0.85 µM 0.075 g 
 
Figure 5.5: Reagents used for bovine chondrocyte culture medium. 
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5.2.7 Pronase and collagenase solutions 
Isolation of bovine chondrocytes from bovine articular cartilage tissue required the use of 
the enzymes pronase and collagenase. Since pronase and collagenase are enzymes, their 
activity varied depending on the batch supplied by Sigma-Aldrich Ltd. Pronase powder (Sigma-
Aldrich Ltd, UK) was added to a specific volume of prepared culture medium to produce a solution 
with an activity of 33 units/ml. For example, pronase with activity 5.9 units/mg would be added to 
175 ml of culture medium. The solution was then sterile filtered using a 0.22 µm pore sized 
cellulose acetate filter, aliquoted and stored at -20°C for up to 1 year. 
For the collagenase solution, collagenase powder derived from clostridium histolyticum 
(Sigma-Aldrich Ltd, UK) was added to an aliquot of culture medium to produce a solution with 
activity of 100 units/ml. The solution was filtered using a 0.22 µm pore sized cellulose acetate 
filter, aliquoted and stored at -20°C for up to 1 year. 
5.2.8 Isolation of primary bovine chondrocytes from metacarpalphalangeal joints 
Bovine chondrocytes (bACs) used in this study were derived from the 
metacarpalphalangeal joints of newly slaughtered 18 - 24-month-old steers (N = 3) acquired from 
a local abattoir (Humphreys and Sons, Essex, UK) with authorisation of the relevant meat 
inspectors. The joints were initially washed thoroughly in hot water to remove the majority of 
contaminating biological matter attached to the hair and hooves of the joint. Following this, the 
joints were immersed in a 70% industrial methylated spirit solution for 5 minutes to remove 
residual smell. Finally, the joints were immersed in a 2% chemgene (STARLAB, UK) disinfectant 
bath for 10 minutes in order to kill any remaining infectious organisms on the surface of the joint. 
The prepared joints were then placed into a sterilised metal dissecting tray and transferred to a 
sterile class II cabinet. 
Firstly, a no.21 scalpel blade was used to make a longitudinal cut along the length of the 
clean joint until reaching the pastern. A perpendicular cut was then made across the pastern just 
above the hoof. The hide of the joint was then peeled back from the underlying tissue beneath 
using the no.21 blade to expose the joint capsule. Before continuing, the tissue was sprayed 
briefly with 70% IMS and any remaining hairs on the tissue were removed using the no.21 blade. 
Care was taken not to cut further into the tissue using this non-sterile blade. Using a fresh no.11 
blade, one insertion was made on each side of the joint capsule and the underlying ligaments and 
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tendons cut back in order to dislocate the joint and expose the condyle surface. A fresh no.10 
blade was then used to cut slices of cartilage from the proximal surface of the condyle. Cartilage 
slices were immersed in warm EBSS within a 50 mm petri dish while the dissection was 
completed. Once the dissection was complete, the petri dish containing the cartilage slices was 
transferred to an incubator at 37°C, 5% CO2 and 21% O2 while the dissected joint was removed 
from the hood, disposed of and the hood cleaned to produce sterile conditions. 
The petri dish containing the cartilage slices was then returned to the sterile hood and 
finely diced using 2 fresh no.10 scalpels using a scissor motion. The slices were then transferred 
to a falcon tube containing 10 ml of the prepared pronase solution for 1 hour at 37°C on a 
rollermixer. The pronase solution was then removed using a Pasteur pipette and replaced with 
30 ml of collagenase solution. The cartilage/collagenase falcon tube was then further incubated 
at 37°C on a rollermixer for a maximum of 16 hours. After this process, the cell supernatant was 
passed through a 70 µm pore cell sieve into a fresh falcon tube, centrifuged at 300 x g for 5 
minutes using a mid-bench centrifuge (ALC International Multispeed Model PK131R). Once 
complete the supernatant was removed, cell pellet washed twice in fresh warm culture medium 
before resuspended in 20 ml of culture medium (DMEM + 20% FCS). A cell count and viability 
assessment of the solution was performed using the standard Trypan blue dye exclusion protocol 
stated in Chapter 2. On average, 2 – 4 x 107 cells are liberated from each joint per dissection with 
a viability of between 95 - 100%. 
5.2.9 Microcapsule incorporation into bovine chondrocyte/agarose construct 
Cells were resuspended in culture medium at a concentration of 8 x 106 cells/ml in 
preparation for the production of 3D chondrocyte/agarose constructs. Prepared CNP containing 
and blank microcapsules were added to the cell suspension in differing volumes to produce 
constructs with different numbers of microcapsules incorporated. A 6% (w/v) suspension of 
agarose type VII in EBSS (Sigma-Aldrich Ltd, UK) was autoclaved at 121°C for 45 minutes, 
transferred to a 60°C oven to cool for 1 hour and then to a 37°C oven to further cool on rollers. 
An equal volume of cell suspension was then added to the agarose solution to yield a cell 
concentration of 4 x 106 cells/ml in 3% (w/v) agarose with either 300,000, 500,000, 3,000,000 or 
5,000,000 CNP containing microcapsules. 
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Constructs were then seeded transferred to a 24 well plate with 1 construct per well 
distributed. 3 ml of chondrogenic media was applied to maintain cell viability within the constructs. 
Control conditions included constructs without cells, constructs with only cells, constructs with 
empty microcapsules and constructs containing cells with CNP microcapsules. Exogenous CNP 
(100 nM) was applied to some constructs containing cells in order to provide a comparison. At 
the end of the culture period, constructs and media samples were transferred into Eppendorf 
tubes and store at -20°C for long term storage before biochemical analysis. 
5.2.10 Microcapsule characterisation 
SEM was used on microcapsules loaded with or without CNP to compare morphological 
characteristics. In brief, samples were prepared by applying a drop of the particle suspension 
onto a glass coverslip and allowed to air dry overnight. The samples were then sputter coated 
using gold and analysed using 10 kv electron beam with spot size 3.5. Mean diameter of the 
microcapsules was calculated by measuring a minimum of 50 particles for each formulation. 
Microcapsules within agarose constructs were imaged using Zeiss LSM710 Confocal and Elyra 
PS.1 Super-resolution microscope. DAPI staining was used to visualise the cell nucleus (blue) 
while microcapsules were visualised as red and green was used to identify CNP in the core of 
microcapsules. 
5.2.11 DMMB assay & Hoechst assay 
DMMB and Hoechst assays were performed identically to the method explained in 
Chapter 2. 
5.2.12 Statistical analysis 
All data are displayed as mean ± SEM values. Statistical analysis for biochemical data 
was conducted using Mann Whitney U test with Bonferroni correction to compare differences 
between treatment groups. In all cases, a significance level of 5% was considered significant 
(p<0.05). 
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5.3 Results 
5.3.1 CNP lost in process of creating CNP microcapsules 
By the end of the microencapsulation process a 2 ml stock solution was derived which 
contained on average 5 x 106 – 1 x 107 microcapsules/ml. From the fluorescence standard curve 
assay used I calculated that the encapsulation efficiency was calculated as 67% based on a loss 
of 33.12 µg of CNP in the collated wash fractions from the initial 100 µg supplied during the 
sacrificial core construction. Based on the amount of CNP detected in the wash fractions 
collected, I identified that most of the CNP lost during the microcapsule synthesis process 
occurred immediately after the formation of the sacrificial cores (13 µg, approximately 40% of the 
total CNP lost). Following this step, the average loss of CNP detected in the wash fractions 
reduced consistently over time with only a few deviations (Figure 5.6A and B). For example, after 
application of the first PLA layer, the amount of CNP detected was 2.3 µg/ml whereas following 
EDTA treatment near the end of the formation process the amount of CNP detected was 0.65 
µg/ml. Microcapsule release profiles from the CNP containing microcapsules was measured at 
between 0.86% and 1.04% of total CNP contained within the microcapsule at each time point 
investigated (Figure 5.6C) based on 3 separate CNP-microcapsule solutions. This release profile 
is consistent with previous CNP microcapsules synthesised by the Chowdhury group (Peake et 
al., 2015). This release was relative stable over the time period investigated with no statistically 
significant differences in release calculated. 
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Figure 5.6: CNP is lost during the microencapsulation process but a consistent release profile 
is detected in solution. A: Fluorescence detected in the wash fractions during CNP microcapsule 
synthesis were collated and compared to a standard curve to calculate CNP concentration in each 
wash fraction (B). C: CNP release profile over a period of 4 days. N = 3 for all graphs. Error bars indicate 
± SEM. 
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5.3.2 Localised release of CNP from polyelectrolyte microcapsules results in enhanced 
GAG synthesis compared to exogenous application 
I examined the effect of different numbers of microcapsules loaded with CNP on 
bAC/agarose constructs in terms of GAG synthesis and DNA content compared to day 0 control 
and exogenous CNP (100 nM) application to culture medium. My results indicated that the 
application of the CNP microcapsules to bAC/agarose constructs resulted in a statistically 
significant increase in GAG synthesis for all quantities assessed compared to day 0 (p<0.01, 
Figure 5.7A). Application of exogenous CNP also stimulated increased GAG synthesis relative 
to the controls (p<0.01).  
CNP microcapsules had a concentration dependent effect on GAG synthesis. For example, 
application of 300,000 and 500,000 microcapsules resulted in GAG synthesis of 8.4 and 8.5 µg/µg 
DNA respectively, while 3,000,000 and 5,000,000 microcapsules resulted in GAG synthesis of 
7.6 and 7.2 µg/µg DNA respectively (Figure 5.7A). In contrast, blank microcapsules whilst still 
stimulating an increase in GAG synthesis relative to day 0 control, showed statistically lower levels 
of GAG synthesis relative to CNP containing MC constructs. By examining the effect of the local 
release of CNP from microcapsules compared to exogenous CNP at a concentration of 100 nM. 
In untreated controls I observed statistically significant increases in GAG synthesis in CNP 
microcapsule constructs compared to the exogenously applied CNP (p<0.01). Total DNA levels 
remained stable throughout the culture period between 2.5 and 3.5 µg/ml for all conditions 
investigated (Figure 5.7B) 
 
 
 
 
 
 
 
 
173 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
2
4
6
8
10
12
14
16
Day 0 Empty MC 3x105 5x105 3x106 5x106 CNP exo
G
A
G
 s
yn
th
e
si
s 
(µ
g
/µ
g
 D
N
A
)
3x105           5x105           3x106           5x106 
0
0.5
1
1.5
2
2.5
3
3.5
4
Day 0 Empty MC 3x105 5x105 3x106 5x106 CNP exo
D
N
A
 c
o
n
te
n
t 
(µ
g
/m
l)
5           5x 05           3x106           5x106 
A 
B 
*** *** 
+++ +++ 
$$$ 
@@@ $$$ $$ 
*** *** 
*** *** 
Figure 5.7: CNP microcapsule incorporation enhances GAG synthesis but is limited by 
concentration. All constructs with MCs incorporated (empty and CNP containing) resulted in 
increased GAG synthesis compared to day 0 control. All CNP microcapsule containing constructs 
resulted in statistically significant increases in GAG synthesis compared to exogenous application. 
Statistically significant differences inverse relationship was detected when comparing 500,000 
microcapsules to 3 x 106 and 5 x 106 with GAG synthesis. N = 3.  Error bars indicate ± SEM. *** 
indicates difference compared to day 0, ++ indicates difference to empty MC, $$ indicates difference 
to 5 x 105, £££ indicates difference to 3 x 105, &&& indicates difference to 3 x 106, @@@ indicates 
difference to 5 x 106. 
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5.3.3 CNP microcapsule characterisation 
Incorporation of CNP did not significantly affect the morphological characteristics of the 
microcapsule (Figure 5.8A) with similar diameter (5 µm) and shape observed compared to empty 
microcapsules (Figure 5.8B). Confocal microscopy showed a distinct localisation of CNP within 
the core of the microcapsule structure highlighted by the presence of the TRITC labelled PLA 
layer surrounding it demonstrating a size comparable to the cell nucleus also pictured (Figure 
5.8C). Some incomplete digestion of the CNP/CaCO3 cores was detected (Figure 5.8D) but the 
majority of the microcapsules investigated demonstrated successful removal of the sacrificial 
core. Confocal imaging indicated clustering of microcapsules around cells with some observations 
of microcapsule internalisation. 
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Figure 5.8: Representative electron micrographs of CNP microcapsule structure. A + B: SEM 
imaging showed uniform microcapsules with a characteristic folded pancake structure caused by drying 
from the sample preparation process for imaging. No morphological differences were detected in size or 
shape when comparing CNP microcapsules (A) to empty microcapsules (B). C: Microcapsule structure 
contains FITC labelled CNP and demonstrates size relative to a DAPI labelled cell nucleus. D: An 
example of an undigested core indicated that not all sacrificial cores were successfully digested using 
EDTA but the relative scarcity of them in the sample imaged suggested this was an uncommon event. 
E + F: Examples of microcapsule internalisation from day 0 (E) to day-2 (F). 
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5.4 Summary of results 
• Encapsulation of CNP in PLA/DS microcapsules resulted in 67% incorporation efficiency 
with an average 1% release rate from the structures. 
• Incorporation of 3 x 105 and 5 x 105 CNP containing microcapsules resulted in the highest 
amount of GAG synthesis in bAC/agarose constructs compared to controls. 
• Incorporation of 3 x 106 and 5 x 106 CNP containing microcapsules resulted in statistically 
significant decreases in GAG synthesis compared to 3 x 105 and 5 x 105 CNP containing 
microcapsules. 
• Exogenous CNP application was statistically significantly lower compared to constructs 
containing CNP releasing microcapsules. 
• Exogenous CNP application was not statistically significantly different compared empty 
microcapsules incorporated into the bAC/agarose construct. 
• Confocal microscopy demonstrated the localisation of FITC-CNP within the core of the 
microcapsules produced. 
• No morphological differences are detected when comparing CNP containing 
microcapsules with empty microcapsules as confirmed by SEM imaging. 
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5.5 Discussion 
In this chapter, I successfully labelled CNP with the fluorescent marker FITC, synthesised 
polyelectrolyte microcapsules containing FITC labelled CNP by alternate deposition of PLA and 
DS on CaCO3 sacrificial cores, characterised the loss and release rate of CNP from these 
microcapsules and measured the GAG synthesis resulting from the application of different 
numbers of CNP containing microcapsules into bAC/agarose constructs. 
5.5.1 CNP containing microcapsules show no morphological differences compared to 
empty microcapsules 
SEM studies revealed that CNP containing microcapsules were morphologically similar 
to empty microcapsules in terms of diameter and shape with only a small number of undigested 
cores detected in the samples imaged (Figure 5.8A and B). Visualisation of microcapsules within 
the hydrogel construct using SEM was unsuccessful, likely due to the collapse of the microcapsule 
structures during drying. Visualisation using fluorescence microscopy was more successful, with 
the addition of a TRITC-PLA layer allowing visualisation of microcapsules relative to cell nuclei 
(Figure 5.8C). Visualisation of FITC-CNP proved more problematic, requiring a high 
magnification to identify FITC-CNP within the core of the microcapsules but was achieved. 
Examples of microcapsule internalisation by cells was observed in some instances (Figure 5.8E 
and F) but were infrequently observed events. Due to the biodegradable nature of the 
microcapsule synthesis materials, this was unlikely to detrimentally affect the cells. 
5.5.2 CNP is lost during the LbL microencapsulation process 
Detection of CNP within the wash fractions taken during the microcapsule procedure 
indicates a significant loss of the original peptide of up to 33% especially following the first wash 
after CNP incorporation into the sacrificial core template (Figure 5.6A and B). This could possibly 
suggest some CNP was loosely bound to the exterior of the sacrificial core templates that was 
washed off during the initial steps. The CNP release profile measured over 4 days indicated a 
consistent steady release rate be sufficient for a prolonged period of time in excess of the 
investigation performed here based on the estimated amount incorporated into the microcapsule 
structure. This release rate is consistent with previous CNP microcapsules manufactured using 
the layer by layer assembly method as demonstrated by Peake et al. Given the daily release rate 
and the concentration of CNP calculated to be encapsulated within the microcapsules 
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synthesised, the expectant concentration of CNP released from the stock of microcapsules is 700 
nM. Based on the average number of microcapsules synthesis in the stock solution (2x107), the 
amount of CNP released from 3x105 microcapsules would be 10.5 nM, 5x105 would be 17.5 nM, 
3x106 would be 100.5 nM and 5x106 would be 175 nM. Relative to the 100 nM supplied via 
exogenous means this indicates that supply of 3x106 and 5x106 microcapsules releases similar 
concentration of CNP to the exogenous supply, whilst the supply of 3x105 and 5x105 
microcapsules releases 10-fold less CNP. This therefore supports the idea that the higher 
concentration of CNP of 100 nM supplied either on a localised level or via exogenous entry is less 
effective than a lower concentration released on a localised level. Oversupply of CNP has been 
associated with a reduction in GAG synthesis when applied to BM-MSCs so this effect is at least 
to a certain degree supported by previous literature (Tezcan et al., 2010). 
5.5.3 Microcapsule release of CNP demonstrates a dose dependent response on GAG 
synthesis in bAC/agarose constructs 
My investigation encompassed a range of different microcapsule numbers within 
bAC/agarose constructs to ascertain if a concentration dependent effect was evident (Figure 
5.7A and B). Empty microcapsules and exogenously applied CNP resulted in similar levels of 
GAG synthesis (5.3 and 5.5 µg/µg DNA respectively) with no statistically significant differences 
detected between the two groups. Since dextran sulfate is derived from glucose, it is possible that 
the internalised microcapsules I observed in some cases served as a glycolytic food source for 
the bACs and stimulated metabolic process including GAG synthesis. Work by Scholnick et al 
previously demonstrated that dextran sulfate can inhibit or consistently stimulate glycolysis in 
ascites tumour cells (Scholnick et al., 1973). However, no previous study to my knowledge has 
observed this in bovine chondrocytes so would warrant further investigation. 
In contrast, the application of 500,000 CNP containing microcapsules demonstrated the 
greatest increase in GAG synthesis (8.5 µg/µg DNA) compared to 300,000 CNP MCs (8.4 µg/µg 
DNA). However, this response was also limited as the application of 3,000,000 and 5,000,000 
CNP containing microcapsules resulted in statistically significant decreases in GAG synthesis 
(7.4 and 7.1 µg/µg DNA respectively) relative to the 300,000 and 500,000 MC containing samples. 
Significantly, statistical differences were detected when comparing samples with CNP 
microcapsules incorporated and exogenously applied CNP to culture medium (Figure 5.7A). 
Here, GAG synthesis from samples with CNP microcapsules were significantly higher than those 
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from cells treated with the exogenous peptide (p<0.01). This suggests that localised release of 
CNP is conducive to an enhanced ECM synthesis response.  
The level of GAG synthesis occurring in bAC/agarose constructs relative to other 
literature is slightly lower than expected given the cell source and time frame investigated here. 
For example, Tilwani et al published data which showed that bAC/agarose constructs of identical 
agarose concentration, oxygen tension, cell type and culture duration (as used herein) produced 
GAG synthesis levels of 12 µg/µg DNA in untreated/unstimulated samples (Tilwani et al., 2017). 
When compared to my CNP treated condition, which is known to stimulate GAG synthesis in 
bovine chondrocytes, this poses a puzzling question. One potential explanation for this deviation 
could be in the donors used. Since this was designed as a pilot study, the number of replicates 
and donors used for these experiments (N = 3, 3 replicates) is different to the Tilwani study (N = 
2, 8 replicates) and so variations in GAG synthesis levels could be attributed to this. In addition, 
damage to the joints from which I derived the articular chondrocytes can potentially stress the 
cells to produce inflammatory cytokines that can reduce GAG synthesis when incorporated into 
the agarose constructs. Furthermore, I used the optimised DMMB assay for agarose constructs 
that I developed in Chapter 2 which used a reduced pH of 1.5 compared to the pH 3.0 used in 
Tilwani’s experiments which could also explain this discrepancy. 
5.6 Summary 
This aspect of my thesis successfully synthesised, characterised and analysed the effect 
of CNP containing polyelectrolyte microcapsules on the GAGs synthesis of bovine articular 
chondrocytes embedded within an agarose construct. Furthermore, the application of CNP 
containing microcapsules resulted in an enhancement in GAG synthesis relative to day 0 control 
and exogenous application, but this effect was also shown to be concentration limited. For the 
first time, I demonstrate that polyelectrolyte release of a chondro-supportive peptide can enhance 
ECM synthesis and could provide an application for stem cell differentiation experiments in the 
future. 
The overall fate of the microcapsules following CNP release is unknown but given the 
biodegradable nature of the materials used in this investigation the long-term implications to 
surrounding cells should be limited. To confirm this, in vivo experiments need to be performed to 
adequately assess this within an agarose hydrogel. In addition, encapsulation within the 
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microcapsule structure was theorised to protect the CNP given its short half-life. This short half-
life is typically due to breakdown by proteolytic enzymes within the cell so encapsulation should 
not affect this process. To confirm this, analysis of the released supernatant of CNP 
microcapsules on cells responsive to CNP over the duration of a prolonged period (7 - 28 days) 
could be performed to determine whether the peptide is still biologically active. 
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Chapter 6: Final Discussion and Future Work 
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Figure 6.1: Overview of experiments performed, methods and findings. Flowchart symbols 
indicate the investigations performed (blue boxes), the techniques utilised to achieve each aim 
(green triangle) and the principle conclusions (orange parallelograms). 
6.1 Introduction 
My approach in this thesis was to effect a thorough, step wise evaluation of a simple 
hydrogel model to achieve chondrogenic differentiation of human AFSCs. In doing so, I sought to 
carefully identify how AFSCs change through early to late stages of a chondrogenic differentiation 
protocol within a 3D environment. I then progressed to use this model to ascertain the effect of 
the peptide CNP on this process. Finally, I applied polyelectrolyte microcapsules containing CNP 
to investigate their potential in the hydrogel model to mediate cellular response in terms of ECM 
synthesis using bovine articular chondrocytes. In this Chapter, I have aimed to summarise the 
findings (Figure 6.1) and provide the limitations of the experimental approaches taken herein. 
Finally, I conclude this thesis by providing potential avenues of future work that builds on the 
investigations performed here and the principal conclusions that I have attained. 
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6.2 Scientific findings 
6.2.1 Analysis of chondrogenic differentiation achieved in an agarose construct model over 
14 days indicates an emphasis on cell proliferation rather than GAG synthesis. 
My initial investigation characterised the biochemical and viability changes associated 
with embedding AFSCs within alginate beads and agarose constructs up to 14-days of culture 
(Chapter 2). I demonstrated that within the first 14 days of my differentiation protocol, only TGFb1-
treated alginate beads showed a clear decrease in GAG synthesis at day 14. TGFb3 treatment 
did not constitute any differences in GAG synthesis at either day 7 or 14. For AFSC/agarose 
constructs, treatment with TGFb1/3 did not confer any statistically significant change. In contrast, 
a marked increase in DNA content was observed when AFSC/alginate beads and AFSC/agarose 
constructs were treated with TGFb1 or TGFb3 compared to all controls. This observation therefore 
suggested that at early stages, the cells are proliferating more than they are synthesising 
proteoglycans, potentially in an effort to recapitulate early stages of stem cell aggregation which 
occurs in early limb formation.  
Viability of the AFSC/agarose constructs was shown to be consistent for all treatment 
conditions with no statistical differences observed. This indicated that treatment of the cells with 
TGFb did not enhance nor reduce cellular viability compared to the control treatments after 14 
days of culture. These values were consistent between the edge and core samples of the 
constructs investigated. In contrast, while AFSC/alginate bead samples did not demonstrate any 
statistically significant differences at 7 days of culture, overt decreases in viability were observed 
at 14 days of culture. This observation also further indicated that treatment with TGFb1 or TGFb3 
resulted in an increased decrease in viability of AFSCs compared to controls. No clear differences 
were detected between TGFb1 and TGFb3 treatment in this regard. Despite these decreases in 
viability, viability of AFSCs within the alginate beads was still high at over 85% for all treatment 
conditions.  
I also found that alginate beads were an unsuitable method for further investigation as 
the bead structure began to degrade within the first 14 days of culture. This observation has not 
previously been noted by other groups, with others able to successfully culture stem cell/alginate 
bead structures for as long as 28 days (Shalini and Debnath, 2015, Deng et al., 2012, Ma et al., 
2003). However, differences in cell density used and viscosity of alginate utilised could contribute 
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to this, thereby suggesting that the alginate used for these experiments is not suitable for stem 
cell differentiation over a prolonged period of culture. In summary, the characterisation of early 
stage AFSC chondrogenic differentiation within simple hydrogel models and the effect of different 
TGFb isoforms on this process is an important evaluation that can elucidate our understanding of 
how AFSCs undergo this procedure. 
6.2.2 Analysis of chondrogenic differentiation achieved in agarose model over 28 days 
indicates greater emphasis on GAG synthesis in TGFb treated samples. 
I further characterised the effect of TGFb1 or TGFb3 treatment on AFSC/agarose 
constructs over a full 28-day culture period by investigating biochemical and morphological 
changes, this time incorporating analysis of hydroxyproline content normalised to DNA content 
and SEM imaging to achieve this (Chapter 3). From my investigation, GAG synthesis and 
hydroxyproline content was enhanced by TGFb1 alone and TGFb3 alone compared to controls. 
From SEM imaging, the most obvious morphological changes observed was the initial presence 
of filopodia like structures within the first 7 days of agarose culture and the apparent loss of these 
structures by the end of my investigation at 28 days. Taken together, these findings suggested 
that the cells initially were attempting to interact with the surrounding environment and between 
14 and 28 days began to stimulate the production and release of proteoglycans and collagens.  
Overall, the basic hydrogel model of AFSCs embedded within agarose constructs shown 
here supports a level of chondrogenic differentiation. However, in contrast to other published work 
the level of GAG synthesis and collagen synthesis achieved here after 28 days was substantially 
lower than that of other studies. This could therefore indicate the importance of cell seeding 
density in relation to chondrogenic differentiation of stem cells or potential limitations in the 
differentiation potential of AFSCs to the chondrogenic lineage. No differences were observed 
between TGFb1 or TGFb3 treatment, thereby suggesting that the mode of chondrogenic 
differentiation triggered by these growth factors are likely similar. Given the similarities between 
the structural and signalling pathways that these isoforms utilise this observation is not 
unexpected and does have some agreement with other studies who also determine a lack of 
difference between the isoforms effects within an in vitro hydrogel model. In summary, further 
culture of AFSC/agarose constructs is possible and results in an increase in GAG synthesis and 
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hydroxyproline content. However, when put into context with other established published work 
the levels observed within my model constitute a reduced level of ECM synthesis in comparison. 
6.2.3 Analysis of CNPs effect on AFSC/agarose chondrogenic differentiation indicates 
positive effect on GAG synthesis when used with TGFb  treated sample. 
After demonstrating that the use of a single factor such as TGFβ to achieve chondrogenic 
differentiation to be possible, I sought to determine the effect of the peptide CNP on this process 
via solitary application or in conjunction with established chondro-inductive growth factors TGFb1 
or TGFb3 (Chapter 4). Whilst I observed that the application of CNP alone did not constitute any 
effect to ECM synthesis relative to control samples, its use in conjunction with TGFb1 or TGFb3 
was able to support an enhanced differentiation effect on par with the traditionally used Dex + 
TGFβ1 treatment. This was also confirmed by SHG imaging which indicates a pericellular 
localisation of collagen around cells in these combination treatment conditions but no formation 
of large fibre networks was shown to be present. Importantly when compared to TGFβ1 or TGFβ3 
treatments, no differences in collagen synthesis were observed in terms of collagen synthesis, 
indicating that CNP has no effect on this part of ECM deposition.  
Histological analysis of OCT embedded AFSC/agarose constructs revealed weak positive 
alcian blue staining localised to pericellular matrix surrounding the cells in CNP + TGFβ1 or CNP + 
TGFβ3 samples compared to Dex + TGFβ1 sample but all treated conditions resulted in significantly 
more alcian blue staining than the day 0 control sample. This observation confirmed my biochemical 
analysis which indicated obvious increases in GAG synthesis for these treatment conditions compared 
to day 0 controls. The analysis of gene expression changes also revealed only one marked difference 
when comparing CNP + TGFβ1 treatment with control for SOX-9 gene expression. All other genes 
investigated, whilst demonstrating fold changes compared to control did not demonstrate any statistical 
significance. This therefore suggested that prolonged culture of my AFSC/agarose constructs and 
treatment with combination therapies did not trigger any significant differences in terms of chondrogenic 
gene expression compared to control. Considering that gene expression analysis is usually subject to 
temporal changes, when put into context of the weak positive alcian blue staining suggests that the 
chondrogenic differentiation achieved in the AFSCs was poor. This is in congruence with my findings 
in Chapter 3. 
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In summary, CNP alone is insufficient to affect AFSC chondrogenic differentiation but when 
used in conjunction with the established chondrogenic growth factor TGFb was shown to act as a 
chondro-supportive agent for TGFb mediated chondrogenic differentiation in terms of proteoglycan 
deposition as confirmed by biochemical and histological analysis. This effect was also shown to be 
comparable to that of the traditionally utilised Dex + TGFb1 treatment. However, CNP application did 
not enhance collagen synthesis of TGFb treated samples relative to samples treated with TGFb 
isoforms alone suggesting a restricted role. 
 
6.2.4 Microcapsule encapsulation of CNP promotes greater GAG synthesis in compared 
to exogenous application in bAC/agarose constructs. 
A wide variety of growth factors and other molecules are used to study and enhance 
chondrogenesis of stem cells for a tissue engineering application. However, given the high doses 
required for exogenous application and the relative costing of growth factors etc, the ability to 
supply a chondro-inductive or chondro-supportive agent to cells over a long period of time at a 
reduced dosage/day would make this model much more feasible for further investigation. Thus, I 
designed and performed a pilot investigation into the use of polyelectrolyte microcapsules 
containing CNP on the GAG synthesis of bovine articular chondrocytes (Chapter 5). 
From this investigation, I successfully synthesised CNP containing polyelectrolyte 
microcapsules from PLA and DS and characterised them morphologically using SEM and 
confocal imaging techniques. No morphological differences were observed between empty 
microcapsules and CNP containing microcapsules according to SEM imaging. In addition, the 
application of CNP containing polyelectrolyte microcapsules stimulated an obvious increase in 
GAG synthesis relative to exogenous application of CNP and the application of empty 
microcapsules. However, this effect did show signs of limitation whereby the application of 3 x 
106 and 5 x 106 microcapsules resulted in a diminishment of this effect relative to the application 
of 3 x 105 and 5 x 105 microcapsules. This therefore indicated that the application of too much 
CNP on a local level can actually inhibit GAG synthesis, which is in accordance with similar 
studies albeit using exogenously applied CNP (Tezcan et al., 2010). The successful 
encapsulation/release of CNP and effect on encapsulated cells is certainly a promising result and 
could open the way to investigate their application to in vivo models of osteoarthritis such as the 
Dunkin Hartley guinea pig (Kuyinu et al., 2016). For example, microencapsulation of CNP can 
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theoretically protect the peptide from potential breakdown by upregulated MMPs present within 
the diseased joint where it can exert its beneficial effects.  
In summary, my findings demonstrated that microcapsule technology has potential 
advantages for use in a 3D hydrogel system relative to exogenous application but much more 
characterisation and investigation into the encapsulation of other pro-chondrogenic growth factors 
must be performed in order to fully ascertain the possibility of this technology for this purpose. 
6.3 Limitations in approach and potential solutions 
The use of alginate constructs of identical size and shape to those of the agarose 
constructs investigated would have been more appropriate to allow direct comparison of the 2 
hydrogel materials for the purpose of chondrogenic differentiation of AFSCs. To create an alginate 
construct, a stainless-steel mould similar in design and identical in dimensions to the one used to 
make agarose constructs is required. By applying and securing a dialysis membrane to the 
surface of a mould using screws, the AFSC/alginate suspension could be held in place within the 
mould’s wells whilst allowing diffusion of the gelling ions into the alginate solution for crosslinking 
to occur. After 2 hours in an incubator the dialysis membrane would be removed, and the 
constructs popped out of the mould wells using a Pasteur pipette. A similar methodology has 
been used by Ragan et al with apparent success (Ragan et al., 1999). Alternatively, dialysis 
membrane tubing of diameter 5 mm could be used whereby the cell/alginate solution is transferred 
inside the tubing, the ends tied off and transferred to a gelling solution for 2 hours. However, this 
method is much more awkward to perform and difficult to ensure uniform sizes of constructs. 
Another potential limitation is the quantification of viability. Manually counting based on a 
grid is subject to human error much like quantification of cells using a haemocytometer. As such 
the use of an automated method using software such as ImageJ for automated cell counting from 
images or the use of an automated cell counter such as a ViCell would be a more accurate reliable 
method that could be used for these measurements. I noted that encapsulation of AFSCs in 
agarose results in an initial decrease in viability compared to a method such as alginate 
incorporation. This is likely a result of the gelling solution being too warm, causing thermal stress 
to the cells and apoptosis. The use of a sensitive temperature probe could be used in order to 
indicate accurately when the temperature is most suitable for cellular encapsulation and improve 
the initial cell viability. 
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Morphological characterisation of cells within complex physiological or manufactured 
materials is often achieved using scanning electron microscopy. However, conventional SEM 
techniques requires the sample to be in a vacuum (10-7 to 10-9 Torr) and removal of the hydrogel’s 
natural hydrated state. Since hydrogel structures are maintained by water absorbed by the 
polymer network, this inherently affects how reliable the images observed in the prepared sample 
relate to the actual state during culture. Specialised microscopy techniques do exist that are able 
to characterise the morphology of hydrogels in their hydrated state such as environmental SEM 
(ESEM). Although it must be noted that techniques such as these do have increased user cost 
compared to conventional vacuum SEM. Environmental SEM differentially pumping the 
microscope column to produce a graduated vacuum from the specimen to the electron gun. By 
maintaining a high humidity, specific temperature and pressure within the microscope chamber, 
ionising collisions between the electrons and water vapour molecules generate positive ions 
which attract to the sample and neutralise the specimens charge. The hydrated environment also 
allows the sample to stay hydrated. Whilst the resolution offered by the ESEM is lower than that 
of conventional SEM, the lack of sample preparation steps except for fixation, a lower chance of 
image artefact formation and the maintenance of the hydrated hydrogel state offers several 
advantages that should produce a more accurate representation of how the cells are sustained 
within the agarose construct. 
While I have demonstrated that chondrogenic differentiation, at least from a biochemical 
standpoint, is facilitated by agarose encapsulation and treatment with TGFb1 or TGFb3, the use 
of agarose itself as a scaffold material is potentially problematic. In vivo, humans lack the 
enzymes required to break down agarose (Emans et al., 2010). As a true tissue engineered 
material is meant to degrade over time as the body naturally replaces the inserted material with 
native tissue, this is a significant issue. As the mechanical properties of agarose are much less 
than that of native cartilage, this could present a focal point of weakness within the tissue and 
increase the chances of degradation of the structure if applied to an osteochondral defect. In 
addition, research conducted in 2011 indicated that chondrogenically primed stem cells when 
applied in vivo within an agarose gel demonstrate an increase in calcification markers (Vinardell 
et al., 2011). Therefore, this suggests that an agarose model is better suited as a means to 
investigate the differentiation of AFSCs and not as a defect implant. 
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The lack of statistically significant differences observed in analysis of common gene 
expression markers, despite the presence of fold changes compared to control, could suggest 
that my study lacked statistical power. To avoid that situation, a study whereby the majority of 
samples are devoted to gene expression analysis would be appropriate. The genes analysed in 
this study were all positive chondrogenic markers, but further analysis is essential to determine if 
hypertrophic markers or osteogenic markers (MMP-13, ALP, collagen X) were also enhanced as 
a result of differentiation. This is especially important as some groups have suggested that TGFβ1 
treatment predisposes cells to a hypertrophic phenotype and it would be interesting to observe if 
CNP has any effect on this incidence (Lolli et al., 2018). Similarly, histological staining used here 
is restricted to confirmation of proteoglycan deposition by cells only. It would be useful to discern 
and support any gene expression data to show if osteogenic or myogenic markers were also 
present. For example, alizarin red solution is commonly used to look at mineralisation to confirm 
osteogenic differentiation. The investigation of CNP only, TGFβ1 only and TGFβ3 only controls for 
histological analysis would have been beneficial to provide a more complete overview of the 
treatment conditions investigated for biochemistry and would be beneficial to correlate whether 
the increases in proteoglycan synthesis observed in controls was also identified at a histological 
level. SHG, while useful to look at collagen deposition, could not be used to distinguish accurately what 
type of collagen was being produced by the cells. This is a significant limitation in regard to identifying 
whether the collagen being produced by the cells is supportive of hypertrophic tissue or mature 
cartilage. Immunohistochemistry could therefore be a useful technique to apply in this circumstance as 
it can be used to identify type I and type II collagen deposition in histological samples although there is 
some debate regarding whether this staining is specific enough to yield definitive conclusions. 
In terms of the CNP microcapsule work, the obvious limitation relative to the rest of this thesis 
was the xenogeneic cell source used. However, there are appropriate reasons for this. Firstly, since 
this investigation serves as a pilot study to investigate whether the application of microcapsules to a 3D 
hydrogel is possible and worthwhile, the use of xenogeneic cells avoids wasting the limited supply of 
AFSCs available. Secondly, I showed in Chapter 4 that CNP has no effect on GAG synthesis of AFSCs 
when applied exogenously to culture medium on its own. Thirdly, whilst human chondrocytes might be 
more relevant for a potential clinical application, human chondrocytes are less readily available since 
they are usually only sourced from patients who have an underlying disease or tissue damage 
and are inherently variable based on the anisotropy of the tissue itself. Since bovine articular 
cartilage is relatively easy to procure, financially reasonable to purchase, well characterised, 
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possess similar biochemical properties and identical phenotypes to human articular chondrocytes 
(Buschmann et al., 1992); the use of bovine articular chondrocytes for this pilot study was 
warranted. 
As a small study, the N numbers used in this investigation is small in terms of donor cells 
despite standard numbers of replicates per treatment group. It would therefore be worthwhile to 
increase the number of donors used in this investigation to increase statistical power. In addition, 
expanding the scope of microcapsule numbers investigated would have been useful to determine an 
optimum concentration required to produce an optimum level of GAG synthesis enhancement. Since I 
demonstrated that extremely high numbers of microcapsules were detrimental to GAG synthesis in 
bACs, it would be useful to distinguish the effect microcapsules within the range of 50,000 to < 
3,000,000 MCs to see how the cells react to the localised release. In this way a concentration profile 
could be determined. The incorporation of an untreated cell only control with no exogenous treatment 
applied would be beneficial to do a comparison with exogenous CNP treatment and the different 
microcapsule combinations. Also, given the microcapsule to cell ratio was <12.5 and the 
microcapsules synthesised were made using biodegradable materials, the chances of significant 
toxicity in this experiment were reasonably low. However, this should still be checked further by 
performing viability profiling of unlabelled CNP and microcapsules structures so as to avoid 
confusion between live cells (green) with FITC-CNP and dead cells (red) with TRITC-PLA. 
The amount of CNP lost during the initial CNP microcapsule manufacture stage is a 
significant issue. Peake et al noted only a loss of less than 20% of the initial CNP supplied during 
their microcapsule synthesis which whilst not as high detected in my experiments is still a 
significant loss and limitation of this method (Peake et al., 2015). For a peptide such as CNP 
which presents a significant investment, 0.5 mg of CNP can cost as high as £352 from some 
suppliers at the time of writing, a loss of this amount is from a financial perspective troubling and 
could have significant effects on the feasibility of applying this technology to the clinic. 
Another potential limitation of the passive release microcapsule model is an issue of 
overstimulation. Whilst, prolonged release of a bioactive molecule is often desirable and avoids 
the issue of reapplication, there is potential for an overstimulation of the cells to occur by the 
released molecule. Since passive release is not governed by an external stimulus, if excessive 
activation of a signalling pathway that is resulting in undesirable effects begins to occur, there is 
no way of stopping the process without disruption of the entire agarose construct used here. This 
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might potentially explain why I saw a decrease in GAG synthesis in bAC/agarose constructs that 
contained 3,000,000 and 5,000,000 microcapsules. Tezcan et al demonstrated the effect of CNP 
on GAG synthesis in MSCs becomes diminished at concentrations of 1µM (Tezcan et al., 2010). 
In that way, stimulus responsive microcapsule technology is a much more desirable method to 
achieving long term coaxing of a specific cellular response.  
One final general limitation for this research is the availability of AFSCs for testing. 
Although extraction of AFSCs is easily performed from the fluid extracted during procedures such 
as amniocentesis, the incidence of these procedures is reducing following the advent of non-
invasive prenatal screening tests such as NACEâ. These tests require a simple blood sample to 
be taken from the mother in order to analyse DNA in the maternal plasma related to the foetus 
via next generation sequencing. Whilst AFSCs can still be derived from other essential 
procedures such as amniodrainage and during laser interventions, the number of AFSCs that can 
be isolated from these procedures is much lower than that of amniocentesis. With an increasing 
interest in the use of these cells for medical and tissue engineering applications, such a small 
supply of AFSC samples will make performing in vitro studies more difficult, especially in regard 
to obtaining sufficient independent samples in which to perform a complex study. 
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6.4 Future research 
 The experimental studies performed within this thesis have provided a basis for 
investigating a variety of different aspects regarding chondrogenic differentiation of human 
AFSCs, the effect of CNP on this process and the utilisation of microcapsule technology within a 
3D model to affect cellular response. As discussed in the limitations section of this chapter, the 
investigations performed require further follow up and in-depth evaluation to fully characterise and 
conclude the effect of TGFb isoforms, CNP and CNP containing MCs on AFSC chondrogenic 
differentiation. Below is a flowchart proposing further investigations that follow on directly from 
the work performed here, followed by in-depth explanations of the rationale for each point. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.4.1 CNP effect on hypertrophic 
marker expression 
6.4.4 Optimising CNP MC number to 
facilitate GAG synthesis in AFSCs 
6.4.5 Investigating TGFb 
microencapsulation on AFSC 
differentiation 
6.4.2 Effect of different cell seeding 
densities on AFSC chondrogenic 
differentiation 
6.4.3 Effect of TGFb2 on AFSC 
chondrogenic differentiation 
6.4.6 Effect of mechanical stimulation 
on chondrogenically primed AFSCs 
6.4.7 AFSC chondrogenic 
differentiation with alginate constructs 
Figure 6.2: Flowchart indicating a potential workflow that can be followed to further build upon 
and characterise the events investigated in this thesis. 
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6.4.1 The effect of CNP on hypertrophic marker expression 
One of the major problems in terms of applying this knowledge to future research is 
primarily a financial one. From the data I have acquired, no statistically significant difference was 
detected between CNP + TGFb isoform treatment with Dex + TGFb1 treatment after 28 days of 
culture. The one caveat before a definitive judgement can be made is the effect that CNP has on 
the expression of hypertrophic/osteogenic markers. Dexamethasone has previously been 
implicated in enhancing chondrogenic gene expression (SOX-9, COL2b1, aggrecan) in addition 
to enhancing hypertrophic markers such as Runx2, ALP and osteocalcin. Therefore, it is essential 
to fully evaluate the effect of CNP on AFSC chondrogenic differentiation by identifying its effect 
on the expression of these hypertrophic markers as well as COL1 and COLX in a much more 
expanded study to ensure appropriate statistical power. In addition to this, histological 
examination of hypertrophic/osteogenic markers should be performed through staining to support 
the findings of the gene expression data retrieved. A more complete understanding of CNP’s 
effect on this process can therefore be achieved and a determination as to whether CNP is a 
more appropriate supplement to this process than dexamethasone can be assessed. 
6.4.2 Effect of different cell seeding densities on AFSC chondrogenic differentiation. 
Healthy articular cartilage contains 9.6 x 106 chondrocytes/cm3 (Hunziker et al., 2002). 
However for chondrogenic differentiation of stem cells, different seeding densities have been 
used in a variety of matrix environments and chondrocyte sources (Heywood et al., 2004, Watt, 
1988). Bernstein et al. demonstrated that a high cell density (7 x 107) of chondrocytes within 
alginate hydrogels did not constitute a significant enhancement in collagen synthesis or gene 
expression compared to a ‘low’ cell density of 4 x 106 per ml, with reduced fibrocartilage markers 
seen in the low cell density group indicating low cell density would be more important for overall 
chondrogenic development (Bernstein et al., 2009). Other groups have utilised cell densities as 
high as 2 - 5 x 107 of MSCs to achieve sufficient chondrogenic differentiation (Thorpe et al., 2013). 
A recent study looking at cell seeding densities for chondrogenic differentiation of BM-MSCs 
performed by Bornes et al showed that cell seeding density of 5 x 107 bovine BM-MNCs resulted 
in the highest levels of aggrecan, collagen II mRNA, GAG synthesis and Bern score compared to 
all other densities investigated (Bornes et al., 2016). Since my study has limitations in terms of 
the level of GAG and hydroxyproline synthesis occurring, it would be beneficial to investigate 
whether an optimum cell density exists to achieve chondrogenic differentiation of AFSCs within 
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this model. This could be achieved by culturing AFSC/agarose constructs of increasing density 
for the same period of time whereby the methods optimised within this thesis can be used to 
compare the biochemical, histological and gene expression changes occurring. The optimum cell 
density can therefore be determined by also assessing these factors against the viability of the 
cells after 28 days. 
6.4.3 Effect of TGFb2 on AFSC chondrogenic differentiation. 
Mesenchymal condensation and chondrogenesis of mesenchymal progenitor cells is 
promoted by TGFβ1, TGFβ2 and TGFβ3 signalling but its role as an essential factor is debated 
(Tuli et al., 2003, Song et al., 2007, Shull et al., 1992, Pelton et al., 1991). Studies regarding the 
role of TGFb in early development are difficult to perform due to the perinatal lethality induced 
when specific TGFβ isoforms are knocked out. Despite this, defects in chondrogenesis have been 
detected upon the loss of TGFβ2 which display general chondrodysplasias and blocking of Shh 
signalling to prevent hypertrophic differentiation ex vivo (Sanford et al., 1997, Alvarez et al.). 
However, when deletion of TGFβ2 occurs at later stages of limb development, the defects are not 
evident suggesting a specific role during pre-chondrogenic stages. Few studies have looked at 
the impact of TGFβ2 on chondrogenic differentiation despite research indicating it plays a more 
integral role in the early chondrogenic differentiation stages. Of the studies that have been 
performed, no difference was reported in effect compared to TGFβ1 and TGFβ3 treatment 
(Jakobsen et al., 2014, Mueller et al., 2010). This would be in agreement with my findings in which 
no differences between TGFβ1 and TGFβ3 were detected. Nevertheless, this would therefore be 
an area of important investigation to determine if chondrogenic differentiation of AFSCs within 
this model is independent of TGFb isoform used. This could easily be achieved by utilising the 
framework initially investigated in this thesis and improved upon by the suggestions made in 6.4.1 
and 6.4.2, with the addition of TGFβ2 and CNP + TGFβ2 treatment conditions. 
6.4.4 Optimising CNP MC number to facilitate GAG synthesis in AFSCs. 
Whilst I demonstrated the local release of CNP from polyelectrolyte microcapsules within 
the agarose construct enhanced bAC GAG synthesis, the more relevant investigation to be 
performed is the effect of CNP microcapsule incorporation on human AFSC differentiation. In 
terms of analysis, the application of this technology could have much wider connotations in 
addition to enhancing GAG synthesis of cells. Gene expression within cells is a dynamic process 
that experiences careful regulation in order to maintain chondrocytes in their mature state. While 
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many groups are able to demonstrate that pro-chondrogenic gene expression occurs during 
chondrogenic differentiation of stem cells, it is often associated with upregulation of hypertrophic 
and osteogenic genes also. It is possible that the prolonged activation of pro-chondrogenic genes 
through the exogenous application of growth factors contributes to this upregulation of 
undesirable genes which contribute to hypertrophic and endochondral ossification processes. By 
carefully regulating the application of growth factors in a more physiological environment, it is 
possible that the desirable aspects of this differentiation ca be achieved whilst minimising the 
undesirable events. Therefore, if future investigations apply this technology for stem cell 
differentiation purposes, the effect of localised release of peptide on chondrogenic/hypertrophic 
gene expression would be an important observation to make in addition to biochemical and 
histological analysis. This investigation could be achieved by repeating the methodology laid out 
in Chapter 5 of this thesis but changing the number of MCs utilised and of course switching the 
cell type encapsulated to AFSCs. In addition to these studies, whilst it is possible to characterise 
the release rates of CNP from MCs in solution, the release rate when placed in the hydrogel 
construct is likely to be different or demonstrate alterations in kinetics. This could be another area 
of novel investigation to characterise the release of peptide load from LbL MCs within an agarose 
construct. A time lapse study using confocal microscopy imaging could potentially be utilised to 
investigate the release of fluorescently labelled peptide from the LbL MCs over a defined time 
period to characterise this. 
6.4.5 Analysis of the effect of TGFβ microencapsulation on chondrogenic differentiation. 
TGFb similarly shares a short half-life to CNP and would benefit from long term, stable 
effective local delivery in a similar way (Shen et al., 2018). Covalent tethering of TGFβ1 within 
PEG hydrogels has already demonstrated the promotion of chondrogenic differentiation in MSCs, 
so an investigation into the localised release of TGFb from microcapsule carriers within an 
agarose hydrogel would be warranted (McCall et al., 2012). However, more recently nanofiber 
scaffold based release of TGFb3 was also shown to driving synovium derived stem cells towards 
a fibrocartilage cell fate (Qu et al., 2019). Despite this, localised release of microencapsulated 
TGFb1 for AFSC differentiation within a 3D model would be an interesting research question to 
answer. As a much larger molecule (25 kD relative to CNPs 2.197 kDa) the use of a passive 
release mechanism as used in my investigation would be inappropriate as the growth factor would 
remain entrapped within the polyelectrolyte layers. However, if applied to a stimuli responsive 
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microcapsule release system, such as ferromagnetic microcapsules which releases its payload 
when exposed to a magnetic field, this could facilitate carefully managed release of TGFb to the 
cells (Figure 6.3). Ferromagnetic microcapsules would possess several advantages to other 
stimuli activated microcapsules such as (ultraviolet) UV and infra-red (IR) responsive 
microcapsules because the magnetic fields applied are unlikely to negatively impact the viability 
or responses of cells. Several groups have already indicated successful stimuli dependent 
release of microcapsules payloads using this technology. 
 
 
 
 
 
 
 
 
 
 
Therefore, incorporation of ferromagnetic particles into a biodegradable LbL 
polyelectrolyte microcapsules would need to be performed and optimised. Following this, a 
method for the encapsulation of TGFb within these structures would need to be developed before 
an investigation into how responsive the produced microcapsules are to a magnetic field. Once 
the stimulus responsiveness of the MCs and the identification of release is identified, then the 
application of these MCs to an AFSC laden hydrogel construct could be performed and 
investigated. 
6.4.6 Effect of mechanical stimulation on chondrogenically primed AFSCs. 
The indication of a pericellular matrix deposition of the cells suggests that the cells could 
be attempting to stimulate mechanotransduction pathways after 28 days of culture. However, 
given the relatively low level of collagen and GAG detected in my samples, application of 
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Figure 6.3: Potential application of ferromagnetic responsive TGFb containing microcapsules. 
Ferromagnetic particles within polyelectrolyte layer can effectively make microcapsules leakier to 
facilitate release of payload, in this case TGFb, in response to a magnetic field. 
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mechanical stimulation is potentially detrimental to the survival of the cells within an agarose 
construct. Once identification of the optimum cell density to perform chondrogenic differentiation 
of AFSCs is performed and well characterised, the application of mechanobiology studies could 
be utilised here to investigate the effect of mechanical stimuli on chondrogenically primed AFSC 
GAG synthesis (Figure 6.4). The most effective way of performing this would be through the use 
of a cell straining apparatus whereby physiological load can be applied of between 0 - 15% strain 
amplitude with sinusoidal waveform and a frequency of 1Hz (Lee and Bader, 1997). In addition, 
if this apparatus was implemented into an oxygen-tension controlled incubator such as a 
Biospherix, the effect of hypoxic oxygen tensions could also be investigated on this process. 
 
 
 
 
 
 
 
 
 
 
 
To complement these studies, RAMAN spectroscopy could be used to identify the 
presence of any calcifications that develop within the construct as a result of de-differentiation of 
the cells over time or mineralisation as a consequence of osteogenic differentiation (Henrionnet 
et al., 2017). RAMAN spectroscopy uses the principle of vibrational inelastic light scattering of an 
incident laser shining on a sample to provide biomolecular and structural information regarding 
the sample. This technology has previously been used to look at the zonal organisation of articular 
cartilage and tissue engineered cartilage (Bergholt et al., 2016). If used in concert with mechanical 
characterisation of the tissue engineered construct, both the mechanical properties (local elastic 
A B 
Load cell 
Actuator 
Cell 
straining 
equipment 
Figure 6.4: Cell straining apparatus for mechanobiology studies. A: Example of Bose bioreactor cell 
straining apparatus consisting of compressive mounting plate and loading pins. B: The 
electromagnetically controlled vertical actuator and load cell attached to the cell straining apparatus 
(BOSE ElectroForce System Group, Minnesota, USA). Figure modified from (Tilwani, 2016). 
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modulus) and the tissue engineered construct’s organisation in terms of collagen, GAG and water 
could be well established and compared to native tissue. In this way, a different perspective is 
provided to support biochemical, gene expression and imaging techniques that I have used in this 
thesis. 
6.4.7 AFSC chondrogenic differentiation within 3D alginate constructs. 
The use of alginate constructs of identical size and shape to the agarose constructs used 
in this thesis would have been ideal for a direct comparison of the hydrogel materials employed 
for the encapsulation of AFSCs. With the construction of a simple mould with attachable glass 
plating that can be secured via screws and a piece of standard dialysis membrane, this should 
be a methodology that is achievable to perform (Figure 6.5). Following the proposed optimisation 
of cell seeding density for constructs as outlined in Chapter 6.4.2, AFSC differentiation could be 
investigated again and prolonged culture used to determine if this hydrogel material is sufficient 
for this purpose. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
Figure 6.5: Alginate construct example. A: Example of alginate construct that can be made 
using dialysis tubing. B: Example of the mould used to create 5 x 5 mm agarose constructs. The 
insertion of screw points into the stainless-steel mould could allow attachment of dialysis 
membrane to the mould for alginate construct construction. 
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6.4.8 Clinical implications 
With the findings presented here, the application of an AFSC embedded hydrogel has a 
limited application for cartilage repair in the clinic without longer term culture in order to stimulate 
further ECM synthesis (>4 weeks). Given the weak mechanical properties of hydrogels, the 
application of an AFSC embedded hydrogel is limited without structural modifications or a therapy 
designed to utilise this effect. However, the basic methodologies developed here and optimised 
can be used to help differentiate any stem cells into lineages whereby a 3D environment is 
beneficial. The immunologic properties, or lack thereof of immunogenic properties, for AFSCs 
presents a desirable situation in terms of a cell only implantation, provided that the cells remain 
in situ and differentiate correctly to the mature chondrocyte phenotype. Incorporation of magnetic 
nanoparticles may be an avenue of research to maintain the cells within a specific location 
however incorporation of cells like this requires further experimental testing regarding how the 
cells process these nanoparticles over the long term. 
Future application of AFSCs is potentially limited for a cartilage repair purpose. The lack 
of substantial ECM synthesis in terms of GAG and collagen within the experiments performed 
here suggests that either further optimisation to stimulate these processes is needed or that the 
cell type itself is limited in terms of chondrogenic differentiation. In comparison to MSC 
chondrogenic differentiation, the work presented here also indicates a reduced capacity to meet 
the needs of a clinically applied tissue engineered tissue. More recent work has focused on the 
use of AFSCs to differentiate along a cardiomyogenic lineage and the results have been 
promising, showing a greater potential relative to bone marrow mesenchymal stem cells (Jain, 
2019). 
Whilst the immunologic properties of AFSCs are desirable, the lack of availability of 
AFSCs provides a limitation especially given the preference for expectant mothers to select non-
invasive procedures for karyotype testing. More expansive in vitro and in vivo studies would 
therefore be limited and effectively provides a bottleneck in terms of further advancement to 
assess the utility of these cells for other applications. The future of these cells is therefore 
potentially ambiguous. However, the advancement of biobanking and research cell bank 
productions could potentially make the scientific investigations of these cells easier. 
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6.5 Thesis conclusions 
Overall, this research has furthered current understanding by: 
• Successfully characterising of the biochemical changes that occur in human AFSCs 
over 14 days when encapsulated in alginate beads and agarose constructs and 
subjected to a defined TGFb mediated chondrogenic differentiation protocol. 
• Demonstrating the limitation of alginate beads for human AFSC chondrogenic 
differentiation for longer than 14 days of culture. 
• Revealing that ECM synthesis of human AFSCs is enhanced within a simple agarose 
construct following a defined TGFb mediated chondrogenic differentiation protocol 
over 21 and 28 days.  
• Indicating the ECM synthesis of human AFSCs undergoing this chondrogenic 
differentiation protocol is not influenced by the TGFb isoform utilised. 
• Identifying CNP is not a chondro-inductive agent for human AFSC chondrogenic 
differentiation. 
• Identifying CNP acts as a chondro-supportive agent for the TGFb mediated 
differentiation of human AFSCs. 
• Revealing an application of CNP containing polyelectrolyte microcapsules can be 
conducive to enhancing ECM synthesis of cells within a 3D hydrogel model compared 
to exogenous application.  
 
My thesis has therefore laid the groundwork for several promising areas of investigations 
by future researchers in this field that can contribute to the development of a robust 3D hydrogel 
model for in vitro study of AFSC and other stem cell chondrogenic differentiation experiments. My 
work has also opened up a new avenue of enquiry into the use of microcapsule technology to 
enhance this process within 3D culture models. 
 
 
 
201 
 
National conference/symposium contributions 
Oral presentations 
• Taylor, J. R. M.; David, A. L.; De Coppi, P.; Chowdhury, T. T. The effect of CNP on the 
chondrogenic differentiation of foetal derived stem cells (AFSCs). Stem Cell Regenerative 
Medicine meeting, Institute of Child Health, UCL, London. 
Date: Tuesday 11th July 2017. 
• Taylor, J. R. M.; David, A. L.; De Coppi, P.; Chowdhury, T. T. The effect of CNP on the 
chondrogenic differentiation of foetal derived stem cells (AFSCs). Russel Binions 
Memorial Symposium 2018, QMUL, London 
Date: Thursday 26th April 2018. 
Poster presentations 
• Industrial Liaison Forum 2016: The effect of CNP and TGFβ on foetal stem cell 
differentiation for chondrogenesis. 
School of Engineering and Materials Science, QMUL, London, UK.  
Date: Friday 11th November 2016. 
• Rosetrees Symposium 2016: The effect of CNP on foetal derived stem cell differentiation 
and GAG production in an alginate bead model.  
Blizard Institute, QMUL, London, UK. 
Date: Wednesday 21st September 2016. 
• Industrial Liaison Forum 2017: Microcapsules encapsulated with CNP enhance GAG 
synthesis in chondrocyte/agarose constructs.  
School of Engineering and Materials Science, QMUL, London, UK. 
Date: 22nd November 2017. 
• BiomedEng18 conference: CNP with TGFb enhanced chondrogenic differentiation of 
human amniotic fluid stem cells cultured in agarose constructs. Poster 63. 
Imperial College, London, UK. 
Date: Thursday 6th and Friday 7th September 2018. 
List of Awards 
3rd place for oral presentation in the Queen Mary 3-minute thesis competition finals 2016.  
Date received: Thursday 16th June 2016. 
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Supplementary materials 
Example consent forms used to procure amniotic fluid from patients 
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Equipment used for RNA optimisation, cDNA synthesis and RT-qPCR. 
A: Qiagen Tissue lyser 
B: Nanodrop One 
C: Techgene thermal cycler 
D: StepOnePlus System 
A 
 
B 
 
C 
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Equipment used for preparation of hydrogel and microcapsule samples for SEM. 
A: Critical Point Dryer 
B: EMITECH sputter coater 
A 
 
B 
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Equipment used for sectioning of hydrogel samples prior to histology. 
A: ThermoScientific HM325 microtome 
B: Leica cryostat 
 
 
 
 
 
 
Equipment used for MACS and FACS analysis of AFSCs. 
A: OCTOMACS separator 
B: BD LSRII cytometer 
 
 
 
A 
 
B 
 
A 
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